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ABSTRACT 
 
SRMS (Src-Related tyrosine kinases lacking C-terminal Regulatory tyrosine and N terminal 
Myristoylation Sites) belongs to a family of non-receptor tyrosine kinases, which also 
includes breast tumor kinase (BRK).  SRMS was first identified in 1994 in a screen for the 
genes that regulate the growth and differentiation of neuroepithelial cells.  This 54 kDa 
protein spanning 488 amino acids, consists of the prototypical Src homology 3 (SH3), Src 
homology 2 (SH2) and a tyrosine kinase domain.  While BRK has been documented for its 
expression in over 60 % of breast carcinomas, information on SRMS on similar grounds 
remains absent from the literature.  Furthermore, unlike BRK, knowledge of how SRMS 
regulates its enzymatic activity as well as the identification of its substrates remains 
unknown.  The work in this thesis demonstrates that SRMS is potentially expressed in the 
majority of breast carcinomas.  To understand the biochemical and cellular functions of 
SRMS, a series of mutants comprising point mutations as well as the deletion of the N-
terminal region and the functional, SH3 and SH2 domains, were generated and assessed for 
enzymatic activity in cells.  This study demonstrates for the first time that the wild type 
protein is apparently constitutively active and that its N-terminal region regulates its 
enzymatic activity.  As well, three critical amino acid residues in the protein namely, lysine 
258 (ATP binding site), tyrosine 380 (auto-phosphorylation site) and tryptophan 223 
(intramolecular interaction) have been characterized. All three residues have been determined 
to be essential for the enzymatic activity of SRMS.  Finally, the adapter protein Dok1 has 
been characterized as a novel substrate of SRMS.  The results from the present study 
underscore the potential significance of the catalytically active non-receptor tyrosine kinase, 
SRMS that should serve as a foundation upon which further research may ensue in the 
context of breast tumorigenesis. 
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1. Review of the Literature 
 
1.1 Tyrosine kinases: 
Protein Tyrosine kinases (PTKs) comprise a distinct cohort of enzymes that function to 
phosphorylate the tyrosine residues on other proteins or alternatively, those that lie within 
their own sequences, by auto-phosphorylation.  Such phosphorylation is orchestrated by the 
catalytic/kinase domain itself and is accomplished by the covalent attachment of a phosphoryl 
group, derived from ATP, onto the tyrosine residues of the protein (Cox et al., 2008).  PTKs 
are known to regulate a plethora of cellular functions including cell growth and proliferation.  
Tyrosine phosphorylation serves as a vital stimulus to initiate a cascade of intra-cellular 
signalling pathways that culminate in events such as the regulation of gene expression in the 
nucleus (Radha et al., 1996).  Tyrosine kinases may broadly be categorized as receptor and 
non-receptor kinases.  The human genome is known to encompass at least 90 tyrosine kinases 
which include 32 non-receptor tyrosine kinases, organized into 10 subfamilies, and 58 
receptor tyrosine kinases distributed in 20 subfamilies (Robinson et al., 2000).  While 
receptor tyrosine kinases, like the epidermal growth factor receptor, are transmembrane 
protein receptors and usually serve as binding sites for extracellular ligands, non-receptor 
tyrosine kinases are intracellular and regulate activities downstream of their surface-based 
counterparts.  
 
1.1.1 Cell signalling pathways: 
Cells possess the biological ability to communicate with each other through a class of 
proteins known as receptors.  A broad physiological class of such receptors exists that help 
transmit signals, and hence enable communication, between cells.  Such receptors may be 
membrane-based (EGFR, TGF, Integrins etc.) or intracellular (steroid hormone receptors 
etc.) and are activated by ligands which are usually small molecules or peptide hormones 
such as EGF, FGF, VEGF and cytokines.  Receptor activation as a result of ligand binding 
may either directly elicit a cell’s physiological response (as in the case of the GABA receptor 
in neurons) or may initiate a cascade of intracellular signalling events before such a 
physiological response is produced.  In most cases, a cell’s functional output is the result of 
an interplay of such intracellular signalling events.  A variety of intracellular signalling 
cascades, organized in a complex network comprising several proteins, exist within various 
cells.  Furthermore, these signalling cascades may also cross-communicate with several 
proteins and thus tend to cross-activate signalling molecules from other cascades. 
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Some of the major signalling pathways involving the FRK/PTK6 family kinases shall be 
described in the subsequent sections.    
 
1.1.1.1  MAPK pathway 
The mitogen activated protein kinases are serine/threonine kinases that are widely conserved 
amongst eukaryotes and are known to regulate cellular processes pertaining to proliferation 
and differentiation as well as cell survival and cell death (Pimienta and Pascual, 2007).  As 
shown in Figure 1.1, the MAPK signalling pathway is hierarchically organized into a three-
tiered signalling module that begins with the activation of MAP3 kinases (MAP3K) through 
the activating stimuli from the cell membrane receptors.  Activated MAP3K phosphorylates, 
and hence activates, MAP2K which in turn activates MAP kinase.  MAPK, upon activation, 
may enter the nucleus and regulate gene expression to produce the appropriate cellular 
response (Pimienta and Pascual, 2007).  
                In contrast to the relatively linear mode of phosphorylation-dependent activation of 
the MAPK and MAP2K, MAP3Ks have a more complex mechanism of activation.  Several 
MAP3Ks such as c-Raf, MEKK4 and MLK3 natively exist in a conformationally inactive or 
autoinhibited state that requires multiple steps for activation (Miyake et al., 2007; 
Rajakulendran et al., 2009).   The activation of MAP3Ks essentially begins with the 
translocation of these proteins to the membrane where activated small G-proteins relieve the 
autoinhibitory constraints on the MAP3Ks.  The conformationally open MAP3Ks then 
undergo homo or hetero-dimerization that subsequently permits the dimers to phosphorylate 
each other on their kinase domains, thereby rendering the MAP3Ks active.   
                 The signalling pathways of the MAPK system that adopt the three-tiered hierarchy 
are described below. 
 
1.1.1.1.1   ERK1/2 pathway: 
Perhaps the most well-characterized of the three pathways, the ERK1/2 pathway receives 
activating stimuli from a variety of cell surface receptors including receptor tyrosine kinases, 
integrins and ion channels (Zhang and Dong, 2007) (Fig 1.1).  The key MAP3Ks of this 
pathway include A-Raf, B-Raf and c-Raf as well as Mos and TPL2 kinases. Activation of 
these proteins allows for the phosphorylation and activation of MEK1/2 which further 
activates ERK1/2.   ERK1/2 can then translocate to the nucleus where it phosphorylates a 
number of substrates that regulate gene expression. This eventually regulates processes such 
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as cell proliferation, cell cycle progression, cell division and differentiation.  Some of the 
ERK substrates include the RSK-related kinases, MSK1 and MSK2 as well as transcription 
factors like AP-1 (Zhang and Dong, 2007). 
 
 
 
 
 
 
FIGURE 1.1: Schematic diagram of the three-tiered MAPK pathways. MAPKKK 
activation, following ligand stimulation, leads to the activation of MAPKK which further 
activates MAPK to allow for its nuclear translocation and the ultimate activation of 
transcription factors to initiate gene transcription and elicit a biological response. The three 
cellular pathways conforming to this hierarchical organization are shown: 1. ERK1/2 
pathway, 2. p38/JNK pathway and 3. ERK5 pathway 
 
 
 
 
 
 
 
 
 
 
 
4 
 
1.1.1.1.2   JNK/p38 pathways: 
Unlike the ERK1/2 pathway, the JNK/p38 pathways are activated in response to 
environmental stresses as well as inflammatory cytokines, growth factors and GPCR.  
Specifically, the MAP3Ks of the p38 pathway include MLK3, TAK and DLK while those of 
the JNK include MEKK1/4, MLK3 and ASK1 (Weston and Davis, 2002; Zarubin and Han, 
2005) (Fig 1.1).  Although apparently discrete, the JNK and the p38 pathways are often found 
to be functionally associated.  Such co-regulation may be attributed to functioning of certain 
MAP2Ks, such as MKK4, that are common downstream activators of both pathways.  The 
JNK and p38 pathways are, thus, often found to be co-activated (Cargnello and Roux, 2011).  
Other corresponding MAP2Ks that activate p38 and JNK1/2/3 are MKK3/6 and MKK7, 
respectively.  Activated p38 and JNK kinases then translocate to the nucleus to phosphorylate 
an array of transcription factors such as Pax6, p53, STAT1, Max, Myc, ELK1, SMAD4, c-
Jun and STAT3, leading to gene transcription and generating cellular responses pertaining to 
inflammation, apoptosis, growth and differentiation (Weston and Davis, 2002; Zarubin and 
Han, 2005).  
 
1.1.1.1.3   ERK5 pathway: 
The ERK5 pathway is also activated by a variety of stimuli such as cellular stress, growth 
factors, mitogens and GPCR. ERK5, also referred to as BMK1, is solely activated by MEK5 
(Zhang and Dong, 2007) (Fig1.1).  MEK5 as well as its upstream activator MEKK2/3 possess 
an N-terminal PB1 domain that permits direct heterodimerization between the two enzymes 
which thus also defines the specificity of such interactions.  The PB1 domain on MEK5 also 
enables interactions with and hence activation of ERK5.  Activated ERK5 translocates to the 
nucleus whereby several transcription factors like c-Fos, MEF2, CREB etc. are activated to 
induce gene transcription (Turjanski et al., 2007).  Besides regulating cell growth and 
differentiation, ERK5 is also known to be involved in mammalian vasculogenesis and 
endothelial barrier functions (Hayashi and Lee, 2004; Regan et al., 2002).  
 
1.1.1.2   JAK/STAT pathway: 
A major pathway of the white blood cells, the JAK/STAT pathway, is known to transmit 
chemical signals from a variety of growth factors and cytokines to initiate gene transcription.  
JAKs bind to certain transmembrane receptors such as the cytokine receptors.  Ligand 
binding to the cytokine receptors leads to the activation of the bound JAKs which 
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phosphorylates tyrosine residues on the receptor (Hebenstreit et al., 2005) (Fig1.2).  These 
phosphorylated tyrosine residues then serve as binding sites for SH2 domain containing 
proteins such as STAT.  There are seven identified STAT proteins in mammals.  Upon 
binding to the receptor, STAT proteins are tyrosine phosphorylated by JAK which results in 
hetero/homo dimerization of the STAT proteins.  Such active STAT dimers then translocate 
to the nucleus where they initiate gene transcription.  Nonetheless, STAT activation via other 
receptor tyrosine kinases like EGFR or non–receptor tyrosine kinases like Src, also leads to 
similar outcomes (Hebenstreit et al., 2005).  Also, multiple avenues exist for the negative 
regulation of the JAK/STAT pathway.  For instance, tyrosine phophatases such as SHP1 or 
certain STAT competitors like SOCS which compete with STAT for binding to the cytokine 
receptors mediate feedback inhibition of the JAK/STAT signalling pathway (Krebs and 
Hilton, 2001; Xu and Qu, 2008).  The JAK/STAT pathway is known to affect cellular 
processes such as growth, proliferation, immune response and haematopoiesis (Hebenstreit et 
al., 2005). 
 
1.1.1.3   PI3K/AKT pathway: 
The activation of the PI3K/AKT cascade begins with signals transmitted from the cell surface 
receptors like the receptor tyrosine kinases, T and B cell receptors, integrins and cytokine 
receptors that trigger the production of phosphatidylinositol 3,4,5 triphosphate (PIP3) from 
phosphatidylinositol 4,5 bisphosphate (PIP2) via PI3 kinase (PI3K) (Carnero et al., 2008) (Fig 
1.3).  Such lipids serve as plasma membrane docking sites for the Pleckstrin Homology (PH) 
domain-containing proteins such as AKT (also known as Protein kinase B or PKB) and 
PDK1 (Carnero et al., 2008).  Binding to the plasma membrane positions AKT for 
phosphorylation by its activating kinases; mTORC2 and PDK1 which phosphorylate AKT at 
S473 and T308, respectively.  Once activated, AKT triggers the activation of several other 
cellular proteins including, but not limited to, mTORC1 and MDM2 (Manning and Cantley, 
2007).  Active mTORC1 phosphorylates and activates the 4E binding protein 1 (4E-BP1) and 
p70S6 kinase to initiate protein translation leading to cell growth.  AKT-mediated 
phosphorylation of MDM2 results in the degradation of the pro-apoptotic p53 protein which 
leads to cell survival (Manning and Cantley, 2007).  FOXO1 is another AKT target which 
upon phosphorylation is sequestered to the cytoplasm and effectively inhibited from exerting 
its transcriptional activity.  FOXO1 is known to regulate the transcription of several genes 
involved in apoptosis, DNA repair and cell cycle arrest. GSK3 is also inhibited by AKT 
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which leads to the translocation of -catenin to the nucleus where it enhances gene 
transcription of genes like cyclin D1 and c-myc, known to initiate the progression of cell 
cycle from the G1 to S phase (Dal Col and Dolcetti, 2008; Zhang et al., 2012).  Thus, the 
PI3K/AKT pathway is intrinsically linked to the regulation of cell  growth, proliferation as 
well as cell survival (Tzivion et al., 2011).  Signalling through AKT may be downregulated 
via PTEN that essentially dephosphorylates PIP3 to yield PIP2.  Thus PTEN is also 
considered a tumor suppressor (Georgescu, 2010). Direct dephosphorylation of AKT via such 
phosphatases as PHLPP 1/2 also serves as a mechanism of negative regulation of the pathway 
(Brognard and Newton, 2008). 
 
 
 
FIGURE 1.2: Schematic representation of the JAK/STAT pathway. Ligand stimulation, 
via growth factors or cytokines, triggers the autophosphorylation and hence the activation of 
the JAK kinases bound to cytokine receptors. Activated JAK kinases phosphorylate the 
cytokine receptors. Tyrosine phosphorylated sites on the receptor serves as binding sites for 
STAT proteins which, upon binding, are in turn phosphorylated by JAK kinases. Upon 
phosphorylation, STAT molecules undergo dimerization and nuclear translocation where the 
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activate dimers initiate gene transcription. Negative regulation of the JAK/STAT pathway is 
mediated by the actions of proteins like SOCS and SHP1.    
 
 
 
 
 
 
 
FIGURE 1.3: Schematic representation of the PI3K/AKT pathway. Ligand stimulation, 
via different growth factors or cytokines, triggers the production of PIP3 from PIP2 via PI3K 
activity. The docking of PDK1 to PIP3 activates PDK1 which phosphorylates AKT on T308 
which together with S473 phosphorylation via mTORC2 fully activates AKT. AKT 
activation then leads to the activation and/or inhibition of several downstream targets to 
promote cell survival, growth and proliferation. Shown here are some of the downstream 
effectors of AKT; MDM2, mTORC2, GSK3 and FOXO1.    
 
 
 
 
 
8 
 
1.1.2 Src- Family Kinases (SFKs): 
The Src family kinases comprise a prominent class of non-receptor tyrosine kinases, whose 
family members include: Src, Yes, Fyn and Fgr forming the SrcA subfamily and Lck, Hck, 
Blk and Lyn in the SrcB subfamily (Hanks and Hunter, 1995; Neet and Hunter, 1996).  While 
v-Src was one of the first viral onco-proteins studied with a well characterized tyrosine kinase 
activity (Smart et al., 1981), its cellular orthologue, c-Src was later identified in mammalian 
cells and shown to be proto-oncogenic (Oppermann et al., 1979).  c-Src maps to two 
chromosomal loci in humans, chromosome 1p36 and 20q13, both of which remain prone to 
genetic re-arrangements in malignancies (Le Beau et al., 1985; Parker et al., 1985).  The 
coding transcript of c-Src comprises eleven exons, a splicing pattern that remains highly 
conserved across the Src family hierarchy (Cetkovic et al., 2004; Kaplan et al., 1987)  (Fig 
1.4).  All SFKs share three conserved functional domains: a poly-proline-binding Src 
homology 3 (SH3) domain, a phosphorylated tyrosine-binding Src Homology 2 (SH2) 
domain and a tyrosine kinase domain (Fig 1.1).  All Src family kinases also contain either a 
myristoylation or palmitoylation signal in the N-terminus that mediates anchorage to the 
plasma membrane.  Phosphorylation of C-terminal Y527 in chicken c-Src by c-Src kinase 
(CSK) allows for an intra-molecular interaction of the C-terminal tail of Src with its SH2 
domain, thereby locking the enzyme in an inactive conformation.  This auto-inhibited 
conformation is further stabilized by intra-molecular interactions between the SH3 domain 
and the poly-proline sequence situated in the linker region, flanked by the SH2 & the kinase 
domains (Cooper et al., 1986; Liu et al., 1993; Superti-Furga et al., 1993; Xu et al., 1997) 
(Fig. 1.4).  Such an autoinhibitory state of Src was evidenced through other studies 
employing mutational analysis where deletions of either the SH3 or the SH2 domains resulted 
in mutants that exhibited substantially higher kinase activity as well as transforming potential 
as compared to the wild-type form (Seidel-Dugan et al., 1992). Interestingly, such deletion 
mutants were demonstrated to be hypophosphorylated at Y527, a condition that was believed 
to account for the higher kinase activity of these mutants.  Nonetheless, a later study 
demonstrated that despite induced phosphorylation at Y527 by c-Src kinase, these mutants 
did not exhibit reduced kinase activity.  This therefore suggests that the presence of 
intramolecular interactions is essential for the maintenance of the autoinhibited state of the 
kinase (Okada et al., 1993). 
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The residues of the SH2-kinase linker segment form a left-handed polyproline type II helix 
that is conformationally sandwiched between the SH3 domain and the N-terminal lobe of the 
kinase domain and has been shown to contribute to the negative regulation of kinase activity 
in Src (Xu et al., 1997).  Unlike Blk, Lyn and Lck, other members of the family, including c-
Src, possess only a single proline residue within the SH2-kinase linker segment that deviates 
from the consensus PXXP type motifs required for binding to the SH3 domain (Fig 4.10).  In 
c-Src the position of the other proline, in the PXXP arrangement, is occupied by Glutamine 
253 that packs against tyrosine 90 and tyrosine 136 within the SH3 domain, thereby yielding 
a characteristic class II binding orientation (Xu et al., 1997).  Additionally, the existence of a 
highly conserved tryptophan in the kinase linker region is known to stabilize an inactive 
conformation as studied in the Src family member, Hck (LaFevre-Bernt et al., 1998).  
Interestingly this tryptophan (W260) is positioned outside of the polyproline helix and 
interacts with the alphaC-helix of kinase domain, upon binding of the linker prolines to the 
SH3 domain, to sustain a catalytically inhibited state.  Furthermore, mutating this tryptophan 
also displaces the SH3 and SH2 domains, allowing them a greater ligand-binding surface for 
mediating substrate interactions (LaFevre-Bernt et al., 1998).   
              In contrast, phosphorylation on the Y419 residue, leaves the protein in an “open-
conformation”, otherwise referred to as the active conformation (Boerner et al., 1996).  Also, 
while substitution of the active site lysine residue; K298 (ATP contacting) with a  methionine 
inactivates the catalytic activity of Src kinase (Luttrell et al., 1996), the substitution Y527F 
yields a constitutively active variant of the protein (Kmiecik and Shalloway, 1987; Roskoski, 
2004). 
               The underlying biochemical events triggering such autophosphorylation and the 
consequent activation of the enzyme are mediated via a defined conformational re-
arrangement of the catalytic domain.  The crystal structure of Src has allowed for the 
structural characterization of the mode of activation of the enzyme (Cowan-Jacob et al., 
2005; Roskoski, 2004; Xu et al., 1999).  The structures studied have identified Src family 
kinase domains as containing two structural lobes; (i) The smaller N-terminal lobe comprised 
of a five-stranded-sheet and a crucial glutamic acid residue (at position 310 in human Src, 
and (ii) a larger C-terminal lobe that is as the primary site of interaction with substrate 
peptides and comprised primarily of -helices. 
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FIGURE 1.4: Schematic representations of c-Src, and FRK/PTK6 family kinases (BRK, 
FRK and SRMS). Src as well as FRK family kinases possess 3 functional domains, namely, 
the Src homology 3 (SH3), Src homology 2 (SH2) and the kinase domains. c-Src (both 
chicken and human orthologues) also possesses an N-terminal myristoylation signal. Shown 
here are the critical residues involved in the regulation of kinase activity of the enzymes. The 
autophosphorylation site in c-Src remains spatially conserved with that of BRK (Y342), FRK 
(Y387) and SRMS (Y380). Other residues that remain conserved include the carboxy 
terminus tyrosine residues, that negatively regulate catalytic activity in c-Src (Y530 and 
Y527 in chicken orthologue), BRK (Y447) and FRK (Y497), as well as the ATP-contacting 
lysine residues; K298, K219, K262 and K258, respectively. Also indicated are the highly 
conserved tryptophan residues within the SH2-kinase linker regions of these tyrosine kinases. 
These tryptophan residues have been implicated in the regulation active/inactive 
conformations of certain tyrosine kinases (LaFevre-Bernt et al., 1998; Qiu and Miller, 2004).   
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Between these lobes lies the active site (Williams et al., 1998).  In the inactive state, the SH3 
and SH2 domains remain associated with their respective intramolecular ligands 
(respectively, the polyproline sequence in the SH2-kinase linker segment and the regulatory 
tyrosine residue in the C-terminal tail region).  These interactions also serve to regulate the 
conformation of the Y416 containing-activation loop located within the C-terminal lobe as 
well as the alphaC-helix loop of the N-terminal lobe.  Typically, the SH3 and SH2 domains 
are conformationally stacked against the N and C-terminal lobes of the kinase domain, 
respectively (Fig 1.5).  The resulting interactions of the SH3 and SH2 domains with their 
intramolecular ligands thus lock the N and C-terminal lobes in an inflexile conformation that 
allows the activation loop to form an inhibitory helix (Fig 1.5 and 1.6).  The partially helical 
structure of the activation loop not only blocks the catalytic cleft of the kinase domain but 
also buries Y416, occluding access to ATP and thus preventing autophosphorylation.  Thus, 
an inactive state of the PTK is maintained.  However, the dephosphorylation of the C-
terminal tyrosine, Y527, and/or the binding of the SH3 and SH2 domains to target peptides 
relieve the conformational constraints imposed on the PTK resulting in increased 
accessibility of the catalytic cleft to the ATP substrate, which essentially occurs with the 
disruption of the helical structure of the activation loop (Cowan-Jacob et al., 2005; Roskoski, 
2004; Xu et al., 1999).    
             From a biochemical perspective, in the inactive state, the glutamic acid residue at 
position 310 interacts with an arginine at position 385, thereby stabilizing the alphaC-helix in 
an outward position which prevents the formation of a salt bridge with K295.  The 
dephosphorylation of Y527 and/or the binding of the SH3 and SH2 domains to the target 
peptides results in autophosphorylation at Y416.  Upon autophosphorylation, Y416 in the 
activation loop forms a salt bridge with R385, an event requiring the restructuring of the 
activation loop to a non-blocking conformation.  This restructuring of the activation loop 
confers structural flexibility to the alphaC-helix so as to allow the latter to swing inwards, 
promoting the formation of the critical salt bridge between E310 and K295, thus activating 
the kinase activity of Src (Fig 1.6) (Breitenlechner et al., 2005; Cowan-Jacob et al., 2005; Xu 
et al., 1999). 
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FIGURE 1.5: Schematic representation of c-Src depicting the conformational shift 
from an inactive to an active state.  (a) The SH3 and the SH2 domains are packed 
against the kinase domain with the  phosphorylated C-terminal tyrosine and the SH2-
kinase linker region serving as intramolecular ligands for the SH2 and the SH3 domains, 
respecively.  Consequently, a closed or inactive conformation is maintained with the 
inhibitory Activation-Loop (A-Loop) occluding access to ATP.  (b) Upon the 
dephosphorylation of the C-terminal tyrosine and/or the binding of the SH3/SH2 ligands 
from target peptides, the intramolecular associations are relieved and the “closed” 
conformation changes to an “open” conformation.  The A-Loop is disordered/destabilized 
and the autophosphorylation site is exposed.  (c) Access to ATP results in the 
autophosphorylation of the tyrosine residue, thus activating the enzyme. (Figure obtained 
with permission from (Xu et al., 1999)). 
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FIGURE 1.6: Schematic representation of the biochemical activation of c-Src.  (a) In the 
inactive state, the binding of the SH3 and SH2 domains to their intramolecular ligands results 
in the conformational rigidity of both the kinase lobes.  E310 within the N-terminal lobe 
forms a salt bridge with R385 which stabilizes an inactive position of the alphaC-helix.  (b) 
The phosphorylation of Y416 triggers a conformational switch, promoting Y416 to form a 
salt bridge with R385 and E310 to salt bridge with  K295, thus re-orienting the alphaC-helix 
in an inward position and activating Src.  (Figure adapted form (Young et al., 2001). 
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1.1.1.1 Src SH3 domain                               
The Src family SH3 domains are involved in intramolecular as well as intermolecular 
interactions. These SH3 domains are typically conserved in most proteins and span 
approximately 50-60 amino acids.  Such prototypical poly-proline-binding domains are 
known to be involved in the propagation of intracellular signalling cascades via interactions 
with proteins from several signalling networks (Pawson, 1994; Pawson and Gish, 1992).  The 
SH3 domain quintessentially binds to short proline-rich motifs on target proteins/ligands in a 
type II helical conformation.  Such motifs are typically sequenced X-P-X-X-P (where “P” 
refers to the Proline separated by two scaffolding residues “X”) (Feng et al., 1994; Lim et al., 
1994; Yu et al., 1994).   Furthermore, while two characteristic hydrophobic pockets on the 
SH3 domain’s ligand-binding groove connects to the X-P dipeptides, a third “specificity 
pocket” contacts the residues flanking the conserved prolines, consequently governing the 
orientation of the resulting interaction.  The “Specificity pocket” is as such negatively 
charged and interacts with a positively charged Arginine or Lysine on the ligand, facilitating 
two possible binding orientations; class I interactions wherein this typical residue lies N-
terminal to the conserved prolines in the sequence +x-X-P-X-X-P or class II interaction with 
the residue being positioned C-terminal to the same, X-P-X-X-P-x+ (Feng et al., 1995).   
                The SH3 domains fundamentally comprise two triple-stranded anti-parallel  sheets 
positioned at right angles to each other with certain conserved hydrophobic residues clustered 
together that participate in ligand-interaction (Erpel et al., 1995; Musacchio et al., 1992).  
Mutational analyses of the Src SH3 domain have identified key residues that are involved in 
ligand binding and recognition. Mutation of certain key residues in the two hydrophobic 
pockets of the chicken Src SH3 domain resulted in significantly reduced SH3-ligand 
interaction.  Such residues include Y92, W118, P133, Y136 and Y90 (Weng et al., 1995).  In 
Lck, Y90 is replaced with H70, which may be reflective of subtle variations in the binding 
affinities of SH3 domains (Erpel et al., 1995).  Likewise, residues that govern ligand 
selectivity were identified via similar mutational studies.  The third “specificity pocket” 
possesses two uniformly conserved residues, D99 and W118. Mutating D99 was specifically 
shown to reduce the binding of the mutant SH3 domain to p68 by 50% and exhibiting 
decreased associations with other SH3 binding proteins (Weng et al., 1995).  Other residues 
potentially involved in ligand selectivity are R95 and S94.  Mutation of these residues 
resulted in an elevated specificity of the Src SH3 mutant towards binding to p85.  Such 
mutations, however, resulted in decreased intramolecular interactions (Erpel et al., 1995). 
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1.1.1.2 Src SH2 domain      
The SH2 domains represent another class of highly conserved protein subunits that are found 
on a variety of signalling proteins dispersed across several signalling cascades (Grucza et al., 
1999; Sawyer, 1998).  These domains functionally recognize and bind to phosphorylated 
tyrosine residues on target proteins (Songyang et al., 1993).  Structural delineation has been 
accomplished for a broad spectrum of proteins including several members of the Src family 
kinases, which reveal a conserved architecture for the SH2 domain as comprising a five 
stranded anti-parallel -sheet core, clasped or sandwiched between two -helices and 
extended by a -strand and a small three-stranded  sheet spanning approximately 100 amino 
acids.  Peptides bind perpendicular to the central five stranded anti-parallel -sheet core.  
Such functional characteristics as ligand binding and selectivity have been attributed to two 
conserved pockets situated within the SH2 domains.  Studies have shown that the 
phosphotyrosine binding pocket comprises several positively charged residues, most critical 
of which is aconserved arginine residue (R175 in v-Src) that forms a part of the SH2 
“signature motif” FLVRES.  Mutation of this arginine residue alone results in significantly 
reduced phosphotyrosine binding in Src (Campbell and Jackson, 2003; Tian and Martin, 
1996).  Another substitution, W148E, was also shown to impair phosphopeptide binding of 
the Src SH2 domain (Bibbins et al., 1993).  The second pocket required for ligand 
recognition/selection contains residues that are less conserved and vary across different SH2-
containing proteins, thus conferring upon these proteins, distinct ligand-binding specificities 
(Campbell and Jackson, 2003).  Earlier studies screening the Src family SH2 domains against 
phosphopeptide libraries with varying residues at the X1, X2 and X3 positions within the pY-
X1-X2-X3 motif, revealed a strong selectivity for the pYEEI motif (Songyang et al., 1993).  
Mutating a conserved threonine, identified as T215 in Src, to tryptophan has been shown to 
alter the specificity of the Src SH2 domain, resulting in an increased preference for a pYVNV 
ligand instead of the putative pYEEI ligand.  Since the pYVNV motif serves as the preferred 
binding ligand for the Grb SH2 domain, the substitution, T215W, in the Src SH2 domain 
was, therefore, shown to biologically behave as the Grb SH2 domain (Pawson et al., 2001). 
                  More recently, a proteomics screen for phosphopeptides that bind to various Src 
family SH2 domains identified a characteristic pattern in the selectivity of the peptide motifs 
(Zhao et al., 2013).  Through the use of binding assays using a generic phosphopeptide motif, 
TAXXpYXXXLNBBRM (where “LNBBRM” represents the C-terminal linker conjugating 
the phosphotyrosine peptide to the beads and used towards facilitating peptide release and 
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mass spectral analyses), randomized for amino acid residues in the “X” positions, the Src 
SH2 domain was specifically shown to exhibit substantial preference for binding to peptides 
containing either a threonine or an alanine at the +1 position (Table 1.1).  At the +2 position 
and +3 positions, specificity was significantly favoured towards a methionine and an 
isoleucine, respectively.  However, at the -1 and the -2 positions, a tyrosine and a histidine 
residue was favoured, respectively (Zhao et al., 2013).  Interestingly, a significant divergence 
could be inferred between the SH2 domain specificities of Src and FRK/PTK6 family 
kinases. Specifically, while Src preferred threonine and methionine residues at the P+1 and 
P+2 positions of the phosphopeptides, respectively, FRK/PTK6 family kinases exhibited a 
relatively similar specificity towards glutamic acid and isoleucine residues at the same 
positions (Table 1.1). 
 
1.1.2 FRK/PTK6 family Kinases 
The FRK/PTK6 family kinases is comprised of four non-receptor tyrosine kinases namely, 
BRK (PTK6), FRK (PTK5), SRMS (PTK70) and Src42a/Dsrc41 with the latter being 
identified as a tyrosine kinase belonging to Drosophila melanogaster (Serfas and Tyner, 
2003).  These four tyrosine kinases have been clustered together in a single family owing to a 
significant similarity in their intron-exon structures.  Like their Src family counterparts, 
members of the FRK/PTK6 family kinases are composed of the classic SH3, SH2 and the 
kinase domains (Serfas and Tyner, 2003).  While the former two domains aid in the 
interaction of these kinases with other proteins targets, the latter confers a catalytic function 
to these, thereby defining their roles as intracellular enzymes and at the same time 
distinguishing these from the other classes of enzymes.  The focus of the subsequent sections 
will be on BRK, FRK and SRMS.  
                The FRK/PTK6 family kinases lack myristoylation and palmitoylation signals, a 
unique feature that is critical for membrane association of Src family kinases.  At the 
genomic level, BRK, FRK and SRMS are  evolutionarily conserved.  The fact that their 
intron-exon structures remain highly conserved with one another, and to a lesser degree with 
that of the Src family members, is a primary reason for their incorporation into a distinct 
family of non-receptor tyrosine kinases.  All three tyrosine kinases possess 8 exons  and 
reflect conserved splicing boundaries that differ from those of Src family kinases (Serfas and 
Tyner, 2003) (Fig 1.7).  
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TABLE 1.1 SH2 domain specificities of Src and FRK/PTK6 family kinases. The SH2 
domain specificities of Src, BRK, FRK and SRMS  as determined by Zhao et al.  using 
phosphopeptide motif TAXXpYXXXLNBBRM (Zhao et al., 2013)., Randomized residues 
are denoted by “X” .  
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FIGURE 1.7: Schematic representation of the Intron-Exon splicing pattern of the 
FRK family (BRK, FRK and SRMS) and Src family kinases.  The FRK family 
kinases possess 8 exons.  This differs from the Src family kinases as shown for Fyn and 
Src kinases which have 11 exons.  Thus, the FRK family not only displays a diverging 
splicing pattern but also an unequal number of introns and exons as compared to the Src 
family.  (Figure adapted from (Serfas and Tyner, 2003)). 
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BRK and FRK have been extensively characterized for their structural and functional 
characteristics.  Furthermore, several substrates/ binding partners have been identified and 
characterized for the two tyrosine kinases.  However, the third member of the FRK/PTK6 
family, SRMS, remains scarce to date.  Indeed, information pertaining to its structural, 
biochemical and functional characteristics is either absent or limited.  The same holds true for 
its substrate-specificity.  Nonetheless, in recent published reports, efforts to determine the 
identity of the novel kinase’s potential substrates (Takeda et al., 2010) and, specifically, its 
SH2 domain recognition motifs (Zhao et al., 2013), have yielded valuable information that 
can potentiate further biochemical and functional research on the kinase.  The subsequent 
sections shall extensively review background information on BRK, FRK and SRMS. 
 
1.1.2.1 Breast tumor kinase (BRK) 
1.1.2.1.1 Gene discovery and organization 
BRK, pronounced as “Berk”, is also referred to by its other synonym, PTK6 whose murine 
ortholog is designated as Sik (Src-like intestinal kinase) (Lee et al., 1993; Llor et al., 1999).  
The gene was first identified as one amongst 25 other novel tyrosine kinases expressed in 
cultured human melanocytes that were surveyed via reverse transcriptase-polymerase chain 
reaction (Lee et al., 1993).  In subsequent studies, the full length BRK cDNA was identified 
and cloned from the breast carcinoma cell lines MCF7 and T47D (Mitchell et al., 1994) and 
later, from a human intestinal cDNA library (Llor et al., 1999).  Through fluorescence in situ 
hybridization (FISH) analysis, the gene encoding BRK has been assigned to chromosome 
20q13.3 in humans and chromosome 2 in mice (Llor et al., 1999; Park et al., 1997).  The 
BRK transcript is composed of eight exons however only the boundaries between exons 1/ 2 
(separating exons coding for the SH3 and the SH2 domains) and 7/ 8 (separating the exons 
encoding the C-terminal region of the kinase domains) remain conserved with members of 
the Src family (Lee et al., 1998; Mitchell et al., 1997) (Fig 1.4).  This becomes particularly 
interesting since BRK otherwise shares nearly 44% amino acid sequence identity with 
members of the Src family.  Furthermore, of the total seven BRK exon boundaries, six are 
conserved with the structurally related Drosophila Src gene, Dsrc41, which itself possesses 
nine exons.  This presents clues about both the genes sharing a common evolutionary 
ancestor or origin (Mitchell et al., 1997).  All in all, the genetic locus of BRK spans about 10 
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kb in comparison to the 20 kb region held by Src (Anderson et al., 1985; Mitchell et al., 
1997). 
              The human BRK gene also encodes an alternate transcript that is spliced 
differentially.  Such a transcript, designated ALT-PTK6 and originally referred to as Lambda 
m5, encodes a 134 amino acid (15 kDa) protein comprising only the N-terminal region fused 
with the SH3 domain and a unique C-terminal tail abundant in proline residues.  A 
consequence of alternative splicing, such an event leads to the omission of exon 2 thereby 
causing a shift in the open reading frame and a termination 172 bp 3′ of the transcript (Brauer 
et al., 2011; Mitchell et al., 1997).                
               Preliminary analysis of the BRK gene promoter revealed a region roughly 800 bp 
upstream of the translation start site to contain nearly 60% of the SV40 promoter activity.  
This region displays critical cis-acting elements including those for Sp1, the STAT1 and three 
binding c-sis-inducible elements (SIE), AP2 and NFkB.  Further studies on this 813 bp BRK 
promoter sequence disclosed two specific regions; -93 to -76 bp proposed as the minimal 
promoter region and the distal -702 to -655 bp region determined to contain the two cis-
acting elements needed for binding to NFkB and Sp1 (Kang et al., 2002). 
 
1.1.2.1.2 Protein structure and activation 
BRK is a 451 amino acid protein that comprises the prototypical SH3, SH2 and the kinase 
domains (Fig 1.8).  While the SH3 domain is composed primarily of -sheets (Koo et al., 
2002), the SH2 domain consists of an / fold and a tyrosine peptide binding surface with 
two of the  helices arranged opposite to each other on the central -sheet (Hong et al., 2001; 
Hong et al., 2004).  Though the calculated molecular weight of protein is 52 kDa, BRK is 
typically found to electrophoretically migrate at around 48 kDa via conventional SDS PAGE 
techniques.    
                   Studies published by Qiu et al. in 2002 and 2004 have described the biochemical 
characterization of BRK in extensive detail (Qiu and Miller, 2002, 2004).  Their studies 
investigated the regulation of the enzymatic activity of BRK via the intramolecular 
interactions involving the SH3 and the SH2 domains with their respective intramolecular 
ligands that reside within the protein.   Analogous to Src, while the selective 
autophosphorylation at Y342 enhanced the catalytic activity via stabilizing the active or the 
“open” conformation of the enzyme, phosphorylation of Y447 had an opposite effect.  
Besides Y342, other tyrosine residues that are phosphorylated on BRK include Y13, Y61, 
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Y66, Y114 and Y351 and may affect effect enzyme activity (Qiu and Miller, 2002) (Fig 1.8).  
A mutation at K219 renders BRK “kinase-dead” since this lysine is required for ATP-
binding.  Likewise, a mutation at the autophosphorylation site Y342 rendered the kinase 
catalytically inactive.  However, mutating the Carboxy terminal Y447 has a pronounced 
effect on enhancing the activity of the kinase via abrogating the catalytically inactivating 
intra-molecular interaction between the SH2 domain and the peptide containing the tyrosine 
(Qiu and Miller, 2002, 2004).   
                    Other critical residues involved in such an “autoinhibitory” interaction include 
the three prolines residues P175, 177 and 179 residing in the N-terminal side of the SH2-
kinase linker region that bind to the SH3 domain and W44 that lies within the SH3 domain 
and initiates contact with the linker region (Kim et al., 2007; Ko et al., 2009; Qiu and Miller, 
2002).  These residues preserve the autoinhibitory conformation of BRK, and mutating these 
to alanine result in increased enzymatic activation of BRK (Qiu and Miller, 2002).  
Specifically, the SH3 domain amino acids reported to be involved in such autoinhibitory 
interactions with the linker region are R22, W44, N65 and Y66, which upon mutation result 
in elevated catalytic activity of BRK (Ko et al., 2009) (Fig 1.8).  Deleting the SH3 and the 
SH2 domains individually also results in a higher kinase activity of BRK as demonstrated via 
autophosphorylation status as well as phosphorylation of the physiological substrate of BRK, 
Sam68.  This suggests the existence of an autoinhibited state of BRK owing to intra-
molecular associations, that when relieved, result in an upregulated kinase activity (Qiu and 
Miller, 2004).  W260 in Src family member, Hck sustains a catalytically inhibited state 
(LaFevre-Bernt et al., 1998).  However, in stark contrast to W260 of Src family member Hck, 
the analogous W184 in BRK plays a pivotal role in the stabilization of the active 
conformation of the kinase domain.  This suggests that unlike Src, the conserved tryptophan 
in BRK interacts in a different manner with the kinase domain (Kim and Lee, 2005; Qiu and 
Miller, 2004). 
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FIGURE 1.8: Schematic representation of BRK.  Schematic diagram of BRK depicting its 
various functional domains; the SH3, SH2 and the kinase domains as well as the critical 
residues involved in the regulation of tyrosine kinase activity. Shown here are the ATP-
contacting K219 and the primary autophosphorylation site, Y342, as well as other tyrosine 
residues known to be autophosphorylated in BRK, namely, Y13, Y61, Y66 and Y114. The 
residues contributing to autoinhibition of catalytic activity in BRK are Y447 and the SH2-
kinase linker residues P175, P177 and P179 which are known to establish intramolecular 
interactions with the SH2 domain and residues R22, W44 and N65 within the SH3 domain, 
respectively. 
 
 
 
 1.1.2.1.3 Expression profile in breast cancer 
In Normal cells: 
As early as 1995, Vasioukhin and colleagues described the expression of the BRK ortholog, 
Sik, to be prevalent in the epithelia of the murine skin and the alimentary canal and its 
expression was found to be exclusive to the renewing epithelial cells in these regions 
(Vasioukhin et al., 1995).  Later studies aimed at delineating tissue-specific BRK expression 
also confirmed its expression in the gastrointestinal tract which, upon exposure to ionizing 
radiation, exhibited a marked increase in not only the villus epithelial cells, but also in the 
crypt compartment of the small intestine (Haegebarth et al., 2009).   Specifically, BRK 
expression was seen in the gastrointestinal tract epithelial cells undergoing terminal 
differentiation (Llor et al., 1999).  Furthermore, BRK was notably expressed in the epithelial 
lining of the colon as well as that of the prostate, accompanied by a dominant nuclear 
expression in the latter case (Derry et al., 2003; Llor et al., 1999).  Other reports classify 
BRK expression to normal activated T-cells as well as the cutaenous T-cell lymphomas and 
transformed T and B-cell populations, characterized by a consistent nuclear localization 
pattern (Kasprzycka et al., 2006). The expression of BRK has also been documented in 
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keratinocytes where it exerts a regulatory role in calcium-induced keratinocyte differentiation 
process (Tupper et al., 2011; Vasioukhin and Tyner, 1997; Wang et al., 2005). 
                    With such a diverse expression profile in normal cells and tissues, it is interesting 
that BRK is not expressed in the normal mammary tissues or fibroadenomas (benign breast 
lesion), while persistently overexpressed in the majority of breast carcinomas in humans 
(Barker et al., 1997; Llor et al., 1999). 
 
In Breast carcinoma 
Published reports have shown that BRK, while being low or completely absent from normal 
mammary tissues, is overexpressed in nearly 86% of breast carcinomas (Aubele et al., 2007; 
Barker et al., 1997; Ostrander et al., 2007).  In a study aimed at determining the cause of 
BRK overexpression from a panel of 426 invasive breast carcinomas, it was discovered that 
BRK gene copy number is increased in 45% of such breast tumors with greater than two 
signals obtained per nucleus via FISH analyses. Furthermore, while gene amplification was 
evidenced in only 15% of these tumors, polysomy of chromosome 20 was seen in nearly 30% 
of the same.  Nonetheless, a clear statistical and quantitative association between the BRK 
gene and its corresponding mRNA or protein could not be drawn (Aubele et al., 2009). 
 
1.1.2.1.4 BRK activation in breast cancer 
1.1.2.1.4.1   Activation 
Besides the ability of BRK to activate via autophosphorylation (Castro and Lange, 2010), 
there are a number of ligands that can trigger the kinase’s activation.  This is primarily due to 
the fact that BRK is involved in several signalling pathways activated by a plethora of ligands 
such as EGF, HGF, IGF etc. that bind to their respective cell surface receptors, thereby 
initiating the activation of several downstream targets, one of which is also BRK.  For 
instance, compared to the control, BRK was shown to enhance the growth properties of the 
MCF10A cell line in response to EGF stimulation (Kamalati et al., 1996).  Additionally, in 
another study that identified IRS-4 as its binding partner, IGF stimulation was shown to 
enhance BRK activation in the MCF7 breast cancer cell line (Qiu et al., 2005).  Furthermore, 
an activator of the Met receptor, HGF (Hepatocyte Growth Factor) stimulation was also 
shown to increase BRK kinase activity, by over two folds, in the MDA-MB-231 and T47D 
breast cancer cell lines (Castro and Lange, 2010).  Since the signalling pathways activated by 
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these ligands tend to promote cell proliferation and migration, it is not surprising that 
activation of BRK downstream in the signalling pathway mechanistically drives oncogenesis. 
 
1.1.2.1.4.2   Negative regulation of activity 
In a recent study, SOCS3 (Suppressor of cytokine signalling 3), was shown to inhibit BRK 
activation through its association with BRK via its SH2 domain.  SOCS3 primarily augments 
the degradation of BRK, an event mediated mainly by its kinase inhibitory region (KIR) (Gao 
et al., 2012). 
                  Overexpression of Sam68 (the Src-Associated substrate in Mitosis of 68 kDa) in 
rat astrocytes was shown to inhibit BRK induced cell cycle progression (Lukong et al., 2005).  
This hinted towards a negative-regulatory role of Sam68 towards BRK and is suggestive of a 
mechanism by which BRK activity might be modulated in cells with elevated levels of the 
Sam68 protein.  
 
1.1.2.1.5 Substrates/binding partners 
 The number of BRK binding partners highlights the potential of the kinase in regulating a 
diverse array of signalling pathways in vivo.  The association of BRK with all four members 
of the ErbB family (ErbB1/2/3/4) has been shown to regulate mammary tumor progression 
and growth through stimulation via such growth factors as EGF and Heregulin (Kamalati et 
al., 2000; Kamalati et al., 1996; Ostrander et al., 2007; Xiang et al., 2008).   Some of the 
early physiological substrates of BRK namely, Sam68, Slm1, Slm2 as well as PSF 
(Polypyrimidine tract-binding protein associated splicing factor) are RNA binding proteins 
which show reduced RNA binding following phosphorylation by BRK (Derry et al., 2000b; 
Haegebarth et al., 2004).  BRK also phosphorylates signal transducing adapter family 
member 2 (abbreviated as STAP-2 and also known as BKS) and indirectly affects cell 
proliferation and differentiation via the subsequent STAP-2 mediated phosphorylation and 
activation of STAT3 and STAT5 (Ikeda et al., 2009; Ikeda et al., 2010; Mitchell et al., 2000).  
                    The association of Insulin-like growth factor receptor 1R (IGF-1R) with BRK 
also holds significance since the former is expressed in many breast cancer subtypes and is 
linked to poor prognoses (Irie et al., 2010).  Regulation of IGF-1R expression and activity by 
BRK modulates anchorage-independent survival of breast and ovarian cancer cells via the 
suppression of caspase-mediated apoptosis (Irie et al., 2010).  Furthermore, insulin receptor 
substrate-4 (IRS-4) has also been established as a BRK binding partner and the association 
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with IRS-4 as well as BRK activity was shown to be enhanced upon IGF-1 stimulation in 
MCF-7 breast cancer cells (Qiu et al., 2005).  ARAP1 (Arf-GAP, Rho-GAP, ankyrin repeat, 
and pleckstrin homology (PH) domain-containing protein 1) was another BRK substrate 
identified recently which, upon phosphorylation by BRK, was shown to down-regulate EGFR 
levels in the BT-474 and T47D breast cancer cell lines (Kang et al., 2010).  
                 Moreover, BRK was also found to complex with AKT in the T47D breast cancer 
cell line upon EGF stimulation (Zhang et al., 2005).  In another study, BRK was shown to 
directly phosphorylate AKT on tyrosines 315 and 326, resulting in an unequivocal 
enhancement of cellular proliferation in response to EGF stimulation in the mouse embryonic 
cell line, SYF (Zheng et al., 2010).   
                  Other associating partners of BRK have been found in the Adamalysins family of 
transmembrane proteins, abbreviated as ADAM (Zhong et al., 2008). Of the four 
alternatively spliced products of the ADAM15 gene, BRK has been characterized to bind 
strongly to ADAM15A and ADAM15B with modest binding to ADAM15C.  While the 
expression of the ADAM15 protein varies significantly amongst breast cancer cells as 
compared to normal mammary cells, higher levels of its two alternatively spliced forms, 
ADAM15A and ADAM15B, have been correlated with poor relapse-free survival in node-
negative patients as opposed to elevated ADAM15C levels correlating with a better relapse-
free survival in node-positive patients (Zhong et al., 2008).   
                 An important component of the Wnt signalling pathway, -catenin, was also 
characterized as a bona fide substrate of BRK. The Wnt/-catenin signalling plays a 
prominent regulatory role in the growth of several types of cancers (Beildeck et al., 2010; 
Robinson et al., 2008).  The phosphorylation of -catenin by BRKcauses a significant drop in 
the transcriptional activity of the -catenin (Palka-Hamblin et al., 2010).  Furthermore, as 
studied in the SW620 human colorectal cancer cell line and mouse intestines, whereas 
nuclear-targetted BRK was found to negatively regulate -catenin/T-cell Factor (TCF) 
mediated transcription, membrane targeted BRK displayed an opposite effect (Palka-Hamblin 
et al., 2010).  Interestingly, even the alternatively spliced variant of BRK, ALT-BRK, has 
been shown to bind to -catenin, but more importantly, has been implicated in enhancing 
BRK-mediated transcriptional repression of -catenin (Brauer et al., 2011).   
                Very recently, a study ascribed the role of BRK to the formation of peripheral 
adhesion complexes via phosphorylation of p130CAS (CRK associated substrate), a protein 
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that condenses at focal adhesions within cells (Zheng et al., 2012a).  p130CAS was validated 
as a direct substrate of BRK and phosphorylation of the same by the membrane-targeted form 
of the kinase, was shown to induce cell migration through ERK5 activation (Zheng et al., 
2012a).   Reminiscent of the role of BRK in cell migration, phosphorylation of its other direct 
substrate, paxillin, upon EGF stimulation was also shown to regulate a similar metastatic 
invasion in cancer cells via GTPase Rac1 activation (Chen et al., 2004).   
                  In a separate publication, Focal adhesion kinase (FAK) was discovered as a 
bonafide substrate of BRK via mass spectrometry analysis of BRK-phosphorylated targets in 
the human SW620 colon cancer cell line (Zheng et al., 2012b).  BRK was shown to activate 
FAK via direct phosphorylation in the murine SYF cell line, thereby protecting the cells from 
contact inhibition-mediated growth suppression.  Furthermore, while knock-down of BRK 
down-regulated FAK activation, exogenous restoration of the latter conferred resistance to 
anoikis (programmed cell-death resulting from the detachment of anchorage-dependent cells 
from the extra-cellular matrix) in the PC3 prostate cancer cell line, demonstrating the 
significance of BRK in suppressing cellular anoikis (Zheng et al., 2012b). 
 
1.1.2.1.6 Cellular roles: proliferation and migration  
1.1.2.1.6.1 Cell proliferation 
That BRK is overexpressed in the majority of breast carcinomas is a good reason to 
investigate its role as an oncoprotein.  Indeed, BRK has been well characterized for its 
prominent role in inducing cell proliferation and regulating cell cycle progression in breast 
carcinomas, substantiating its function as an oncoprotein (Brauer and Tyner, 2010).   In one 
of the early published reports highlighting the involvement of BRK in cell growth, it was 
shown that the BRK-transfected human mammary cell lines, Hb4a and MCF10A, exhibited 
an increase in their growth properties following EGF stimulation (Kamalati et al., 1996).  The 
same study also described a significant transforming potential of BRK since the Hb4a and 
mouse fibroblast, NIH3T3, cell lines both demonstrated the ability to grow in an anchorage-
independent manner following stable transfection with BRK.  Relevant to these results, in a 
very recent study, it was demonstrated that BRK directly phosphorylates tyrosine 845 on 
EGFR and confers resistance against cetuximab (an antibody against EGFR) (Li et al., 2012).  
This has important implications since EGFR activation via ligand stimulation leads to cell 
proliferation (Schlessinger and Ullrich, 1992; Tajeddine and Gailly, 2012; Vieira et al., 
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1996).  In the non-tumorigenic cell line MCF10A, BRK was also shown to associate with 
ErbB2, a receptor tyrosine kinase belonging to the EGFR family, and induce cell proliferation 
via the activation of the Ras/MAPK pathway (Xiang et al., 2008). 
                  Another study revealed that phosphorylation of P190-RhoGAP-A (p190) by BRK 
elicits an increase in cellular proliferation in the MCF7 breast cancer cell line by inducing the 
formation of a complex between p190 and p120RhoGAP (p120). This results in the 
stimulation and attenuation of p190 and p120 functions, respectively (Shen et al., 2008).  
Other researchers have also described a direct role of BRK towards cell proliferation.  BRK 
has been shown to directly phosphorylate AKT on tyrosines 315 and 326, thereby activating 
the serine/threonine protein kinase and potentiating cell proliferation in response to growth 
factor stimulation (Zheng et al., 2010).  Under conditions of EGF and heregulin stimulation, 
breast cancer cell lines such as T47D, MCF7 and MCF10A showed enhanced endogenous 
BRK autophosphorylation resulting in cell proliferation via the activation of Rac GTPase, 
extracellular signal regulated kinase 5 (ERK5) and p38 mitogen-activated protein kinase 
(MAPK) (Ostrander et al., 2007).  The involvement of canonical adaptor proteins such as that 
of STAP-2 in BRK-induced cell proliferation has also been investigated.  Robust tyrosine 
phosphorylation of STAP-2 by BRK was shown to initiate the activation of STAT3 as well as 
STAT5b and promote increased transcriptional activity and proliferation in breast cancers 
(Ikeda et al., 2011; Ikeda et al., 2010). Relevant to its role in enhancing cell proliferation, it 
was also discovered that the suppression of BRK in breast carcinoma induces autophagic cell 
death while the ectopic expression of the same was found to enhance cell survival (Harvey et 
al., 2009). 
                     The oncogenic function of BRK was attributed to its cytosolic/membrane 
localization, while an antagonistic (tumor suppressive) role was ascribed to its nuclear 
containment (Ie Kim and Lee, 2009).  For instance, while incorporation of a myristoylation 
signal leading to membrane localization caused BRK to promote cell proliferation and 
migration via enhancing -catenin transcription and Wnt/-catenin signalling, a nuclear 
distribution of the kinase inhibited such functions (Palka-Hamblin et al., 2010).  However, 
the nuclear distribution of BRK may not necessarily correlate with anti-tumorigenic effects. 
For instance, the co-localization of BRK with Sam68 in Sam68-like nuclear bodies (SNBs) 
within the nucleus results in reduced RNA binding properties of Sam68, a functional 
characteristic that is believed to be a mechanism by which BRK contributes to oncogenecity 
(Derry et al., 2000b; Lukong et al., 2005).  Furthermore, cellular re-distribution may not 
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always be limited to BRK as an outcome of target protein phosphorylation, but also to the 
target protein itself.  For instance, BRK was shown to phosphorylate and yield a cytoplasmic 
re-localization of PSF from the nucleus and which subsequently lead to cell cycle arrest 
(Lukong et al., 2009).  
                    Other functions of BRK have been noted in DNA damage/apoptosis. For 
instance, BRK overexpression was found to sensitize rat fibroblast cells to conditions of 
stress (serum starvation) and apoptotic stimuli (UV radiation) (Haegebarth et al., 2005).  
However, in a very recent study BRK knockdown displayed enhanced apoptosis upon UV 
radiation in colon tumor cells (Gierut et al., 2012).  Interestingly, there are also reports of a 
tumor suppressive role of BRK in esophageal carcinoma with BRK expression determined to 
be downregulated in tumorigenic tissues derived from the larynx and esophagus compared to 
matched adjacent normal tissues (Liu et al., 2013; Ma et al., 2012).  
 
1.1.2.1.6.2 Cell migration 
Besides positively regulating cellular proliferation in breast carcinomas, BRK can also 
influence the cells’ migratory properties.  Upon EGF stimulation, BRK is activated by EGFR 
resulting in the phosphorylation of paxillin specifically at tyrosines 31 and 118.  The cellular 
ramifications of such a post-translational modification on paxillin involve the binding of 
CRKII to paxillin resulting in the activation of Rac and the formation of lamellipodia leading 
to cell motility/migration (Chen et al., 2004).  Other factors causing BRK-mediated cell 
migration involve the stimulation of cells via such ligands as Heregulin, EGF and HGF 
(Castro and Lange, 2010; Chen et al., 2004; Ostrander et al., 2007).  Phosphorylation of 
p190RhoGAP by BRK also results in an enhanced chemotactic migration of cells as studied 
in mouse embryonic fibroblasts (Shen et al., 2008).  Furthermore, its physiological substrate, 
KAP3A (kinesin superfamily-associated protein 3) was also shown to necessitate BRK-
induced cell migration in the BT20 breast cancer cell line (Lukong and Richard, 2008). 
 
 
1.1.2.1.7 Mouse models 
The role of BRK in tumor formation has been investigated through comprehensive studies on 
mouse models. Such animal models have proved invaluable towards deciphering the function 
of BRK in the context of tumorigenesis.  Intriguingly, BRK null (knockout) mice displayed 
characteristics of enhanced cellular proliferation and growth, in the enterocytes of their small 
 
 
29 
 
intestines as compared to their BRK-positive counterparts (Haegebarth et al., 2006).  
Additionally, consistent with its role in promoting cell differentiation, intestinal samples 
derived from such BRK knockout mice also showed delayed expression of the differentiation 
marker I-FABP (Intestinal fatty acid binding protein) (Haegebarth et al., 2006).  These results 
are however indicative of a growth-inhibitory role of BRK, consistent with this group’s prior 
data.  
                  In a more recent publication, in vitro results demonstrating the ability of BRK to 
suppress cellular anoikis was confirmed in in vivo experiments using xenograft mouse 
models.  Sub-cutaenous injection of SYF cells over-expressing membrane-targeted BRK 
(designated Palm-BRK-YF), into nude mice, led to the formation of tumors 4 weeks post-
injection (Zheng et al., 2012b).  This, therefore, validates the novel means by which BRK 
induces oncogeneis in transformed cells via suppressing anoikis. 
                  Transgenic mouse models exhibiting an inducible BRK targeted expression in the 
mammary gland have been developed and characterized for tumorigenesis.  The effects of 
targeted wild type BRK expression in mouse mammary glands was studied on involution and 
tumor formation as well as the associated signalling pathway through which such oncogenic 
functions are manifested.  It was found that BRK overexpression resulted in delayed 
involution of the mammary glands and early tumor growth via the p38 MAPK cascade 
activation (Lofgren et al., 2011).  In a subsequent study which examined the oncogenic 
function of a constitutively active variant of BRK, it was reported that the stable expression 
of Y447F (constitutively active variant) BRK in the MDA-MB-231 breast cancer cells 
resulted in a higher rate of cell proliferation as well as migration, in comparison to wild-type 
BRK (Miah et al., 2012).  Furthermore, in vivo results from xenograft mouse models also 
indicated the need for the full activation of BRK to promote a malignant phenotype (Miah et 
al., 2012). 
 
1.1.2.2 Fyn-related Kinase (FRK) 
1.1.2.2.1 Gene discovery and organization 
Another member of the FRK/PTK6 family kinases, FRK, is also known as PTK5.  As early 
as 1993, attempts to identify novel tyrosine kinases in the human breast cancer cell line 
PEI600 as well as in primary breast carcinoma, led to the discovery of FRK (then designated 
as TK1, for tyrosine kinase 1) (Cance et al., 1993).  Endeavours to further characterize this 
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505 amino acid protein also brought about its new designation, RAK, which is a Russian 
word for “cancer” (Cance et al., 1994).  The protein displayed 49% amino acid sequence 
similarity to the human proto-oncogene FYN kinase and was therefore termed Fyn-Related 
Kinase (FRK) (Lee et al., 1994).  Besides being expressed in breast carcinomas, such as the 
breast cancer cell line BT20 and the LS180 colon cancer cell line, FRK was also found to be 
expressed in epithelial cells of the human kidney and liver while being absent from the cells 
of mesenchymal origin such as that of the skeletal muscle (Cance et al., 1994).  FRK maps to 
chromosome 6q21-q22.3 in humans (Brauer and Tyner, 2009) within a region that is 
atypically destabilized by loss of heterozygosity (LOH) in nearly 48% of breast tumors 
(Sheng et al., 1996) as well as malignant melanomas (Becher et al., 1983a; Becher et al., 
1983b).  
                  The identification and expression profile of the murine orthologs of FRK have 
also been documented and account for its varied nomenclature.  Designated IYK (Intestinal 
tyrosine kinase) or BSK (beta-cell Src-homology kinase), murine FRK was cloned from the 
mouse pancreatic cell line, RINm5F (Oberg-Welsh and Welsh, 1995) as well as the mouse 
mammary gland (Thuveson et al., 1995).  Northern blot analysis and RT-PCR techniques 
confirmed the expression of the genes in the kidney, liver, lung as well as the intestines 
(Oberg-Welsh and Welsh, 1995; Thuveson et al., 1995).  Another FRK homologue, named 
GTK (Gut tyrosine kinase), was cloned from the small intestine in rats and also displayed a 
similar expression pattern (Sunitha and Avigan, 1994, 1996).  However, the focus of this 
section shall rest primarily with the human form of the kinase and referred to as FRK for 
simplicity.  
                  As mentioned in the previous sections, like SFK’s as well as BRK and SRMS, 
FRK also possesses all three functional domains, i.e., the SH3, the SH2 and the kinase 
domain.  A unique feature in FRK is the presence of a nuclear localization signal (NLS) 
within the SH2 domain.  Such a bipartite motif, organized in two clusters of basic amino 
acids and separated by a spacer of nine amino acids, has the characteristic sequence: 
KRLDEGGFFLTRRR.  The motif was shown to dictate nuclear localization of endogenous 
FRK in the monkey kidney cell line, COS7 (Cance et al., 1994).  Other reports indicated that 
in the lactating normal human breast tissues, the proliferating epithelial cells display a 
predominant cytoplasmic localization of FRK, while a more prominent nuclear distribution 
was noted in the post-menopausal epithelial cells (Kaplan et al., 1987).  In a study aimed at 
investigating the biological implications of ectopic IYK expression in the murine fibroblast 
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cell line NIH3T3, it was shown that a C-terminal mutation, Y497F, conferred upon the 
protein the ability to re-localize to the nucleus since the wild type protein was predominant 
only in the cytosolic sub-cellular compartment (Oberg-Welsh et al., 1998).  In a subsequent 
report, these findings were corroborated in another experimental cell line, the murine 
pancreatic RINm5F cell line (Anneren and Welsh, 2000).  In yet another study, the deletion 
of the NLS-containing SH2 domain was shown to cause a diffuse cytoplasmic localization of 
FRK as opposed to the perinuclear distribution of the ectopically expressed wild-type protein 
(Meyer et al., 2003).  Whereas deletion of the SH3 domain did not impact sub-cellular 
localization, mutation of the ATP-contacting lysine (K262) residue lying within the kinase 
domain yielded a punctate-perinuclear distribution of FRK in the BT474 breast cancer cell 
line (Meyer et al., 2003).  However, even as FRK possesses a nuclear localization motif, it 
lacks a plasma membrane-directing myristoylation signal, a feature found in its murine 
homologue (Serfas and Tyner, 2003).  
 
1.1.2.2.2 Protein structure and activation 
The 1.9 kb cDNA of FRK encodes a 505 amino acid protein with a molecular weight of 
roughly 54 kDa.  The orientations of the functional domains, namely, SH3, SH2 and the 
kinase, remain conserved with BRK and SRMS and these domains do not deviate from their 
respective modes of action, although ligand specificity may vary.   In comparison to BRK, 
FRK has been only modestly characterized for its enzymatic activity.  The earliest reports of 
intrinsic FRK kinase activity came from a study that also identified the protein.  Through an 
in vitro kinase assay using 
32
P, performed on immunoprecipitated FRK from the BT20 breast 
cancer cell line, it was shown that the wild-type kinase demonstrated the capability of 
autophosphorylation and also immunospecificity towards an anti-phosphotyrosine antibody, 
thereby presenting itself as a functional tyrosine kinase (Cance et al., 1994).  The study had 
identified Y387 as the putative autophosphorylation site in FRK (Cance et al., 1994).  
Experimental corroborations were illustrated in another study aimed at investigating the 
enzymatic ramification of point-mutations made in the carboxy-terminus of FRK’s highly 
homologous relative, IYK.  Analogous to c-Src, IYK possesses a tyrosine- Y497 in addition 
to another Y504, in its C-terminal region (Fig 1.9).  Like Src and BRK, the presence of a 
spatially conserved tyrosine (Y504) in the C-terminal region of IYK is expected to exert a 
regulatory effect on its enzymatic activity, via binding to the SH2 domain upon 
phosphorylation.  The study supported this hypothesis, noting that while Y504F (single) and 
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Y504F/Y497F (double) mutations on IYK resulted in increased autophosphorylation, Y497F 
alone did not appreciably exhibit such an increase in intrinsic kinase activity, in comparison 
to the wild-type protein (Anneren and Welsh, 2000; Oberg-Welsh et al., 1998).  A subsequent 
report characterized the catalytic activity of FRK.  The study published that while the 
deletion of the SH2 and SH3 domains had no impact on the autophosphorylation of FRK, 
mutation of a single lysine (K262R) within the kinase domain rendered the protein 
catalytically inactive (Meyer et al., 2003). 
                 CSK was originally  identified to phosphorylate members of the Src family kinases 
and down-regulate their enzymatic function (Nada et al., 1991; Okada et al., 1991; Okada 
and Nakagawa, 1989; Partanen et al., 1991; Sabe et al., 1992).  Cance and colleagues remain 
the only group to date to highlight CSK (c-Src kinase) as a potential regulator of FRK kinase 
activity (Cance et al., 1994).  Through the generation of four disparate peptides matching the 
carboxy terminus tail of FRK, but individually mutated for each of the four tyrosines Y450, 
Y463, Y490 and Y497, it was determined in an in vitro kinase reaction that CSK 
demonstrates a greater phosphotransfer affinity towards Y497 over the other tyrosines and 
that this could potentially confer a regulatory effect on the catalytic activity of FRK (Cance et 
al., 1994).  
 
1.1.2.2.3 Substrates/binding partners 
To date, PTEN and EGFR remain the sole authenticated substrates of FRK, even as there 
have been reports of several binding partners.  Furthermore, minimal information regarding 
SH3/SH2 interactions of FRK with its binding partners, hinders the understanding of the 
cellular functions of FRK.  Nonetheless, the FRK SH2 domain has been recently 
characterized for its ligand specificity.  Through a proteomics study encompassing binding 
assays coupled with mass spectrometry analyses, it was shown that for a given 
phosphotyrosine-containing ligand, the FRK SH2 domain prefers a glutamic acid or cysteine 
residue at the P+1 position (where “P” refers to the phosphotyrosine residue) while at the P+3 
position, an isoleucine is favoured in addition to a cysteine (Zhao et al., 2013) (Table 1.1).  
Preceding the phosphotyrosine residue, a methionine or a tyrosine residue is favoured at the 
P-1 position on the ligand.  While there exists a certain degree of overlap in the positional 
variation in amino acids between FRK, SRMS and BRK, certain residues as described above 
define the characteristic preference of the FRK SH2 domain in establishing distinct 
interactions with specific ligands/binding partners (Zhao et al., 2013).  
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FIGURE 1.9: Schematic representation of FRK.  Schematic diagram of the human and 
mouse variants of FRK depicting the various functional domains; the SH3, SH2 and the 
kinase domains as well as the critical residues involved in the regulation of tyrosine kinase 
activity, namely the ATP contacting K262 (K269 in IYK), the autophosphorylation site, 
Y387 (Y394 in IYK) and an autoinhibitory tyrosine residue, Y497 (Y504 and Y497 in IYK), 
within the C-terminus of FRK. Also shown is W227 (conserved with W234 in IYK), situated 
within the SH2-Kinase linker segment, which is highly conserved amongst Src family kinases 
as well as BRK and SRMS and has been reported to be involved in the regulation of the 
active/inactive conformation of certain tyrosine kinases.  
 
Interestingly, with FRK, the canonical SH3 and SH2 domains were recently shown to 
function in a manner distinct from BRK as well as the Src family.  While individual deletion 
of the FRK SH3 or the SH2 domains did not influence the interactions of the tyrosine kinase 
with EGFR, composite deletion of both domains together resulted in diminished associations 
with EGFR, thus suggesting a cooperative mechanism of functioning by both, the SH3 and 
SH2 domains (Jin and Craven, 2013). 
                     The human retinoblastoma protein, abbreviated pRb, was the first documented 
binding partner of FRK and primarily accounted for the association of a potential tumor 
suppressor function to the non-receptor tyrosine kinase. pRb, a tumor suppressor (Benedict et 
al., 1983), possesses two protein binding pockets: the larger A/B pocket, which has been 
shown to interact with proteins such as E2F and cyclin D (Weinberg, 1995) and a smaller C 
pocket reported to interact with the c-Abl tyrosine kinase (Welch and Wang, 1993).  It is 
through the A/B pocket that FRK associates with pRb (Craven et al., 1995).  However, the 
biological significance of such a binding interaction is not clear with only minor speculations 
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of FRK’s greater proximity to other cellular substrates via pRb association being noted (Yim 
et al., 2009b).   
                 PTEN, another tumor suppressor, was reported as a bonafide FRK substrate in a 
study that not only characterized the mechanistic association between the two proteins but 
also decoded a functional relevance of the same (Yim et al., 2009a).  FRK was shown to 
phosphorylate PTEN specifically on Y336, upon binding, requiring the FRK SH3 and the 
PTEN C2 domain.  Thus, via phosphorylation, FRK was also shown to stabilize PTEN by 
protecting PTEN from the cell’s degradative machinery involving poly-ubiquitination (Yim 
et al., 2009a). 
                  In a recent report, it was shown that FRK enhances EGFR phosphorylation at 
Y1173 while suppressing its phosphorylation at Y1068 (Jin and Craven, 2013).  Such site-
specific and direct phosphorylation of EGFR by FRK was depicted to result in the 
internalization of the cell surface-bound EGFR (Jin and Craven, 2013).  
                  Other binding partners reported for FRK include CDC2 and Cdk4 (Pendergast, 
1996).  While evidence in support of this information remains absent from the literature, it 
was nonetheless only mentioned in a study on nuclear tyrosine kinases that FRK associates 
specifically with CDC2 and Cdk4 and not with Cdk5, Cdk6 or Cdk7 (Pendergast, 1996).   
Furthermore, the functional significance of such interactions also remains unexplored. 
                In another study evaluating the physiological significance of GTK (an FRK 
homologue), its exogenous expression was demonstrated to correlate with both the 
quantitative enhancement as well as the phosphorylation of several protein targets to induce 
neurite outgrowth in the mouse PC12 cell line, upon nerve growth factor stimulation 
(Anneren et al., 2000). These include proteins such as Focal Adhesion Kinase (FAK), SHB 
(an adapter protein that stands for Src homology 2 protein of Beta cells) and TrkA (a 
neuronal receptor).  However, their molecular interactions with GTK were not determined in 
the same report.  A subsequent article further reported on the functioning of FRK upstream of 
SHB towards enhancing PC12 cell differentiation and beta-cell proliferation (Anneren et al., 
2003). 
 
1.1.2.2.4 Expression profile in breast cancer 
In Normal cells: 
While varying mRNA levels were detected, via Northern blot analysis, in the epithelial 
tissues derived from the adult human liver, muscle, kidneys and pancreas, expression of the 
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corresponding protein was observed only in the kidney and liver (Cance et al., 1994).  A later 
study suggested that while significant FRK mRNA expression was observed in the normal 
tissues derived from the lungs, a minimal expression was also seen in liver tissues (Chen et 
al., 2013).  Moreover, FRK expression was also reported in the normal human breast 
epithelial tissues (Berclaz et al., 2000). 
 
In Breast carcinoma: 
Unlike BRK, FRK expression in the multitude of breast carcinomas remains poorly 
characterized.  The only investigation on its expression pattern in breast cancer comes from 
the group which also identified the protein.  The first reports of FRK expression came from 
the human breast cancer cell lines, SKBR3, BT-20 and PEI600 including primary breast 
tumors (Cance et al., 1994; Cance et al., 1993; Craven et al., 1995).  Other reports from 
analyses on a panel of 21 invasive breast carcinoma samples revealed either a complete loss 
or significantly diminished expression of FRK compared to normal breast tissues (Berclaz et 
al., 2000).  Subsequent studies also reported on the presence of FRK transcripts in the MDA-
MB-468 and MCF-10A breast-derived cell lines (Yim et al., 2009a; Yim et al., 2009b).   
              Additionally, FRK expression was also illustrated in the colon cancer cell lines; 
LS180 and Colo205 as well as the hematopoietic tumor cell lines, K562 and HL60 besides 
being detectable in the human lymphoma cell line U937 and a rhabdomyosarcoma (RD) cell 
line (Cance et al., 1994).  FRK has also been characterized as an aberrantly overexpressed 
protein in hepatocellular carcinoma (Chen et al., 2013). 
 
1.1.2.2.5 FRK activation in carcinomas 
Cance and colleagues showed via immunoprecipitation that in the metastatic liver tumors, 
FRK is highly autophosphorylated (Cance et al., 1994).  This not only correlated with the 
expression levels of the protein, but also contradicted the condition observed in the normal 
colonic tissues and those obtained from primary tumors where a limited expression of FRK 
paralleled a low autophosphorylation status (Cance et al., 1994).  Nonetheless, the underlying 
mechanism governing such activation of the kinase is yet to be explored. 
 
1.1.2.2.6 Cellular roles- proliferation and migration 
Even in the absence of adequate data on FRK, compelling evidence is available to support its 
status as a potential tumor suppressor.  Oberg-Welsh and colleagues reported that ectopic 
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expression of its constitutively active mutant, harbouring a double mutation in its C-terminus 
region (Y497F/Y504F), resulted in an impaired/reduced cellular proliferative rate in the 
NIH3T3 cell line in comparison with cells transfected with either the wild type or the kinase-
dead mutant (K269A) (Oberg-Welsh et al., 1998).  FRK was shown to exhibit such a function 
via regulating cell cycle progression as evidenced from cell cycle analysis as well as 
quantitative measurement of exogenous thymidine (methyl-
3
H) incorporation into the DNA 
of actively dividing cells (Oberg-Welsh et al., 1998).  These findings suggest the non-
receptor tyrosine kinase as a negative regulator of cell proliferation.  As well, in their 
subsequent publication, the group demonstrated that the overexpressed IYK mutants, Y504F 
and Y497F/504F also negatively impacted cellular proliferation rates in the rat pancreatic cell 
line, RINm5F by promoting cell cycle arrest in the G1 phase besides modulating glucagon 
synthesis via inducing an increase in the mRNA levels of IYK (Anneren and Welsh, 2000).  
Furthermore, such ectopic expression of IYK was also found to sensitize the cells to cytokine 
induced cell death (Anneren and Welsh, 2000).  However, an interesting feature noted in both 
studies was the association between the nuclear distribution of IYK and its inhibitory effect 
on cell proliferation.  
                Another early study that also identified pRb as its first binding partner in the 
SKBR3 breast cancer cell line, provided possible biological basis for the tumor suppressive 
function of FRK (Craven et al., 1995).  The association between active pRb and FRK in the 
G1 and S phases of cell cycle and not in the Mitotic phase, together with the knowledge of 
sporadic mutations in the A/B pocket (site for FRK binding) of pRb in several cancers, 
suggested a potential mechanism supporting the tumor suppressive role of FRK (Craven et 
al., 1995).  
              Another major study revealed that while the sub-cellular distribution of FRK in the 
normal human breast tissues was hormone-dependent; the expression of the kinase was lost in 
malignant breast carcinomas (Berclaz et al., 2000).  Immunohistocytochemical analysis of 
breast tissue sections obtained at different stages of the menstrual cycle showed a strong 
cytoplasmic staining of FRK during the more proliferative follicular and luteal phases in 
contrast to the predominant nuclear distribution of the kinase post-menopause.   Furthermore, 
such dependence on the estrogen-progesterone hormonal status was virtually lost in breast 
cancer where diminished expression of FRK was seen in the invasive carcinomas (Berclaz et 
al., 2000).  Results from this investigation not only reinforced the significance of the nuclear 
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localization of the kinase for mediating a growth-inhibitory effect but also partially reasoned 
the maintenance of proliferative abilities in breast carcinomas.  
               Direct evidence, in the context of FRK-mediated attenuation of cell proliferation, 
was also presented by another group which demonstrated that in the BT474 and MCF7 breast 
carcinoma cell lines, ectopic FRK resulted in growth arrest in the G1 stage of cell cycle and 
that such an outcome was dependent on its kinase activity since its kinase-inactive mutants 
exhibited a null effect on cellular proliferation (Meyer et al., 2003).  Furthermore, it was also 
noted that the ability of FRK to down-regulate cell proliferation in these cell lines was 
independent of pRB association (Meyer et al., 2003).   
                 Negative regulation of cellular proliferation via PTEN stabilization is a concept 
that was recently put forth (Yim et al., 2009a).  The study reported that FRK stabilizes the 
potent tumor suppressor PTEN by phosphorylating it on Y336, thereby protecting PTEN 
from ubiquitin-mediated proteasomal degradation.  Furthermore, the same study also 
demonstrated that the in vitro knockdown of FRK in the non-tumorigenic MCF10A breast 
epithelial cell line was sufficient to transform the cells via PTEN degradation, thus ascribing 
a bonafide tumor-suppressive role to FRK (Yim et al., 2009a). 
              More recently, in a novel discovery of the signalling pathway associated with FRK 
functions, Zhou et al., presented evidence for the role of FRK in suppressing glial cell 
tumorigenesis (Zhou et al., 2012).  While FRK mRNA and its associated protein levels were 
found to be low in the glioma tissues as compared to their non-tumorous brain counterparts, 
scratch test as well as three-dimensional invasive assays conducted on the U251 and U87 
glioma cell lines, demonstrated the ability of ectopic FRK to suppress cell migration and 
invasion.  Furthermore, FRK was shown to potentiate such tumor-suppressive effects via 
suppressing JNK and consequently, c-Jun phosphorylation (Zhou et al., 2012).  Another 
study supporting the tumor-suppressive role of FRK, described the mechanistic potential of 
the tyrosine kinase in phosphorylating EGFR at the cell-surface, thus triggering the 
internalization of the receptor (Jin and Craven, 2013).  Since EGFR overexpression is 
implicated in cellular oncogenesis (Bhargava et al., 2005; Rimawi et al., 2010), FRK-
mediated downregulation of the surface-bound receptor population could potentially suppress 
the propagation of signalling pathways involved in cell proliferation and migration.   
                 In another interesting discovery from the genome of a chronic leukemia patient, a 
chimeric fusion of the FRK protein with the oncogenic ETV6 transcription factor was 
reported as a consequence of an unusual in-frame mutagenic union between exon 4 of the 
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ETV transcript and exon 3 of FRK (Hosoya et al., 2005).  The chimerically fused protein was 
found to be biologically active as evidenced not only by its ability to transform the Baf3 and 
NIH3T3 murine cell lines in a kinase dependent manner, but also by the observation of 
tyrosine autophosphorylation within the protein as well as the direct phosphorylation of 
histone targets H2B and H4.  Furthermore, its intrinsic kinase activity together with its 
inhibited capacity in inducing ETV-mediated transcriptional repression, collectively support 
the involvement of the chimeric protein in leukemogenesis (Hosoya et al., 2005).  
                Nonetheless, contrasting a widely speculated cancer-antagonistic role of FRK, there 
was the recent discovery of the expression and correlation of FRK in hepatocellular 
carcinoma (HCC) (Chen et al., 2013).  In their study, Chen et al. reported on the generation 
of a comprehensive, web-based tumor-associated gene (TAG) database to facilitate the 
exploitation of cancer gene annotation.  The results of the investigation demonstrated that 
both, the mRNA transcript as well as the protein levels of FRK were more than twice the 
normal levels in over 50% of HCC tissue samples.  Furthermore, an in vitro invasive ability 
of FRK was witnessed in the human liver cell lines, HepG2 and Hep3B as monitored in a 
matrigel invasion assay since FRK- knockdown HepG2 cells exhibited diminished migration 
over its FRK-overexpressing counterpart (Chen et al., 2013).  Nevertheless, that FRK 
overexpression correlates with HCC in a manner analogous to BRK and breast cancer is not 
quite surprising.  FRK has been previously documented for its elevated expression in breast 
carcinomas as well as colon cancers (Armistead and Thorp, 2002; Cance et al., 1994).  
Hints towards the involvement of FRK’s other homologue, GTK, in cellular differentiation 
stemmed from the observation of an unusual concentration of the active kinase at the 
membrane borders of the epithelial cells, lining the murine small intestine.   The observation 
of such in vivo localization of the hepatocyte growth factor (HGF)-stimulated enzymatically 
active kinase, at all stages of cellular maturation, suggested a mode of signalling that could 
potentially promote gut epithelial cell differentiation in rats (Sunitha and Avigan, 1996).  
However, another study reported IYK deficient mice (IYK knockout mice) to be generally 
devoid of phenotypic variations. Specifically, no alterations were observed in the intestinal 
brush border epithelial morphology, suggesting an expendable need for IYK in intestinal cell 
differentiation, results that contrast those of Sunitha et al. (Sunitha and Avigan, 1996).  Yet, 
overexpressed GTK was also found to enhance FAK, TrkA and SHB phosphorylation via 
Rap1 activation to promote cellular differentiation in the PC12 murine cell line (Anneren et 
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al., 2000).  Therefore, while in vitro evidence exists for a positive outcome for FRK in 
cellular differentiation, in vivo results seem elusive and need further investigation. 
 
1.1.2.2.7  Mouse models 
Mouse models for FRK/IYK have been described in several studies.  Nonetheless, while only 
a few of them address tumor/cancer biology, the majority of such investigations direct 
attention towards other functional consequences that appear to be tissue-specific.  
                In one of the first reports characterizing IYK knockout mice, IYK deficiency 
yielded no obvious phenotypical deviations in the mice litter (Chandrasekharan et al., 2002).  
Such mice were viable, healthy and fertile and survived without developing any physiological 
deficits.  However, such loss of IYK expression was compensated by elevated RNA levels of 
certain Src family kinases (SFK) like c-Src and YES in the colonic and intestinal cells 
(normal sites of basal IYK expression in normal/wild-type mice), indicative of a 
compensatory role of SFK’s towards IYK.  This apart, a significant reduction of over 80%  in 
the circulatory levels of the T3 thyroid hormone was also detected in these mice 
(Chandrasekharan et al., 2002).  However, while being apparently redundant due to the 
absence of phenotypical changes in these mice, IYK functions need further investigation. 
                 Other IYK-null mice were developed in a series of studies that were focussed on 
assessing an endocrinological impact of FRK.  Even in the absence of observable 
physiological changes in IYK-null mice, subsequent studies managed to discover subtle 
deviations from a normal phenotype.  For instance, FRK-deficient mice were reported to 
exhibit a marked reduction in pancreatic cell number in the embryonic and early post-natal 
stages of their life-cycle (Akerblom et al., 2007).  These reports gained momentum from two 
separate investigations employing GTK-overexpressing transgenic mice.  Mice expressing a 
kinase active (Y504F) mutant of GTK, not only exhibited increased pancreatic -cell mass 
and area but such extracted islets also demonstrated a pronounced sensitivity to cytokine-
mediated cell death upon exposure to IL-1 and ILF-(Anneren and Welsh, 2001).  
Furthermore, elevated phosphorylated levels of ERK1/2 with a concomitant activation of 
mitogen activated protein kinase, were hallmarks exclusive to the transgenic pancreatic islets 
as opposed to the controls (Anneren and Welsh, 2001).  In the other study that also examined 
the ramifications of Src Homology 2 protein of Beta cells (SHB) in rat endocrinology, the 
GTK overexpressing transgenic litter exhibited increased -cell proliferation to levels 
comparable with those of SHB overexpressing mice.  As well, an enhanced chemical 
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sensitivity to the toxin Streptozotocin (STZ) was observed, which potentiated -cell loss and 
an impaired glucose tolerance in these mice (Anneren, 2002).  Taken together, these results 
demonstrate a positive role for GTK in -cell proliferation, yet a concurrent accession in 
sensitivity to cytokines leading to -cell loss also indicates an impact of the tyrosine kinase in 
type-I Diabetes (Anneren, 2002; Anneren and Welsh, 2001, 2002).  Consolidating results 
were also presented in a subsequent study, wherein such transgenic mice demonstrated 
reduced islet blood flow per islet volume, a condition that accompanied a physiological 
reduction in the pancreatic capillary lumen diameter as well as a type-II diabetic condition as 
evidenced from reduced in vivo insulin secretion (Anneren et al., 2007).  
                  In the only mouse model generated to date to progress knowledge on FRK’s anti-
tumorigenic armament, control MCF-10A cells injected into the mice mammary glands, 
failed to produce tumors, while FRK-knockdown MCF-10A cells led to tumor development 
in as early as 3 weeks post injection (Yim et al., 2009a).  Similarly, mice injected with 
control MCF7 cells developed tumors in 8 weeks whereas those injected with the FRK-
overexpressing cells remained tumor-free.  With these experimental results, FRK was 
deemed a bonafide tumor suppressor (Yim et al., 2009a).  
                However, as progressive knowledge on FRK’s role in the propagation of 
intracellular signalling cascades becomes available, further supporting investigations are 
anticipated to be conducted in vivo, employing specific repertoires of mouse-models with 
targeted gene disruptions or transgene introductions, akin to the types described above.   
 
1.1.2.3 Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal 
myristoylation sites (SRMS) 
 
1.1.2.3.1 Gene discovery and organization  
The third member of the FRK/PTK6 family, PTK70 or SRMS (Src Related tyrosine kinases 
lacking C-terminal Regulatory tyrosine and N terminal Myristoylation Sites) (pronounced 
“shrims”) is the least characterized of the three and a relatively new protein kinase to be 
discovered.  SRMS was first reported by Kohmura et al.  in their attempt to elucidate the 
genes that regulate the growth and differentiation of neuroepithelial cells (Kohmura et al., 
1994).  The gene encoding SRMS maps to chromosomal locus 20q13.33 in humans and 2.1 
cM distal to locus D2Mit25 in mice which are conserved regions that lie adjacent to the 
PTK6 genetic locus (Kohmura et al., 1994).  That this gene maps to a region conserved 
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around PTK6, indicates that both genes may interact genetically.  While SRMS bears 
functional units similar to the members of this family, its enzymatic activity, substrate 
specificity as well as its physiological function have not been characterized yet.  The 54 kDa 
protein spanning 488 amino acids harbors an SH3, SH2 as well as a protein kinase domain; a 
structural framework common to both, BRK and FRK (Fig 1.10).  However, unlike BRK and 
FRK, SRMS lacks a C-terminal regulatory region and has an extended N-terminal region (Fig 
1.6). Furthermore, sequence homolgy also predicts K258 and Y380 as the potential ATP-
contacting and autophosphorylation sites, respectively (Fig 1.10). 
 
1.1.2.3.2 Expression in tissues  
Through Northern blot analyses, SRMS expression was detected in the various murine 
tissues, with highest expression being observed in the lung, testes and liver (Kohmura et al., 
1994).  While a moderate expression pattern was observed in murine spleen, kidney and 
ovary, the lowest level was seen in the intestine, muscle, thymus, heart, cerebellum and 
cerebrum (Kohmura et al., 1994).  A subsequent study also characterized the expression of 
SRMS in the murine skin with the highest detectable levels observed in the epidermis and in 
the murine keratinocyte cell lines as compared to those derived from melanomas (Kawachi et 
al., 1997). 
 
 
   
FIGURE 1.10: Schematic representation of SRMS.  Schematic diagram of SRMS 
depicting its various functional domains; the SH3, SH2 and the kinase domains as well as the 
critical residues that are conserved with Src and FRK/PTK6 family kinases, and predicted to 
be involved in the regulation of tyrosine kinase activity. These are K262 and Y387 as the 
potential ATP-contacting and autophosphorylation sites, respectively. Also shown is W223, 
situated within the SH2-Kinase linker segment, which is highly conserved amongst Src 
family kinases as well as BRK and FRK and has been reported to be involved in the 
regulation of the active/inactive conformation of certain tyrosine kinases.  
 
 
 
 
 
42 
 
1.1.2.3.3 Substrates and binding partners 
Intriguingly, while a multitude of substrates have been identified and extensively studied for  
BRK with a reasonable number of binding partners/substrates reported for FRK as well, no 
SRMS substrate has been characterized to date.  However recently, Takeda et al., described a 
proteomics study which revealed for the first time, the novel potential substrates of the Src 
family kinases including SRMS (Takeda et al., 2010).  The study was conducted with an aim 
to shed light on the substrate-specificity of the various human Src family kinases on a 
common platform. The research, predominantly based on a customized high-throughput in 
vitro kinase assay, examined a total of 519 unique substrates, utilizing mass spectrometry 
analysis for subsequent protein identification. The results of the comprehensive analysis 
categorized 11 prominent Src family Kinases including SRMS, into three groups; the first one 
indicating maximal substrate-specific interactions while the third one exhibiting limited 
substrate interactions. The potential substrate hits were ranked based on their relative 
substrate-specificity towards CRK (an adapter protein also designated as p38) as a common 
target. Although this study ascribed SRMS to the third group, a fair number of potential 
substrates were identified (Table 1.2).  Dok1 was identified as one of the potential targets of 
SRMS in the highthroughput proteomic assay (Takeda et al., 2010).   
              Recognition of the SRMS SH3/SH2 ligands may provide vital cues about the 
substrate selectivity pattern of SRMS.  Information on the SH2 binding interactions of SRMS 
became available with a recent proteomics study (Zhao et al., 2013) (Table 1.1).  From a 
composite library of phosphotyrosine peptides screened against the SH2 domains of several 
tyrosine kinases, the SRMS SH2 domain recognition motifs were identified in ligands 
possessing hydrophobic residues at the P+3 position (where P is the phosphotyrosine).  
Specifically, it was noted that the SRMS SH2 domain favours binding to peptides distinctly 
possessing a phenylalanine or a methionine besides a cysteine residue common to BRK and 
FRK, at the P+3 position.  At the P+1 position, the SRMS SH2 domain displays preferential 
selectivity for a histidine in addition to a glutamic acid residue as with BRK and FRK.  
Likewise, at the P-1 position, SRMS SH2 prefers a histidine or a tyrosine residue with the 
latter being a common choice, at the same position, for both BRK and FRK (Zhao et al., 
2013). 
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1.1.2.3.4 Mouse models 
In an attempt to potentially uncover the physiological functions of the novel kinase, 
homozygous SRMS-knockout mice were generated.  Such transgenic mice did not exhibit a 
change in the phenotype (Kohmura et al., 1994).  These SRMS-deficient mice were 
determined to be viable and fertile with normal off-springs and no apparent histological 
abnormalities in the body organs (Kohmura et al., 1994).  A similar observation was later 
made for BRK-deficient mice by Tyner and colleagues as well (Haegebarth et al., 2006).  
 
TABLE 1.2 List of the potential substrates of SRMS identified by Takeda et al., 2010. 
 
 
 
 
 
S.No FLJ ID Accession 
no. 
Protein name Category Relative 
activity 
(CRK 
=1) 
Rank 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
FLJ95985 
FLJ31382 
FLJ54992 
FLJ80078 
FLJ42825 
FLJ81679 
FLJ81679 
FLJ83777 
FLJ90539 
FLJ38194 
FLJ53493 
FLJ23495 
AK315002 
AK055944 
BC013200 
BC013200 
AK124815 
BC053532 
BC001718 
BC065912 
AK075020 
AK095513 
AK295613 
AK027148 
Tom1 like 1 
Dok1 
Tom1 like 1 
Lck 
CRK associated substrate 
CRK associated substrate 
CRK 
ARG 
SYK 
Disabled 1 
HEF-like protein 
NEK11 
 
Adapter molecule 
 
Tyrosine Kinase 
Adapter molecule 
Adapter molecule 
Adapter molecule 
Tyrosine Kinase 
Tyrosine Kinase 
Adapter molecule 
HisKa Domain 
S/T kinase 
2.05 
1.68 
1.52 
1.22 
1.10 
1.05 
1.00 
0.84 
0.43 
0.39 
0.26 
0.26 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
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1.2 Downstream of tyrosine kinase (Dok) family proteins 
The Dok family of proteins comprises seven members; Dok1 –Dok7.  That these proteins are 
phosphorylated downstream of several tyrosine kinases is a primary reason attributing to its 
nomenclature, Downstream of tyrosine kinases (Dok).  The structures of all seven members 
of the Dok family remain highly conserved with each possessing two N-terminal functional 
domains, namely, a Pleckstrin homology (PH) domain and an Insulin receptor substrate (IRS) 
type phosphotyrosine binding (PTB) domain (Niu et al., 2006; Shi et al., 2004).  The PH 
domain has a sequence length of about 120 amino acids and is organized into 2 anti-parallel 
Beta sheets together with a C-terminal amphipathic helix.  Through its documented 
interactions with the phosphatidylinositol lipids of the biological membranes such as 
phosphatidylinositol (3,4,5)-trisphosphate and phosphatidylinositol (4,5)-bisphosphate (Wang 
and Shaw, 1995) as well as the beta-gamma heterotrimeric G proteins (Wang et al., 1994) 
and protein kinase C (Yao et al., 1994), the PH domain plays a role in recruiting proteins to 
different cellular membranes and enables their interaction with components of different 
signalling pathways.  The IRS type PTB domain, on the other hand, is 112 amino acid 
residues long and is structurally similar to the PH domain in which a beta sandwich is capped 
by an alpha helix (Zhou et al., 1996).  PTB domains characteristically bind to 
phosphotyrosine-containing ligands with the sequence; NPXpY, where “X” represents any 
amino acid (Yaffe, 2002).  IRS1 is known to bind to the autophosphorylated insulin receptor 
via the PTB domain which further leads to the phosphorylation of IRS1 and the subsequent 
recruitment of other SH2 containing signalling proteins (Yaffe, 2002).              
               Even as the structural topology of the seven Dok proteins remains extensively 
conserved, the genetic loci  of the Dok family members are spatially unclustered across the 
human genome, suggesting limited genetic linkage between the respective Dok genes.  The 
genetic loci and the corresponding protein size for each of the seven members are; Dok1: 
2p13.1 (481 amino acids and 52.3 kDa), Dok2: 8p21.3 (412 amino acids and 45.3 kDa), 
Dok3: 5q35.3 (496 amino acids and 53.2 kDa), Dok4: 16q21 (326 amino acids and 37 kDa), 
Dok5: 20q13.2 (306 amino acids and 35.4 kDa), Dok6: 18q22.2 (331 amino acids and 38.3 
kDa) and Dok7: 4p16.3 (504 amino acids and 53 kDa).   
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1.2.1 Cellular and physiological roles of Dok1 proteins 
The Dok family proteins generally regulate a diverse set of physiological functions with 
Dok1-Dok3 functioning synergistically towards suppressing several intracellular signalling 
pathways thereby promoting a tumor suppressive role in vivo. (Berger et al., 2010; Mashima 
et al., 2009; Niki et al., 2004; Yasuda et al., 2004).  The noted exception comes from a recent 
study that reported on the contrasting roles of Dok1 and Dok2 in CD200 receptor signalling 
(Mihrshahi and Brown, 2010).  Upon CD200 ligand stimulation, Dok1 and Dok2 recruit 
diverse downstream proteins, with Dok1- CrKL (CT10 sarcoma oncogene cellular 
homologue-like) interaction negatively regulating the Dok2-mediated CD200R signalling 
cascade (Mihrshahi and Brown, 2010).   
                       Dok4 was also identified as a negative regulator of ERK signalling as well as 
T-cell activation with its PH domain implicated in the cytoplasmic shuttling of the protein 
(Gerard et al., 2009).  Furthermore, the presence of a shortened C-terminal tail extending 
from the PTB domain as well as a rare single nucleotide polymorphism, R186H, within the 
same domain in Dok4, was shown to diminish its molecular interactions with Ret kinase and 
potentially yield a rare Dok4-related phenotype in humans, respectively (Hooker et al., 2012).  
Dok5 expression, as determined by its transcriptional regulator FOXO3a, has been shown to 
correlate with cardiomyocyte differentiation (Wen et al., 2009) and also promote neurite 
outgrowth in the mouse Neuro2A cells (Cai et al., 2003; Grimm et al., 2001).  Additionally, 
Dok5, as a substrate of TrkB and TrkC (Tropomysin related kinase) also leads to the 
upregulation of the MAPK pathway upon neurotrophin stimulation (Shi et al., 2006).  Like 
Dok5, Dok6 is also a substrate of the TrkC receptor and has also been shown to promote Ret-
mediated neurite outgrowth in murine cortical neurons (Li et al., 2010). 
                  The newest member of the Dok family, Dok7 was identified as a critical 
component in the muscle-specific tyrosine kinase (MuSK) mediated post-synaptic 
specialization of the neuro-muscular junction.  In vivo studies demonstrated that mice 
deficient for Dok7 display impaired MuSK activation in muscle cells, thereby attesting to the 
role of Dok7 in the regulation of neuromuscular synapse formation (Okada et al., 2006).  
Furthermore, a spectra of Dok7 mutations have also been identified in patients diagnosed 
with congenital myasthenia syndrome (CMS).  Such mutations in the Dok7 gene have been 
reported to cause aggressive general impairments in the motor functions of the muscles 
including those of the eyes, jaws and limbs (Palace et al., 2007; Srour et al., 2010).  
Nonetheless, clinical treatment through the oral administration of Salbutamol, a β(2)-
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adrenergic receptor agonist, has been used as a therapy against congenital myopathy with 
proven efficacy in adult and children (Burke et al., 2013). 
 
1.2.2 Downstream of tyrosine kinase 1 
The Docking protein 1 (Dok1/p62) is a scaffolding protein which functions to mediate 
protein-protein interactions.  Analogous to the other members of the family, the adapter 
protein is composed of an N-terminal PH domain and one IRS1 Type PTB domain besides a 
C-terminal Proline Rich region and several phosphorylation sites (Carpino et al., 1997; 
Yamanashi and Baltimore, 1997) (Fig. 1.11).  The gene encoding the approximately 53 kDa 
protein maps to the chromosomal locus 2p13.1, a region prone to rearrangement in several 
malignancies including leukemia (Saulnier et al., 2012).  
 
 
 
FIGURE 1.11: Schematic representation of Dok1: A schematic figure of the 481 amino 
acid Dok1 protein depicting the two functional domains, namely, the N-terminal situated 
Pleckstrin Homology (PH) Domain and the Insulin Receptor Substrate (IRS) type 
Phosphotyrosine binding (PTB) domain. The C-terminal segment of Dok1 is replete with  
proline and tyrosine residues.   
 
 
Published data suggests Dok1 to be a phosphorylated protein downstream of several tyrosine 
kinases (Bhat et al., 1998; Neet and Hunter, 1995; Wang et al., 1995; Yamanashi and 
Baltimore, 1997).  Dok1 was originally identified as a substrate of v-Src, c-Abl and p210-
Bcr-Abl (Bhat et al., 1998; Neet and Hunter, 1995; Woodring et al., 2004a).  The protein has 
been documented for its role as a key down-regulator of several tyrosine kinase signalling 
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pathways.  For instance, Dok 1 is a negative regulator of cell-proliferation and lymphocyte 
signalling (Yamanashi et al., 2000; Zhao et al., 2001).  The protein also inhibits mitogen-
activated protein (MAP) kinase activity and mediates activin-induced apoptosis (Di 
Cristofano et al., 2001; Noguchi et al., 1999b; Yamakawa et al., 2002; Zhao et al., 2001).  
Additionally, Dok1 is known to promote cell growth and migration (Hosooka et al., 2001).  
In mice, Dok1 was shown to suppress cell transformation and leukemogenesis (Di Cristofano 
et al., 2001; Lee et al., 2004a; Niki et al., 2004).  The cellular roles of Dok1 have been 
reported to be dictated by its cytoplasmic/membrane localization which is mediated by a 
characteristic nuclear export signal (NES) between amino acids 348-359 (Niu et al., 2006).                                        
                    Moreover, while prior reports suggest a cell transformation-suppressive role for 
Dok1 (Niki et al., 2004), it was more recently demonstrated that oncogenic tyrosine kinases, 
p210 (Bcr-Abl) and v-Src, phosphorylate and target Dok1 for ubiquitin-mediated 
proteosomal digestion to stimulate cell transformation (Janas and Van Aelst, 2011).  
Hypermethylation of Dok1 has been reported to be a critical event mediating primary 
tumorigenesis in several cancer types (Saulnier et al., 2012).  Along these lines, a recent 
study suggested that Dok1 downregulation in epithelial ovarian cancer is attributed to 
promoter hypermethylation and that ectopic expression of the tumor suppressor results in 
better sensitivity to cisplatin treatment (Mercier et al., 2011).  Furthermore, the expression of 
the adapter protein was shown to be regulated mainly by a transcription factor, E2F1 for 
which there exists three response elements, designated E2F1 response elements (ERE) within 
the core promoter region of Dok1. It was also noted that E2F1 recruitment to the promoter 
region was hampered by DNA methylation (Siouda et al., 2012).     
                 Other etiological implications of Dok1 have also been reported. Recent reports 
demonstrated that Dok1 deficiency augments a physiological reduction in bone mineral 
density, a condition referred to as Osteopenia (Kawamata et al., 2011).  Murine models of 
asthma have demonstrated a therapeutic potential of Dok1 in treating allergic respiratory 
diseases.  Specifically, Dok1 was shown to negatively regulate allergen-induced Th2 
inflammation, mucus production and airway hyper-responsiveness in mice models of asthma 
(Lee et al., 2012).  Dok1 expression is also known to exert direct effects on the immune 
system.  For instance, ectopic expression of Dok1 interferes with the development of T-cells, 
thus causing the accumulation of an innate-like sub-population of eomesodermin expressing 
CD8+ T cells (Besin et al., 2012).  A computational platform based on such parameters as 
cellular protein concentration, supported a model for Dok1-integrin complex formation under 
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low cellular  concentration of the cytoskeletal protein, talin (Geier et al., 2011).  The model, 
thus, endorses a potential role of Dok1 in integrin receptor-mediated signalling (Geier et al., 
2011).  
                With such physiologically diverse functions, Dok1 presents itself as an exciting 
target to pursue for examining further implications, if any, on the vast repertoire of the cell’s 
intrinsic signalling pathways.  More importantly, Dok1 has recently garnered widespread 
attention for its potential role as a tumor suppressor in a variety of cancers.  In a recent 
proteomics study, Dok1 was identified as a potential substrate of SRMS (Takeda et al., 
2010).  However, Dok1 has yet to be validated as a cellular target of SRMS and the 
functional link between Dok1 and SRMS has not been established.  This thesis, in part, 
describes the characterization of Dok1 as a substrate of SRMS.  
 
1.3 Breast cancer clinical subtypes 
Breast cancer is divided into several clinical subtypes that include ductal carcinoma in-situ 
(DCIS), infiltrating ductal carcinoma (IDC), lobular carcinoma in-situ (LCIS), infiltrating 
lobular carcinoma (LC), as well as into different stages from 0 to IV (based on tumor size and 
metastatic propensity) (Fadare and Tavassoli, 2008; Guiu et al., 2012).  Primary breast 
tumors are classified into at least five different molecular types based on gene expression 
profiling and immunohistochemistry (Fadare and Tavassoli, 2008; Guiu et al., 2012).  They 
include i) normal-like breast cancers; ii) basal-like breast cancers, which are negative for 
estrogen receptor (ER), progesterone-receptor (PR), and human epidermal growth factor 
receptor 2 (HER2 or ERBB2 ) overexpression iii) luminal-A cancers, which are mostly ER-
positive and histological low in grade; iv) luminal-B cancers, which are also mostly ER-
positive but may express low levels of hormone receptors and are often high-grade; v) HER2-
positive cancers, associated with aggressive tumor behavior; and vi) Claudin-low, Basal-like) 
(Fadare and Tavassoli, 2008; Guiu et al., 2012; Prat et al., 2013).  Of note is that a recent 
integrated analysis of copy number and gene expression in a total of about 2000 primary 
breast tumours led to the reclassification of breast cancers into 10 subgroups (Curtis et al., 
2012).   
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2. Hypothesis: 
Dok1 possesses several proline and tyrosine residues and was also identified as a potential 
substrate of SRMS in a proteomics study (Takeda et al., 2010).  We, therefore, hypothesize 
that Dok1 is a substrate of SRMS and associates with SRMS via SH3 and/or SH2 
interactions.  The expression profile in breast cancer as well as the biochemical 
characterization of BRK and FRK have been extensively studied (Barker et al., 1997; Berclaz 
et al., 2000; Cance et al., 1994; Meyer et al., 2003; Qiu and Miller, 2002).  Since SRMS is a 
novel tyrosine kinase that remains largely understudied, it was imperative that this study 
included the characterization of the tyrosine kinase.  Therefore, the  following specific aims 
were developed towards testing the broad hypothesis: 
 
2.1 To determine the expression and sub-cellular localization of SRMS in various 
human breast cell lines. 
SRMS is a non-receptor tyrosine kinase belonging to the BRK kinase family (Serfas and 
Tyner, 2003).  There exists a significant divergence in a multitude of cellular characterictics 
among breast cancer cell lines (Neve et al., 2006).  While the expression of BRK and FRK 
has been determined in several breast-derived cell lines, that for SRMS is as yet unknown.  
The expression pattern of SRMS shall be determined via Western blotting in nine select 
human breast cell lines:- a non-tumorigenic breast epithelial cell line; 184B5 and eight breast 
cancer cell lines namely, BT20, MCF7, MDA-MB-231, MDA-MB-435, MDA-MB-468, 
HBL100, SKBR3 and AU565.  These breast cancer cell lines express different hormone 
receptors (estrogen, progesterone, HER2 or triple-negative) on their cell membranes, and 
shall thus contribute to the heterogeneity of the study based on hormone receptor status 
(Table 2.1).  Sub-cellular localization of SRMS in selected cell lines shall also be investigated 
using immunocytochemistry techniques.  
 
 
 
 
 
 
 
 
 
 
50 
 
 
TABLE 2.1: Classification of breast cancer cell lines according to their clinical and 
molecular characteristics including hormone receptor status and site of primary tumor and 
invasive capacity.  The breast cancer cell lines used in the study express either the estrogen 
(ER), progesterone (PR) or HER2 receptors (HER2) or none of these three (triple negative 
breast cancers or TNBC).  Based on the site of primary tumor and cell type, these breast 
cancer cell lines are also classified as adenocarcinoma (AC) or invasive ductal carcinoma 
(IDC).  HBL-100 is a cell line derived from normal tissues (N) isolated from the breast milk 
(BM). 
 
S. No Cell Line ER PR HER2 TNBC Derived 
tumor 
type 
1 BT-20    + IDC 
2 MCF7 + +   IDC 
3 MDA-MB-231   +  AC 
4 MDA-MB-435    + IDC 
5 MDA-MB-468    + AC 
6 HBL-100 +    N,BM 
7 SKBR3   +  AC 
8 AU565   +  AC 
 
 
2.2 To validate the activity of SRMS and generate a series of SRMS mutants to study 
catalytic regulation and effect on sub-cellular localization. 
Owing to extensive sequence homology, SRMS retains a notably conserved framework of 
functional domains critical for mediating protein-protein interactions (SH3/SH2 domains) as 
well as for sustaining a catalytic potential (Kinase domain) as observed in the other members 
of its family, BRK and FRK.  Furthermore, certain amino-acids remain conserved as 
observed through the CLUSTAL W multiple sequence alignment tool.  Using site-directed 
mutagenesis and conventional cloning strategies, several point mutations and deletions shall 
be introduced within the SRMS sequence to study catalytic regulation.  Additionally, the 
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repercussions of these mutations on influencing the sub-cellular localization of SRMS shall 
also be studied via fluorescence microscopy.  Specifically, these mutations include: 
 
        I.  Y380F     - Predicted autophosphorylation site. 
       II.  K258M   - Residue predicted to be involved in ATP-binding. 
      III.  W223A  - Residue predicted to be involved in intra-molecular associations with the 
                               kinase domain.                                                                       
      IV.  R147A    - SH2 domain residue predicted to be involved in phosphotyrosine binding. 
       V.  P214A     - SH2-kinase linker residue predicted to be involved in intra-molecular                                        
                                associations. 
      VI.  P218A+P226A (2PA SRMS)   - SH2-kinase linker residue predicted to be involved   
                                                                  in intra-molecular associations. 
    VII.  N-terminus deleted SRMS (N-SRMS) 
   VIII.  Partial N-terminus deleted SRMS (PN-SRMS) 
      IX.  Deletion SH3 SRMS (SH3-SRMS) 
  X.  Deletion SH2 SRMS (SH2-SRMS) 
 
 
2.3 To determine the expression and localization of Dok1 in selected cell lines. 
To date, there exists no information on the expression of Dok1 in breast tissue-derived cell 
lines.  However, since Dok1 is a putative tumor suppressor known to be down-regulated in 
several cancer types, it is critical that the expression profile of the same be determined in 
breast cancer.  The expression profile of Dok1 shall be determined in selected cell lines (as 
mentioned above) via Western blotting and sub-cellular-localization studied via 
immunocytochemistry and sub-cellular fractionation. 
 
2.4  To determine the molecular interactions between SRMS and Dok1 through GST-
pulldown assays. 
A recent proteomics study determined Dok1 to be a potential target of the tyrosine kinase, 
SRMS (Takeda et al., 2010).  However, Dok1 is yet to be validated and characterized as a 
SRMS substrate.  GST-pull down assays shall be utilized towards ascertaining SH3/SH2 
dependent interactions of SRMS with Dok1.  Recombinant GST-fused SRMS SH3 and SH2 
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proteins shall be used to investigate the molecular association of SRMS with Dok1.  
Furthermore, since Dok1 has several potential SH3-binding ligands along its extended C-
terminus segment, C-terminal truncated mutants of Dok1 shall be generated and binding with 
SRMS studied via co-immunoprecipitation studies.   
 
2.5 To validate Dok1 as a substrate of SRMS. 
Validation of Dok1 as a substrate of SRMS shall be carried out via immunoprecipitation and 
in vitro kinase assays.  Furthermore, co-localization analyses of SRMS and Dok1 in vivo, via 
immunocytochemistry shall be employed as well. 
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3.  Materials and methods: 
3.1 Reagents and chemicals 
The reagents and chemicals used towards the experiments described in this thesis have been 
compiled in Table 3.1. 
 
TABLE 3.1 List of Reagents and Suppliers 
Reagent/ Chemicals               Supplier and Catalogue numbers. 
2x Laemmli                Sigma-Aldrich, S3401 
Acrylamide                                                                           Sigma-Aldrich, A5934 
Acetic Acid                                                                           Fisher Scientific, A465250  
Agar                                                                                      Fisher Scientific, BP1425-2 
Agarose                                                                                 Fisher Scientific, BP1360 
Albumin (Bovine)                          Amresco, 0332 
Aprotinin                                                            Sigma-Aldrich, A6279 
Ampicillin                            EMD Millipore, 171255 
Ammonium Persulfate (APS)                                               Sigma-Aldrich, A3678 
Adenosine triphosphate (ATP) 10mM                                  New England Biolabs, P0756S                
Bovine Calf Serum                                 Thermo Scientific, SH30087.02              
Bisacrylamide N'N-methylene                                              Amresco, 0172 
Boric acid                                                                              EMD Millipore, 203-667 
Coomassie Brilliant blue                                                       G Biosciences, 786-497                                                 
Disodium Phosphate (Na2HPO4)                                         Fisher Scientific, S375-500                                         
Dimethyl Sulfoxide (DMSO)                                     Fisher Scientific, TS-20684                   
Dulbecco's modified Eagle's medium (DMEM)                   Thermo Scientific,SH30023.01 
Ethylenediaminetetraaceticacid (EDTA                               EMD Millipore, 324503 
Glutathione Sepharose beads                                                Novagen, 70541                                                                                     
Gel Red                                                                                 Biotium, 41002 
Glycerol                                                                                 Sigma-Aldrich, G5516 
Glycine                                                                                  Fisher Scientific, S80028 
Ethyl alcohol (EtOH)                                                            Fisher Scientific, S25310 
ECL (Enhanced Chemiluminescence solution)            Perkin Elmer, NEL103001EA  
Hydrochloric Acid (HCl)                          Fisher Scientific, A508-P500 
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HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Sigma-Aldrich, H3375                                                  
Kanamycin                                                                             EMD Millipore, 420311                       
Methanol                                                                                EMD Millipore, MX0475 
Magnesium Chloride (MgCl2)                                               Fisher Scientific, 232-094-6  
Manganese Chloride (MnCl2)                                               Fisher Scientific, M87-500                                   
Monopotassium Phosphate (KH2PO4)                                   Fisher Scientific, BP-362-500                                                                                                                                                                          
Nitrocellulose Membrane                                                      Pall Life sciences, 66489 
Penicillin /Streptomycin                                                         Fisher Scientific, BP2959-50 
Potassium Chloride (KCl)                                                      Fisher Scientific, AC193780000 
Polyethyleneimine (PEI)                                                        Sigma-Aldrich, 408727                                 
Protein A beads                             Santacruz Biotech, sc-2001                                       
Protein G beads                                                                      Santacruz Biotech, sc-2002                                                                                                          
Phenylmethylsulfonylfluoride (PMSF)                                  Fisher Scientific, 329-98-6 
Sodium Dodecyl sulfate (SDS)                                              Sigma-Aldrich, L3771 
Sodium Azhide (NaN3)                                                         Fisher Scientific, S227-100 
Sodium Orthovanadate (NaVO4)                                          EMD Millipore, 567540                                                 
Skim Milk                                                                               Carnation 
TEMED ((N,N,N´,N´-tetramethylethylenediamine)             Sigma-Aldrich, T9281                                                                                
Tris Base                                                                                 Fisher Scientific, BP152-5                                   
Triton X-100                                                                           Fisher Scientific, AC215680000 
Tryptone                     EMD Millipore, BP1421-500 
Tween-20                                                                               Fisher Scientific, BP337500 
Yeast Extract                                                                         Fisher Scientific, BP9727-2 
 
TABLE 3.2 Names and Addresses of Suppliers 
Supplier      Address 
Fisher Scientific                                                Walton, Massacheusetts, USA 
Sigma-Aldrich                            St. Louis, Missouri, USA 
EMD Millipore                 Cambridge, United Kingdom 
EMD Chemicals       San Diego, California, USA 
Invitrogen Life Technologies     Green Island, New York, USA 
Santacruz Biotechnologies                                Santa Monica, California, USA  
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Thermo Scientific                 Logan, Utah, USA 
Biotium                             Burlington, Ontario, Canada 
Bio-Rad Inc.                                        Hercules, California, USA 
Amresco Inc.                                                     Solon, Ohio, USA  
New England Biolabs                 Ispwich, Massacheusetts, USA 
Perkin Elmer                                        Waltham, Massacheusetts, USA 
 
3.2 Expression vectors 
All PCR amplifications were performed using Econotaq polymerase supplied with Taq buffer 
and dNTP mix (300031-1, Lucigen) with the following reaction and cycling conditions: 
Reactions Components (50 µl reaction):  
10X Standard Taq Reaction Buffer with Mg
2+
 (1X), 10 mM dNTPs (200 µM), 10 µM Forward Primer 
(0.2 µM), 10 µM Reverse Primer (0.2 µM), Template DNA (<100 ng), Taq DNA Polymerase (1.25 
units), Nuclease-free water (to 50 µl). 
 
Cycling Conditions: 
1. Initial Denaturation                                95°C (30 seconds)  
2.  Extension (30 Cycles)                           95°C (30 seconds) 
                                                         45-68°C (30-60 seconds)   
                                                         68°C  (1 min/kb) 
3. Final Extension                                      68°C (5 min.) 
 
3.2.1 SRMS expression vectors 
 All primers used towards PCR reactions were purchased from Invitrogen Life Technologies, 
(New York, USA). The full length SRMS cDNA amplified from the pANT7-cGST-SRMS 
plasmid, purchased from DNASU Plasmid Repository (Tempe, AZ) via PCR was cloned C-
terminal to the GFP sequence into the HindIII and BamHI sites of the pEGFP-C1 plasmid 
using the oligonucleotide primers shown in Table 3.3.  The same primers were also used to 
clone the SRMS cDNA C-terminal to the mCherry sequence, into the same sites of the 
pmCherry-C1 plasmid (a kind gift from Dr Scot Stone, Department of Biochemistry, 
University of Saskatchewan).  All other deletion variants of SRMS were generated using the 
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GFP-SRMS construct as the template employing single or double pairs of  primers as shown 
in Table 3.3.  
           GST-SRMS constructs were generated by cloning the SRMS-SH3 and SH2 cDNAs 
into the BamHI and XhoI sites located within the multiple cloning site, C-terminal to the GST 
sequence, in the pGEX-6-p-3 vector backbone [Table 3.3].  All constructs were verified via 
sequencing (sequencing facility: NRC-PBI, University of Saskatchewan, Saskatoon.) 
 
3.2.1.1 Site directed mutagenesis was employed to introduce point mutations in the SRMS 
sequence via the commercially available QuikChange site-directed mutagenesis (Stratagene) 
kit, according to the manufacturer’s protocol as outlined below:   
Reaction Components: 
Standard Reaction Buffer with Mg
2+
 (1X), 20 ng Template DNA, 125 ng forward primer , 
125 ng reverse primer, 200 µM dNTP mix, nuclease free water (to 50 µl) and Pfu turbo DNA 
polymerase (1.25 units). 
 
Cycling Conditions: 
1. Initial Denaturation                                          95°C (30 seconds)  
2.  Extension (18 Cycles)                                     95°C (30 seconds) 
                                                                         55°C (30-60 seconds)   
                                                                         68°C  (1min/kb)  
3. Final Extension                                                68°C (5 min.) 
 
The PCR-mutagenesis products were incubated with the restriction enzyme, DpnI at 37 °C 
for 1 hour, to digest the parental cDNA in the PCR product and the digested samples directly 
used for transforming the commercially procured X-Gold ultra-competent cells (#200315, 
Agilent Technologies).  The following day, independent bacterial colonies were picked, DNA 
extracted from the clones and screened via sequencing (sequencing facility: NRC-PBI, 
University of Saskatchewan, Saskatoon.)  
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TABLE 3.3: List of SRMS expression constructs generated via cloning and site-directed 
mutagenesis. 
S.
No 
DNA Construct Restriction 
Sites 
Primers 
1. 
 
 
2. 
 
 
3. 
 
 
4. 
 
 
 
 
5. 
 
 
 
 
6. 
 
 
 
 
7. 
 
 
 
8. 
 
 
 
9. 
 
 
10. 
 
 
11. 
GFP-SRMS 
 
 
mCherry-SRMS 
 
 
GFP-ΔN-SRMS   
 
 
GFP-PΔN-
SRMS 
 
 
 
GFP-ΔSH2-
SRMS 
 
 
 
GFP-ΔSH3-
SRMS 
 
 
 
GST-SRMS-
SH2 
 
 
GST-SRMS-
SH3 
 
 
GFP-SRMS-
K258M 
 
GFP-SRMS-
W223A 
 
GFP-SRMS-
Y380F 
 
HindIII,  
BamHI 
 
HindIII,  
BamHI 
 
HindIII,  
BamHI 
 
HindIII, XhoI  
BamHI 
 
 
 
HindIII, XhoI  
BamHI 
 
 
 
HindIII, XhoI  
BamHI 
 
 
 
BamHI, XhoI 
 
 
 
BamHI, XhoI 
 
 
 
HindIII,  
BamHI 
 
HindIII,  
BamHI 
 
HindIII,  
BamHI 
 
5′-CTC AAG CTT CGG AGC CGT TCC TCA GGA GGC G-3′ 
5′-CCG GGA TCC TCA GGG GTG GCA TCT GGT GGA-3′ 
 
5′-CTC AAG CTT CGG AGC CGT TCC TCA GGA GGC G-3′ 
5′-CCG GGA TCC TCA GGG GTG GCA TCT GGT GGA-3′ 
 
5′-CTC AAG CTT CGG AGC CGT TCC TCA GGA GGCG-3' 
5′-CCG GGA TCC TCA GGG GTG GCA TCT GGT GGAT-3′ 
 
5′-CTC AAG CTT CGC CCT TCC CTC AGC TCT TCC TT-3′ 
5′-AAA CTC GAG GCC ATG GTC CGG CTC GCC-3′ 
5′-AAA CTC GAG CCC CAG AAG GCC CCG AGG-3′ 
5′-CCG GGA TCC TCA GGG GTG GCA TCT GGT GGA-3′  
 
5′-CTC AAG CTT CGG AGC CGT TCC TCA GGA GGCG-3′ 
5′-AAA CTC GAG TTG GTC TGA GAG CGT CTC-3′  
5′-AAA CTC GAG CCC CAG AAG GCC CCG AGG-3′ 
5′-CCG GGA TCC TCA GGG GTG GCA TCT GGT GGAT-3′ 
 
5′-CTC AAG CTT CGG AGC CGT TCC TCA GGA GGCG-3′ 
5′-AAA CTC GAG GCA AGG CTC GGC GGG GAG-3′ 
5′-AAA CTC GAG ACG CTC TCA GAC CAA CCC-3′ 
5′-CCG GGA TCC TCA GGG GTG GCA TCT GGT GGAT-3′ 
 
5′-CTG GGA TCC GAG ACG CTC TCA GAC CAA CCC-3′ 
5′-CGG CTC GAG TCA CCT CGG GGC CTT CTG GGG-3′ 
 
 
5′-CTG GGA TCC CCC GCC GAG CCT TGC AGC CCC-3′ 
5′-CGG CTC GAG TCA GTC TGA GAG CGT CTC AGG-3′ 
 
 
5′-CCC GTG GCG ATC ATG GTC ATC AAG TCA-3′ 
5′-TGA CTT GAT GAC CAT GAT CGC CAC GGG -3′ 
 
5′-AGG CAG GAC GTG GCT GAG CGG CCA CAC-3′ 
5′-GTG TGG CCG  CTC AGC CAC GTC  CGT CCT-3′ 
 
5′-AAG GAC GAC ATC TTT TCC CCG AGC AGC-3′ 
5′-TTC CTG CTG TAG AAA AGG GGC TCG TCG-3′ 
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3.2.2 Dok1 expression vectors 
GFP-Dok1 construct was a kind gift from Dr. Bakary S. Scylla, Lyon, France.  Five Dok1 
deletion mutants were generated using the GFP-Dok1 construct as the template.  Using the 
same PCR conditions as mentioned above, five pairs of primers were used to amplify five 
Dok1 cDNA variants differing progressively in length and cloned C-terminal to the GFP 
sequence in the EcoRI and SmaI sites of the pEGFP-C1 vector backbone [Table 3.4] 
                The GFP-Dok1 template was also utilized, via PCR, to clone Dok1 C-terminal to 
the GST cDNA sequence into the EcoRI and NotI sites of the pGEX-5-x-3 vector, using the 
oligonucleotide primers shown in Table 3.4.  All constructs were verified via sequencing 
(sequencing facility: NRC-PBI, University of Saskatchewan, Saskatoon.) 
 
TABLE 3.4: List of Dok1 expression constructs generated. 
 
S.
No 
DNA 
Construct 
Restriction 
Sites 
Primers 
1. 
 
 
2. 
 
 
3. 
 
 
 
4. 
 
 
5. 
 
 
6. 
 
GFP- Dok1 
 
 
GFP- Dok2 
 
 
GFP- Dok3 
 
 
GFP- Dok4: 
 
 
GFP- Dok5 
 
 
GST-Dok-C-
Term 
 
 
 
EcoRI, 
SmaI 
 
EcoRI, 
SmaI 
 
EcoRI, 
SmaI 
 
EcoRI, 
SmaI 
 
EcoRI, 
SmaI 
 
EcoRI, 
NotI  
 
 
 
5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA A-3′ 
5′-ATT CCC GGG TCA AGT CTC AAC TGC CTG-3′ 
 
5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA A-3' 
5′-ATT CCC GGG TCA CTT CCG TTG TAC TCC-3′ 
 
5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA A -3′ 
5′-ATT CCC GGG TCA CTT GGC CTT CAG CAA-3′ 
 
5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA A-3′ 
5′-ATT CCC GGG TCA CTT CAC CCG AGC TTG-3′  
 
5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA A-3′ 
5′-ATT CCC GGG TCA CTT GGG AGC AAG GAG-3′  
 
5′- ATA GAA TTC CGA CGG AGC AGT GAT GGA A -3′ 
5′- ATA GCG GCC GCT CAG GTA GAG CC -3′ 
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3.3 Cell lines and cell culture: 
 HEK293, HeLa, BT20, MCF7, MDA-MB-231, MDA-MB-435, MDA-MB-468, AU565, 
SKBR3 and HBL100 were purchased from the American Tissue Type Culture Collection 
(ATCC, Manassas, VA, USA).  All cell lines were maintained in High glucose (4.5g/L) 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% bovine calf serum 
(Thermo Scientific, Logan, USA), 4 mM L-Glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin (Sigma Aldrich, St. Louis, MO, USA).  The required personal protective 
equipment was used for the purpose.  Waste solution comprising exhausted media, trypsin or 
other liquids, was de-contaminated with 30% bleach solution prior to disposal.  All other 
forms of waste including gloves, plastic pipettes, Pasteur pipettes etc. were decontaminated 
with bleach solution, sealed in autoclavable double bags and sent for disposal.  The working 
area was decontaminated with 70% ethanol before and after use.  
                 Generally, the HEK293 cell line was chosen for the purpose of characterizing the 
biochemical properties of SRMS including its sub-cellular localization and substrate-
specificity towards Dok1 via immunoprecipitation analyses.  HEK293 is an immortalized cell 
line isolated from the human embryogenic kidneys that expresses very low level of SRMS.  
The relative ease associated with the growth and maintenance of the cell line as well as high 
transfection efficiency and high protein production were inherent traits that were deemed 
useful towards the use of the cell line for the aforementioned experiments.   
 
3.3.1 PEI-mediated transfection:  
All transfections were carried out in the HEK293 cell line, cultured as described above.  
Cells, cultured in 6 well plates, were transiently transfected with a total of 2.5 µg DNA using 
1% Polyethyleneimine ‘Max’ (PEI) (Polysciences Inc., Warrington, PA, USA) at a DNA to 
transfection reagent ratio: 1:3.  For each well in the 6-well plate, 2.5 µg of the appropriate 
DNA was mixed with 107.5 µl of 0.15 M sterile NaCl via gentle vortexing for 10 seconds.  
15 µl of the transfection reagent, PEI, was then added to this mixture followed by another 10 
seconds of gentle vortexing.  DNA-PEI complex formation was allowed to take place by 
incubating the mixture at room temperature for 10 minutes followed by dispensing it 
dropwise into the wells.  The cells were incubated for 24 hours post transfection, transfection 
efficiency checked the following day using the Olympus 1x71 inverted fluorescence 
microscope and cells harvested for use towards the experiment. 
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3.4 SDS-PAGE and Western Blotting: 
3.4.1 SDS-PAGE:  
Whole cell lysates were prepared directly in 2x Laemmli (Sigma-Aldrich). Total cell lysates 
were prepared in lysis buffer comprising 20 mM Tris pH 7.5, 1% Triton X-100, 150 mm 
NaCl, protease inhibitors: Aprotinin 5 mg/l and 0.1 mM PMSF as well as 0.3 mM sodium 
orthovanadate.  Protein samples derived from either lysates (whole cell lysates/ total cell 
lysates) or immunoprecipitates, were resolved via sodium dodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis (PAGE). SDS-PAGE was carried out using the Mini-
PROTEIN 4 gel electrophoresis system (Bio-Rad-165). 1.5 mm gels were cast using the 
appropriate glass plates designed and manufactured to include a permanently articulated 
spacer (Bio-Rad).  10% polyacrylamide gels were used for all experiments.  The resolving gel 
comprises 29.2% acrylamide, 0.8% bis-acrylamide, 0.4% SDS, 375 mM Tris HCl pH 8.8, 
0.16% ammonium persulfate (APS), 0.1% N,N,N’,N’ Tetramethylenediamine (TEMED) and 
H2O.  The stacking gel comprises 29.2% acrylamide, 0.8% bis-acrylamide, 0.4% SDS, 125  
mM Tris HCl pH 6.8, 0.24% (w/v) ammonium persulfate (APS), 0.1% (w/v) N,N,N’,N’ 
Tetramethylenediamine (TEMED) and H2O. 
                 Pre-stained protein ladder (NEB, #P7711S) and the protein samples (boiled at 100 
°C in 2x laemmli buffer for 5 minutes) were loaded onto the gels (10 wells or 15 wells) and 
the samples electrophoresed in 1x SDS running buffer at a constant voltage of 150 volts for 1 
hour or for the duration required for the bromophenol blue dye front to completely pass 
through the gel.  
 
3.4.2 Western Blotting:  
Following electrophoresis, the gels were carefully removed from the glass plates, the stacking 
gel discarded and the resolving gel placed over 5 sheets of 3 MM filter papers (with 
dimensions equalling the length and breadth of the gel) pre-soaked in transfer buffer.  
Nitrocellulose membrane, soaked in transfer buffer and cut to the dimensions of the gel was 
placed above the gel and over which an additional 5 sheets of 3 MM filter papers were 
stacked to yield a composite “sandwich-like” assembly.  The assembly was placed into the 
gel holder cassette and the cassette inserted into the Western blotting apparatus (Bio-Rad) 
filled with transfer buffer (refer to Table 3.5) up to the manufacturer’s indicated mark.  
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Protein transfer was allowed to proceed for 1 hour at a constant voltage of 100 volts at 4 
degrees.                                                                                                                                      
            Following the completion of the transfer, the nitrocellulose membranes were removed 
and subject to blocking via incubation with blocking buffer (refer to Table 3.5) at room 
temperature for 40 minutes.  The blot was then washed briefly with 1x TBST buffer (refer to 
Table 3.5) and incubated with the appropriate primary antibody (as enlisted below) diluted at 
a ratio of 1:1000 in a primary antibody buffer (refer to Table 3.5) and incubated overnight at 
4°C on a rocker.  The following day, the membrane was washed for 15 minutes three times 
with 1x TBST buffer.  The membrane was then incubated with the appropriate secondary 
antibody (HRP-conjugated goat anti mouse/ goat anti rabbit, as mentioned below) at a 
dilution of 1:10000 in a secondary antibody buffer (refer to Table 3.5) at 4°C on a rocker for 
40 minutes.  The membrane was subsequently washed three times with 1x TBST, incubated 
with Enhanced chemiluminiscence solution (ECL) (Perkin Elmer, Netherlands) for 1 minute 
and the immunoreactive proteins detected via exposing the membranes to X-ray films. 
 
3.4.2.1 Primary and Secondary Antibodies 
 All primary and secondary antibodies were purchased from Santa-Cruz Biotechnology Inc., 
Santa Cruz, CA, USA. Primary antibodies include: anti-SRMS (sc-68341), anti-GST (sc-
33613), anti--tubulin (sc-9104), anti-GFP (sc-8334) and anti-phosphotyrosine (sc-508).  
Anti-Dok1 was a kind gift from Dr. Ryuji Kobayashi (University of Texas, Austin, USA).  
The anti-Sam68 (AD1) polyclonal antibody has been previously described (Chen et al., 
1999).  The working concentrations/dilutions of the primary antibodies are indicated in Table 
3.5.  Secondary antibodies used towards Western blotting include: goat HRP-conjugated 
secondary antibodies against rabbit (sc-2004) and mouse (sc-2005).  Secondary antibodies, 
used towards immunocytochemistry experiments include: goat anti-rabbit IgG-FITC (sc-
2012) and goat anti-mouse IgG-Texas Red (sc-2979).  Working dilutions of the secondary 
antibodies are indicated in Table 3.6. 
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 TABLE 3.5 List of media/buffers and their composition 
 
 
BUFFER/ MEDIA COMPOSITION 
1X PBS  137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM 
KH2PO4, pH 7.4 . 
1x TBST 150 mM NaCl, 10 mM Tris pH 8.0, 10% Tween-20 (final 
at 0.1% v/v) 
 
Blocking buffer 5% Skim milk in TBST buffer (5 g Skim milk in 100 mL 
TBST buffer) 
 
Primary antibody buffer  0.1% Tween-20, 5% BSA in 1x TBS 
 
Secondary antibody buffer 0.1% Tween-20, 5% BSA in 1x TBS 
 
1X Tris buffered saline 
(TBS)  
150 mM NaCl, 10 mM Tris pH 8.0 
Western blotting Transfer 
buffer 
25 mM Tris, 192 mM glycine, pH 8.3, 20% methanol. 
SDS PAGE Running buffer 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3. 
 
Mammalian cell lysis 
buffer 
20 mM Tris pH 7.5, 1% TritonX-100, 150 mM NaCl, 
protease inhibitors: Aprotinin 5 mg/L, 0.1 mM PMSF, 
phosphatase inhibitor: 0.3 mM sodium orthovanadate. 
Bacterial cell lysis buffer 50 mM Tris 7.5, 150 mM NaCl, 1% TritonX-100 
 
2XYT Media for bacterial 
cultures 
1.0% Tryptone, 0.5% Yeast Extract, 1.0% NaCl, pH 7.0 
 
 
63 
 
 
TABLE 3.6 List of chemicals/reagents and their composition 
 
 
TABLE 3.7: Working concentrations/dilutions of primary antibodies used in Western 
blotting (WB) and immunocytochemistry (IC) experiments. 
 
Primary antibody Working 
Concentration/Dilution 
Anti-SRMS (sc-68341) 0.2 µg/mL (WB), 2 µg/mL (IC) 
Anti-GST (sc-33613) 0.2 µg/mL (WB) 
Anti--tubulin (sc-9104) 0.2 µg/mL (WB) 
Anti-GFP (sc-8334) 0.2 µg/mL (WB) 
Anti-phosphotyrosine (sc-508) 0.2 µg/mL (WB) 
Anti-Dok1  1:2500 (WB), 1:300 (IC) 
Anti-Sam68 (rabbit) (AD1) 1:1000 (WB) 
CHEMICALS/REAGENTS 
STOCK 
COMPOSITION 
10 mg/mL Kanamycin  0.5 g 50 mL ddH2O (double distilled H2O). 
 
50 mg/mL Ampicillin 0.5 g in 10 mL ddH2O.  
1 M IPTG (Isopropyl β-D-1-
thiogalactopyranoside) 
 
1 g IPTG dissolved in 4.2 mL ddH2O, filtered through 
0.22 μm.  
100 mM PMSF 
(Phenylmethylsulfonylfluoride) 
1.74 g PMSF in 100 mL Isopropanol. 
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TABLE 3.8: Working dilution range of secondary antibodies used towards Western blotting 
and immunocytochemistry experiments. 
 
Secondary antibody Working 
Dilution 
Goat anti-rabbit IgG-HRP (sc-2004) 1:10000 (WB) 
Goat anti-mouse IgG-HRP (sc-2005) 1:10000 (WB) 
Goat anti-rabbit IgG-FITC (sc-2012) 1:200 (IC) 
goat anti-mouse IgG-TR (sc-2979) 1:200 (IC) 
 
3.5 Immunocytochemistry: 
Cells, seeded on coverslips, were cultured in 6-well plates, fixed with 1% paraformaldehyde 
in 1x PBS (Phosphate buffered saline), pH 7.4, for 5 minutes and permeabilized with 0.5% 
Triton X-100 in PBS for 5 min at room temperature, and incubated with anti-SRMS or anti-
Dok1 antibodies (dilution factor- 1:200) for 1 h in PBS at room temperature.  The cells were 
washed with 0.1% Triton X-100 in PBS and incubated with the appropriate secondary 
antibodies (dilution factor- 1:200) in PBS for 30 minutes.  Goat anti-mouse coupled to Texas 
Red (Sc-2781, Santa Cruz Inc.) and goat anti-rabbit coupled to FITC (Sc-2012, Santa Cruz 
Inc.) were used as secondary antibodies.  The coverslips were then mounted onto glass slides 
with glycerol containing 3 mg/mL 4',6-diamidino-2-phenylindole (DAPI) to stain the nuclei.  
For cells transfected with the GFP-fused constructs, following cell permeabilization, the 
coverslips were directly mounted onto glass slides with glycerol containing DAPI for nuclei 
staining.  The cells were observed under an Olympus 1X-71 inverted microscope and the 
images captured at 60x magnification using the “Infinity Analyze” software platform 
(Lumina Inc.).  
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3.6 Immunoprecipitation 
All transfections were carried out in the HEK293 cell line, cultured as described above. Cells 
washed in cold 1x phosphate-buffered saline (PBS), were lysed in freshly prepared lysis 
buffer constituting 20 mM Tris pH 7.5, 1% TritonX-100, 150 mm NaCl, protease inhibitors: 
Aprotinin 5 mg/L and 0.1 mM PMSF as well as 0.3 mM sodium orthovanadate (Enzo life 
sciences).  Lysates were prepared by incubating the harvested cells in ice-cold lysis buffer for 
30 minutes followed by centrifugation for 10 minutes at 13k xg.  Supernatants were collected 
and transferred into fresh tubes and incubated with 1ug of the appropriate antibody and 
maintained on a gyrorotator for 1 hour at 4°C.  20 μl of Protein A agarose beads were then 
added to the samples and incubated for another 40 minutes on the gyrotator at 4°C.  The 
beads were washed twice with ice-cold lysis buffer and 1x PBS before the 
immunoprecipitated proteins were denatured in 2x Laemmli buffer via boiling at 100°C for 5 
minutes and resolved via SDS-PAGE. 
 
3.7 Sub-cellular fractionation  
Sub-cellular fractionation was carried out using the ProteoExtract Sub-cellular Proteosome 
Extraction Kit (#539790, Calbiochem, San Diego CA, USA) as instructed by the 
manufacturer.  All buffers/solutions were provided in the kit.  Briefly, cells grown in 100 mm 
culture plates were harvested using the manufacturer’s “wash buffer” and lysed in an 
eppendorf tube using 1 mL of “extraction buffer I”.  Cellular lysis was allowed to proceed for 
10 minutes at 4°C.  The lysate was then subjected to centrifugation at 1000 xg for 10 minutes 
at 4°C.  The supernatant obtained was collected as the cytosolic fraction.  Subsequently, 1 
mL of “extraction buffer II” was added to the remaining cellular components and the mixture 
left to incubate at 4°C for 30 minutes.  These lysates were then subjected to centrifugation at 
6000 xg for 10 minutes at 4°C.  The supernatant was collected as the membrane fraction.  
Finally, 500 μl of “extraction buffer III” was added to the remaining cellular components and 
the mixture incubated for 10 minutes at 4°C.  The lysate was subjected to centrifugation at 
6800 xg for 10 minutes at 4°C.  The supernatant obtained was collected as the nuclear 
fraction.  Proteins from the three cellular fractions were eventually resolved via SDS-PAGE 
and detected using the appropriate antibodies.  
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3.8 Recombinant GST-fused protein expression and GST pull down assay 
With the exception of GST-SRMS that was procured from SignalChem (#S20-11G, 
Richmond, BC, Canada), all other GST-tagged constructs were expressed in E. coli (BL21 
strain), cultured in 2XYT media at 37°C.  Protein induction was initiated with the addition of 
1 mM IPTG to the bacterial cultures at an optical density of 0.6 at 260 nm wavelength. 
Bacterial cultures were maintained in a 37°C shaker for 1h.  Bacterial cells were then lysed 
via sonication using short intermittent pulses, in ice-cold 1xPBS buffer containing protease 
inhibitors: 1 µg/mL aprotinin, and 0.01% phenylmethylsulfonyl fluoride (PMSF), 
supplemented with a protease inhibitor cocktail comprising 23 mM AEBSF (4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride), 2 mM Bestatin, 100 mM EDTA 
(Ethylenediaminetetraacetic acid), E-64 0.3 mM trans-epoxysuccinyl-L-leucylamido-(4-
guanidino) butane (E 64), 0.3 mM Pepstatin A, in dimethylsulfoxide (DMSO) (P8465, 
Sigma-Aldrich).  Lysates were then incubated with the Glutathione sepharose beads (GST, 
Novagen) overnight at 4°C on a gyrorotator.  The following day, the beads were washed 6-8 
times with ice-cold 1x PBS and the beads used for GST- pull down assays.  
                  The pull-down experiments were carried out using GST, GST-SRMS-SH3 and 
GST-SRMS-SH2 proteins immobilized on glutathione Sepharose beads.  The GST-SH3 
beads were incubated with HEK293 cell lysates overnight at 4°C on a gyrorotator.  Likewise, 
GST–SH2 beads were incubated with lysates derived from HEK293 cells untransfected or 
transfected with GFP-SRMS wild-type.  Subsequently, the beads were centrifuged, 
supernatant aspirated and the beads washed 2 times with lysis buffer and 1x PBS.  2x 
Laemmli buffer was then added to the beads and proteins denatured via incubation at 100°C 
for 5 minutes before resolving the same via SDS-PAGE.    
 
3.9 In vitro kinase assays 
In vitro kinase assays were performed using 50 ng GST-SRMS (SignalChem, Richmond, BC, 
Canada) and 10 µl bed volume of substrate (GST-Dok1 wild type or GST alone)  in a 
reaction volume of 50 µl comprising 20 µl kinase buffer (25 mM MOPS, pH 7.2, 2.5 mM 
DTT, 12.5 mM and 5 mM EGTA) and 20 µl H2O with or without 200 µM ATP.  The reaction 
was allowed to proceed by incubating the mixture at 30°C for 30 minutes and was terminated 
by the addition of 2x Laemmli buffer.  The samples were then boiled at 100°C for five 
minutes and resolved via SDS-PAGE (as described above).  
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4. Results 
4.1 Expression and localization of SRMS in eight human breast cancer cell lines 
4.1.1 Relative expression of SRMS in various breast cancer cell lines  
While BRK expression has been catalogued in a wide panel of cell lines derived from the 
normal and tumorigenic human breast, that for SRMS remains undetermined.  Therefore, a 
panel of eight distinct breast cancer cell lines comprising namely, BT-20, MCF7, MDA-MB-
231, MDA-MB-435, MDA-MB-468, Au565, HBL-100 and SKBR3 along with a non-
tumorigenic mammary epithelial cell line, 184B5 were evaluated for SRMS expression via 
Western blotting.  Since BRK is its closest relative and a known oncogenic protein in breast 
cancer, SRMS expression was evaluated alongside BRK to facilitate a comparative analysis 
of the two tyrosine kinase expression profiles.  The results indicated a general overexpression 
of SRMS in six out of eight breast cancer cell lines with HBL-100 exhibiting the highest 
expression of the protein (Fig 4.1).  Still, the expression of SRMS was not absent in any of 
the cell lines as it was expressed in all eight breast cancer cell lines, albeit low in two of these 
namely, MDA-MB-468 and AU565 (evidenced upon longer exposure of the X-ray film to the 
immunoblotted membrane).  Interestingly, SRMS expression was also found to be low in the 
non-tumorigenic mammary epithelial cell line, 184B5.  In contrast, BRK expression, while 
also observed in the majority, was found to be very low or absent in certain cell lines, 
namely, MDA-MB-435, MDA-MB-468 and HBL-100.  The data suggests that (a) SRMS is 
potentially overexpressed in the majority of breast cancer cell lines and (b) the expression of 
SRMS appears to be very low in the normal human breast cells while being significantly 
expressed in the cells derived from breast cancer.  
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FIGURE 4.1: SRMS is overexpressed in human breast carcinomas.  Lysates prepared 
from breast carcinoma cell lines and a cell line derived from the normal mammary epithelial 
tissue (184B5), were evaluated for SRMS and BRK expression via immunoblotting with 
antibodies against SRMS and BRK, respectively.  -tubulin was used as the loading control. 
The x-ray films were subjected to long and short exposures to determine the expression levels 
of proteins.  
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4.1.2 Sub-cellular Distribution of SRMS  
The sub-cellular localization of SRMS is unknown and in the absence of a putative 
myristoylation signal (dictating plasma-membrane localization) as found in Src (Neet and 
Hunter, 1996) or a characteristic FRK-like nuclear localization signal (directing nuclear 
localization) (Cance et al., 1994), it was imperative to determine its cellular localization 
pattern.  In order to determine the intracellular localization of the protein, we pursued 
immunocytochemical analysis of endogenous SRMS in three breast cancer cell lines MDA-
MB-231, AU565 and SKBR3 as well as  one cervical cancer cell line, HeLa, to determine if 
the localization varied across different cancer cell lines.  Immunofluorescence analysis 
revealed a predominantly cytoplasmic distribution of endogenous SRMS visible with a 
distinct punctate pattern in all the cell lines examined (Fig 4.2).  No obvious nuclear staining 
was observed, indicating that SRMS is a predominantly cytoplasmic protein.  
                        Next we wished to compare the endogenous localization pattern with that of 
ectopically expressed SRMS.  GFP-tagged SRMS was transiently transfected in the HEK293 
cell line and localization was determined via fluorescence microscopy.  Consistent with 
endogenous SRMS, over-expressed SRMS was also found to localize to punctate regions, 
which were visible as bright spots in the cytosol of the cells (Fig 4.3). 
                    To further substantiate these results based on the immunofluorescence technique, 
sub-cellular fractionation was employed in the breast cancer cell lines MDA-MB-231 and 
AU565 as well as the cervical cancer cell line, HeLa.  Indeed, out of the three cellular 
fractions that were isolated from total cell lysates, endogenous SRMS was found to be 
exclusive to the cytosolic fraction in all the four cell lines (Fig 4.4). 
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FIGURE 4.2: Endogenous SRMS localizes to punctuate cytoplasmic structures in cells.  
Intracellular localization of endogenous SRMS was detected via indirect immunofluorecence 
in the MDA-MB-231 (a-c), AU565 (d-f) and SKBR3 (g-i) human breast cancer cell lines as 
well as the human cervical cancer cell line, HeLa (j-l).  Immunoreactivity was visualized 
using anti-SRMS and secondary FITC (green) antibodies.  Cells were counterstained with 
DAPI (blue) and images were captured at 60x magnification using the Olympus 1x inverted 
fluorescence microscope.  Similar results were obtained in at least three different 
experiments. 
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FIGURE 4.3: Ectopically expressed SRMS localizes to punctate cytoplasmic structures 
in cells.  Intracellular localization of exogenous GFP-tagged SRMS (a,b and c) was detected 
via fluorescence microscopy in the HEK293 cells.  pEGFP control vector localization in the 
same cell line is depicted. (d,e and f).  Cells were counterstained with DAPI.  Images were 
captured at 60x magnification using the Olympus 1x51 inverted microscope.  Similar results 
were obtained in at least three different experiments. 
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FIGURE 4.4: Sub-cellular fractionation reveals that SRMS is a cytosolic protein.  Cells, 
from the indicated cell lines, were fractionated into the cytosolic, membrane and nuclear 
fractions and immunoblotted for the detection of SRMS.  -tubulin and Sam68 were used as 
the controls for the cytosolic/membrane and nuclear compartments, respectively.  SRMS is 
found in the cytosolic fraction of the indicated cell lines.  Similar results were obtained in at 
least three different experiments. 
 
4.2 Biochemical Characterization of SRMS. 
4.2.1 Role of the unique N-terminal region of SRMS  
Even as SRMS belongs to the same family of non-receptor tyrosine kinases as BRK and 
exhibits significant structural homology with the latter, there exist subtle variations in their 
overall protein sequences.  One such variation is the absence of a C-terminal region 
extending beyond the kinase domain in SRMS that is otherwise common to BRK and c-Src 
(Fig 4.5).  The C-terminal region of the latter two PTKs invariably possess a “regulatory” 
tyrosine, so named for its ability to bind to the respective SH2 domain upon phosphorylation 
and locking the enzyme in an inactive conformation.  SRMS lacks a C-terminal regulatory 
region but possess an extended and unique N-terminal sequence.  In order to understand the 
functional significance of this N-terminal region and assess the enzymatic activity of SRMS, 
a truncated mutant of SRMS was generated that lacks the entire N-terminal sequence.  
Furthermore, utilizing the web-based multiple-sequence alignment tool, CLUSTALW, 
 
 
 
73 
 
certain potentially critical residues in SRMS were identified as conserved with BRK and c-
Src.  These residues have been previously characterized for their dynamic roles in regulating 
the catalytic activities of BRK and c-Src.  These residues in SRMS correspond to W223, 
K258 and Y380 (respectively analogous to the functionally diverse: W184 in BRK and W260 
in c-Src; ATP-contacting: K219 in BRK and K298 in c-Src and finally, the site for 
autophosphorylation: Y342 in BRK conserved with Y419 in c-Src).  To probe their 
significance, these residues were mutated independently via site-directed mutagenesis to 
yield 3 SRMS mutants, namely, SRMS-W223A, SRMS-K219M and SRMS-Y380F. 
 
 
FIGURE 4.5: Schematic representation of SRMS, BRK and c-Src.  Shown here are the 3 
functional domains, i.e., the SH3, SH2 and the kinase domains, common to the three PTKs.  
Also shown are the potentially functional residues in SRMS (W223, K258 and Y380) 
remaining conserved with those that are well characterized in BRK and c-Src.  The non-
conserved N-terminal region of SRMS and the myristoylation signal in c-Src (represented by 
“M”) are also depicted. 
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To assess the outcome of such mutations, including N-SRMS, on the overall catalytic 
activity of SRMS, the GFP-tagged mutants (GFP-SRMS-K258M and GFP-SRMS-W223A), 
along with wild-type SRMS, were transiently transfected in HEK293 cells.  As well, to draw 
comparative analysis, GFP-tagged BRK wild-type as well as its kinase-dead (GFP-BRK-
K219M) and constitutively-active (GFP-BRK-Y447F) mutants were also transiently 
transfected in the same cell line.  Immunoblotting was performed using anti-GFP and anti-
phosphotyrosine (pY20) antibodies to determine, respectively, the levels of the overexpressed 
proteins and the relative levels of tyrosine phosphorylation via evaluating total 
phosphorylation of endogenous targets.  
                    Firstly, it was noted, from anti-phosphotyrosine immunoblotting, that wild-type 
SRMS exhibits strong intrinsic tyrosine kinase activity that is almost comparable to that of 
the wild-type BRK, but not to that of its hyper-active mutant, BRK-Y447F (Fig 4.6).  
Secondly, it was also noted that the deletion of the 51 amino acid N-terminal segment (N-
SRMS), preceding the SH3 domain of SRMS totally abolishes the enzymatic activity.  
Thirdly, an anticipated absence of kinase activity with the K258M mutant was also observed 
since interfering with the ATP-contact site is expected to abolish the kinase’s ability to 
acquire and utilize the phosphate group derived from ATP for phosphorylation (Qiu and 
Miller, 2004).  This result validates the SRMS K258 as a critical residue of the ATP-binding 
site within the PTK’s kinase domain, akin to K219 and K298 of BRK and c-Src, respectively.  
However, mutating the conserved tryptophan (W223) within the SH2-kinase linker, also 
resulted in a sharp decrease in the overall tyrosine kinase activity.  This was particularly 
interesting since an analogous mutation in the Src family kinase, Hck, (W260) caused an 
increase in its kinase activity (via SH3-dependent kinase inhibition) (LaFevre-Bernt et al., 
1998).  The outcome in SRMS was similar to that in BRK wherein a significantly decreased 
kinase activity was observed upon mutation of the conserved tryptophan W184 (Qiu and 
Miller, 2004).   
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FIGURE 4.6: The N-terminal region of SRMS regulates its kinase activity.  Lysates 
prepared from HEK-293 cells transfected with the indicated SRMS and BRK constructs, 
were evaluated to determine the relative kinase activity of the variants using antibodies 
against total phosphotyrosines (bottom panel).  Expression of the ectopic proteins was probed 
via anti GFP (Top panel). -tubulin was used as the loading control.  Similar results were 
obtained in at least three different experiments. 
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Autophosphorylation is a measure of enzyme activation as studied in Src family kinases as 
well as in BRK.  In order to determine whether the levels of total tyrosine phosphorylation 
observed in Figure 4.6 corresponded to the autophosphorylation levels of the enzymes, wild-
type SRMS as well as its three mutants, N, W223A and Y380F, were transiently transfected 
in HEK293 cells.  The overexpressed proteins were then immunoprecipitated from the cell 
lysates using anti-GFP antibodies and analysed by immunoblotting with anti-GFP and anti-
phosphotyrosine antibodies.  As shown in Fig. 4.7, while wild-type SRMS and BRK 
displayed prominent autophosphorylation, the SRMS-Y380F exhibited markedly reduced 
autophosphorylation, thereby validating that this tyrosine residue is indeed the site for 
autophosphorylation in SRMS.  Furthermore, upon longer exposure of the X-ray film, a 
subtle degree of autophosphorylation was noticed in the W223A mutant, whereas ΔN-SRMS 
displayed no detectable autophosphorylation. 
             From investigations on a small cohort of mutations introduced in the SRMS protein 
sequence (Fig 4.6 and Fig 4.7), it was evident that the linker region W223, the ATP-
contacting K258, the autophosphorylation site Y380 and the N-terminus segment are 
involved in the enzyme activity.  Yet the involvement of other potential regulatory elements 
in SRMS was unknown.  Therefore, the study was extended to include additional SRMS 
mutants (as described below and shown in Fig 4.8, 4.9 and 4.10).  Catalytic regulation via the 
SH3 and SH2 domains has been documented for Src family kinases as well as BRK (Qiu and 
Miller, 2004).  In order to understand the role of these domains in regulating enzymatic 
activity of SRMS, GFP-tagged mutants comprising deletions of either the SH3 domain 
(SH3 SRMS) or the SH2 domain (SH2 SRMS) were generated.   
              In Src family kinases, there exists a highly conserved arginine residue that forms part 
of the “signature FLVRES motif” within the SH2 domain and contacts the target 
phosphotyrosine.  Mutation of the conserved R175 in Src has been shown to destabilize 
phosphotyrosine binding (Campbell and Jackson, 2003).  Also, mutation of a similar arginine 
in BRK (R105) resulted in reduced phosphorylation and binding to the BRK substrate, 
STAP2 (Mitchell et al., 2000).  Nonetheless, while the SH2 mutant of BRK exhibits higher 
kinase activity, the effect of the R105 mutation has not been reported on the enzyme’s 
catalytic activity (Qiu and Miller, 2004).  Sequence alignment using CLUSTALW revealed 
that SRMS also possesses an arginine (R147) that remains conserved with BRK and c-Src. 
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Arginine 147 in SRMS was thus mutated to alanine to assess the catalytic repercussions 
alongside its SH2 mutant.  
 
 
 
FIGURE 4.7: SRMS is autophosphorylated on Y380.  Wild-type BRK and wild-type 
SRMS as well as its indicated mutants were immunoprecipitated from HEK-293 cell lysates 
and immunoblotted with anti-phosphotyrosine (top panel) to reveal autophosphorylation of 
the respective proteins.  The immunoprecipitated proteins were probed via anti GFP (bottom 
panel). .  Similar results were obtained in at least three different experiments. 
 
From the results in Figure 4.6 and 4.7, it was demonstrated that the N-terminal region plays a 
critical role in stabilizing the intrinsic tyrosine kinase activity of SRMS.  The primary amino 
acid sequence of this N-terminal region shows that this region is replete with proline residues.  
In fact, out of the total 50 amino- acids constituting the N-terminal region, nine were prolines.  
Furthermore, six such prolines, located proximal to the SH3 domain, were found to be closely 
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stacked in a manner that was indicative of a discrete proline-rich motif.  This small proline-
rich segment was therefore deleted and the resulting mutant was designated PN-SRMS 
(where “P” stands for Partial).  
                       The SH2-kinase linker region of BRK contains three proline residues, 
conforming to the PXXP motif that participates in intra-molecular interactions with the SH3 
domain, thus facilitating the inactive state of the PTK (Qiu and Miller, 2003).  The SRMS 
SH2-kinase linker region also possesses three invariable proline residues, albeit not 
conforming to a PXXP type motif.  Two different mutants were constructed taking into 
account the spatial arrangement of these prolines. In one mutant, a single proline situated 
proximal to the SH2 domain was mutated to alanine (P214A) and the mutant designated 
SRMS-PA.  The other variant contained mutations in the remaining two prolines 
(P218A+P226A) located distally from the SH2 domain and was designated SRMS-2PA 
 
 
 
FIGURE 4.8: Schematic representation of SRMS mutants.  Shown here is the wild type 
SRMS containing the globular functional domains SH3, SH2 and the kinase domain. SRMS 
mutants; N-SRMS (N-terminally deleted), PN-SRMS (Partial N-terminal deletion), SH3 
(SH3 deletion), SH2 (SH2 deletion) as well as its point mutated variants for the indicated 
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amino acid residues are also shown.  The critical residues W223A, K258, Y380 and R147 are 
conserved with BRK.  
 
 
 
sp|P42685|FRK_HUMAN       ------MSNICQRLWEYLEP----------YLPCLSTEA-DKSTVIEN--PGALCSPQS- 40 
sp|P12931|SRC_HUMAN       MGSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPS-KPASADGHRGPSAAFAPAAA 59 
sp|Q9H3Y6|SRMS_HUMAN      ------MEPFLRRRLAFLSFFWDKIWPAGGEPDHGTPGSLDPNTDPVPTLPAEPCSPFP- 53 
sp|Q13882|PTK6_HUMAN      ---------MVSRDQAHLG----------------------------------------- 10 
                                      :    *                                           
 
sp|P42685|FRK_HUMAN       -----------------QRHG------HYFVALFDYQARTAEDLSFRAGDKLQVLDTLHE 77 
sp|P12931|SRC_HUMAN       EPKLFGGFNSSDTVTSPQRAGPLAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEG 119 
sp|Q9H3Y6|SRMS_HUMAN      ---------------------------QLFLALYDFTARCGGELSVRRGDRLCALE-EGG 85 
sp|Q13882|PTK6_HUMAN      ---------------------------PKYVGLWDFKSRTDEELSFRAGDVFHVAR-KEE 42 
                                                       ::.*:*: :*   :**.: *: :         
 
sp|P42685|FRK_HUMAN       GWWFARHLEKRRDGSSQQLQGYIPSNYVAED--RSLQAEPWFFGAIGRSDAEKQLLYSEN 135 
sp|P12931|SRC_HUMAN       DWWLAHSLSTGQTG-------YIPSNYVAPS--DSIQAEEWYFGKITRRESERLLLNAEN 170 
sp|Q9H3Y6|SRMS_HUMAN      GYIFARRLS---GQPSAG---LVPITHVAKASPETLSDQPWYFSGVSRTQAQQLLLSPPN 139 
sp|Q13882|PTK6_HUMAN      QWWWATLLDEAGGAVAQG---YVPHNYLAER--ETVESEPWFFGCISRSEAVRRLQAEGN 97 
                           :  *  *.             :* .::*     ::. : *:*. : * :: : *    * 
 
sp|P42685|FRK_HUMAN       KTGSFLIRESESQKGEFSLSVLD-----GAVVKHYRIKRLDEGGFFLTRRRIFSTLNEFV 190 
sp|P12931|SRC_HUMAN       PRGTFLVRESETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFNSLQQLV 230 
sp|Q9H3Y6|SRMS_HUMAN      EPGAFLIRPSESSLGGYSLSVRA-----QAKVCHYRVSMAADGSLYLQKGRLFPGLEELL 194 
sp|Q13882|PTK6_HUMAN      ATGAFLIRVSEKPSADYVLSVRD-----TQAVRHYKIWRRAGGRLHLNEAVSFLSLPELV 152 
                            *:**:* **.  . : ***          * **::     * :.:     *  * ::: 
 
sp|P42685|FRK_HUMAN       SHYTKTSDGLCVKLGKPCLKIQVPAPFDLSYKTVDQWEIDRNSIQLLKRLGSGQFGEVWE 250 
sp|P12931|SRC_HUMAN       AYYSKHADGLCHRLTTVCPTSKP----QTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWM 286 
sp|Q9H3Y6|SRMS_HUMAN      TYYKANWKLIQNPLLQPC---MP-----QKAPRQDVWERPHSEFALGRKLGEGYFGEVWE 246 
sp|Q13882|PTK6_HUMAN      NYHRAQSLSHGLRLAAPCRKHEP-----EPLPHWDDWERPREEFTLCRKLGSGYFGEVFE 207 
                           ::          *   *                * **  :..: *  :**.* ****:  
 
sp|P42685|FRK_HUMAN       GLWNNTTPVAVKTLKPGSMDPNDFLR-EAQIMKNLRHPKLIQLYAVCTLEDPIYIITELM 309 
sp|P12931|SRC_HUMAN       GTWNGTTRVAIKTLKPGTMSPEAFLQ-EAQVMKKLRHEKLVQLYAVVS-EEPIYIVTEYM 344 
sp|Q9H3Y6|SRMS_HUMAN      GLWLGSLPVAIKVIKSANMKLTDLAK-EIQTLKGLRHERLIRLHAVCSGGEPVYIVTELM 305 
sp|Q13882|PTK6_HUMAN      GLWKDRVQVAIKVISRDNLLHQQMLQSEIQAMKKLRHKHILALYAVVSVGDPVYIITELM 267 
                          * * .   **:*.:.  .:    : : * * :* *** ::: *:** :  :*:**:** * 
 
sp|P42685|FRK_HUMAN       RHGSLQEYLQNDTGSKIHLTQQVDMAAQVASGMAYLESRNYIHRDLAARNVLVGEHNIYK 369 
sp|P12931|SRC_HUMAN       SKGSLLDFLKGETGKYLRLPQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCK 404 
sp|Q9H3Y6|SRMS_HUMAN      RKGNLQAFLGTPEGRALRLPPLLGFACQVAEGMSYLEEQRVVHRDLAARNVLVDDGLACK 365 
sp|Q13882|PTK6_HUMAN      AKGSLLELLRDSDEKVLPVSELLDIAWQVAEGMCYLESQNYIHRDLAARNILVGENTLCK 327 
                           :*.*   *       : :.  :.:* *:*.**.*:*  . :**** * *:**.:    * 
 
sp|P42685|FRK_HUMAN       VADFGLARVFKVDNEDIYESRHEIKLPVKWTAPEAIRSNKFSIKSDVWSFGILLYEIITY 429 
sp|P12931|SRC_HUMAN       VADFGLARLIE-DNE--YTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTK 461 
sp|Q9H3Y6|SRMS_HUMAN      VADFGLARLLK---DDIYSPSSSSKIPVKWTAPEAANYRVFSQKSDVWSFGVLLHEVFTY 422 
sp|Q13882|PTK6_HUMAN      VGDFGLARLIK---EDVY-LSHDHNIPYKWTAPEALSRGHYSTKSDVWSFGILLHEMFSR 383 
                          *.******:::   :  *      ::* *******     :: ********:** *: :  
 
sp|P42685|FRK_HUMAN       GKMPYSGMTGAQVIQMLAQNYRLPQPSNCPQQFYNIMLECWNAEPKERPTFETLRWKLED 489 
sp|P12931|SRC_HUMAN       GRVPYPGMVNREVLDQVERGYRMPCPPECPESLHDLMCQCWRKEPEERPTFEYLQAFLED 521 
sp|Q9H3Y6|SRMS_HUMAN      GQCPYEGMTNHETLQQIMRGYRLPRPAACPAEVYVLMLECWRSSPEERPSFATLREKLHA 482 
sp|Q13882|PTK6_HUMAN      GQVPYPGMSNHEAFLRVDAGYRMPCPLECPPSVHKLMLTCWCRDPEQRPCFKALRERLSS 443 
                          *: ** ** . :.:  :  .**:* *  ** ..: :*  **  .*::** *  *:  *   
 
sp|P42685|FRK_HUMAN       YF-ETDSSYSDANNFIR 505 
sp|P12931|SRC_HUMAN       YFTSTEPQYQPGENL-- 536 
sp|Q9H3Y6|SRMS_HUMAN      IHRCHP----------- 488 
sp|Q13882|PTK6_HUMAN      FTSYENPT--------- 451 
 
FIGURE 4.9: Multiple sequence alignment of c-Src and FRK/PTK6 family kinases.  
FRK, BRK and SRMS with c-Src depicting their autophosphorylated tyrosines (red), ATP-
binding lysines (dark green) and auto-regulatory tryptophans (light green).  Other amino 
acids selected for point-mutations in SRMS are highlighted: P214 and P218+P226 (yellow) 
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and R147 (light grey).  A short proline-rich segment at the N-terminus of SRMS (highlighted 
and underlined in gold) was deleted to generate the PN SRMS mutant.  The SRMS SH3 
domain (51-112) amino acids are in orange, the SH2 domain (120-212) in blue and the kinase 
domain (230-488) in red. “*” represent conserved amino acid residues across the given amino 
acid sequences.  “:/.” represent partially conserved amino acid residues. 
 
 
 
 
 
        10         20         30         40         50         60  
MEPFLRRRLA FLSFFWDKIW PAGGEPDHGT PGSLDPNTDP VPTLPAEPCS PFPQLFLALY  
 
        70         80         90        100        110        120  
DFTARCGGEL SVRRGDRLCA LEEGGGYIFA RRLSGQPSAG LVPITHVAKA SPETLSDQPW  
 
       130        140        150        160        170        180  
YFSGVSRTQA QQLLLSPPNE PGAFLIRPSE SSLGGYSLSV RAQAKVCHYR VSMAADGSLY  
 
       190        200        210        220        230        240  
LQKGRLFPGL EELLTYYKAN WKLIQNPLLQ PCMPQKAPRQ DVWERPHSEF ALGRKLGEGY  
 
       250        260        270        280        290        300  
FGEVWEGLWL GSLPVAIKVI KSANMKLTDL AKEIQTLKGL RHERLIRLHA VCSGGEPVYI  
 
       310        320        330        340        350        360  
VTELMRKGNL QAFLGTPEGR ALRLPPLLGF ACQVAEGMSY LEEQRVVHRD LAARNVLVDD  
 
       370        380        390        400        410        420  
GLACKVADFG LARLLKDDIY SPSSSSKIPV KWTAPEAANY RVFSQKSDVW SFGVLLHEVF  
 
       430        440        450        460        470        480  
TYGQCPYEGM TNHETLQQIM RGYRLPRPAA CPAEVYVLML ECWRSSPEER PSFATLREKL  
 
     488 
HAIHRCHP  
 
FIGURE 4.10: Amino acid sequence of SRMS highlighting the various residues that 
were mutated.  These include P214A, P218A+P223A, W223A, K258 and Y380F.  The short 
N-terminal proline-rich segment (highlighted and underlined in gold) was deleted to generate 
the PN SRMS mutant.   The amino acids comprising the SH3 domain (51-112) are in 
orange, those comprising the SH2 domain (120-212) are in blue and those for the kinase.  
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All of these mutants together with wild-type SRMS, N-SRMS, SRMS-K258M and SRMS-
W223A were transiently transfected in HEK293 cells.  Whole cell lysates were utilized for 
immunoblotting with antibodies against GFP, SRMS and phosphotyrosines.  All these 
mutants together with wild-type SRMS, ΔN-SRMS, SRMS-K258M and SRMS-W223A were 
transiently transfected in HEK293 cells to test the overall effects on kinase activity.  Cell 
lysates were analyzed for immunoreactivity with anti-phosphotyrosine antibodies to assess 
the relative kinase activity (Fig. 4.11,  panel A and B).  The variants were generally expressed 
at comparable levels (Fig. 4.11, panel C and D).  Note that since anti-SRMS targets an 
epitope spanning the N-terminal region of the protein, the detection of the PN SRMS was 
reduced while that of N SRMS was significantly decreased. Of all the SRMS mutants 
examined, ΔSH2-SRMS (lane 7) displayed the lowest kinase activity compared with the 
wild-type SRMS, suggesting that SH2 domain is essential for SRMS kinase activation.  
However, deletion of the SH3 domain did not significantly affect kinase activity (lane 8).  
P214A (lane 4) and 2PA (lane 5) mutations in the linker region also had little effect on kinase 
activity.  As well, the R147A mutantdisplayed kinase activity that was similar to that of the 
wild-type SRMS (compare lane 1 and lane 6).  Also, the PΔN-SRMS failed to alter the 
catalytic activity of SRMS, suggesting that the short segment rich in proline residues does not 
display a critical role towards regulating SRMS tyrosine kinase activity.  Taken together, our 
data demonstrates that the kinase activity of SRMS is regulated by its unique N-terminal 
sequence.  Furthermore, contrarily to BRK (Qiu and Miller, 2004), deletion of the SH2 
domain of SRMS resulted in a significantly reduced kinase activity.  Overall, these data 
demonstrate that the catalytic activity of SRMS is regulated by its unique N-terminus 
sequence as well as its SH2 domain.   
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FIGURE 4.11: The N-terminal region of SRMS and its SH2 domain promotes a 
constitutively active form of the kinase.  Transiently transfected variants of SRMS were 
analysed for relative catalytic activity in comparison to wild type SRMS via immunoblotting 
with phosphotyrosine antibodies (panel A and B).  Anti-GFP was used to probe the 
ectopically expressed proteins (panel C).  Anti-SRMS antibodies, targeting an epitope in the 
N-terminus region of SRMS, depict commensurately abrogated immunoreactivity with N-
SRMS and PN-SRMS (panel D).  Protein bands were quantified using the IMAGE J 
software (1.24) and expressed in terms of fold increase relative to the controls (anti-GFP).  
Similar results were obtained in at least three different experiments. 
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4.2.2 Sub-cellular localization of SRMS mutants 
From the data in Figure 4.3 and 4.4 it was shown that endogenous as well as overexpressed 
SRMS exhibits a punctate cytoplasmic sub-cellular distribution pattern. The cellular 
mechanisms regulating such a characteristic localization pattern are unknown.  SRMS has 
functional SH3 and SH2 domains that mediate intermolecular interactions with cellular 
targets.  It is therefore conceivable that SRMS is directed to specific sub-cellular 
compartments through its SH3 and/or SH2 mediated interactions with endogenous protein 
targets.  It is also possible that the unique N-terminal region of SRMS regulates not only 
kinase activity but also sub-cellular localization.  To this end, wild type SRMS as well as its 
mutants SRMS-K258M, SRMS-Y380F, SRMS-W223A, SH3-SRMS, SH2-SRMS and 
N-SRMS were transiently transfected in HEK293 cells and localization analysed through 
fluorescence microscopy.  We observed that while wild-type SRMS localized to punctate 
cytoplasmic structures in over 90% of transfected cells, the SRMS-K258M mutant displayed 
a diffuse pattern in approximately 80% of transfected cells (Fig. 4.12).  However, the SRMS-
W223A as well as the SRMS-Y380F mutants exhibited a predominant punctate sub-cellular 
distribution comparable to wild-type SRMS (Fig 4.12 and 4.14).  Interestingly, while the 
SH3 mutant produced a punctate pattern in approximately 80% of transfected cells, SH2-
SRMS as well as N-SRMS exhibited a diffuse localization pattern in roughly 90% and 70% 
of the transfected cell population, respectively (Fig 4.13 and 4.14).  Together, these data 
suggest that the N-terminal region of SRMS not only regulates the enzyme’s activity, but can 
also modulate the sub-cellular localization.  These findings also indicate that the SH2 domain 
of SRMS may contribute to sequester SRMS in specific cytoplasmic structures. 
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FIGURE 4.12: Sub-cellular localization of wild type SRMS and its mutants; SRMS-
K258M and SRMS-W223A. Intracellular localization of exogenous GFP-tagged wild-type 
SRMS and its indicated mutants, was detected via fluorescence microscopy in HEK293 cells.  
Cells were counter-stained with DAPI.  Images were captured at 60x magnification using the 
Olympus inverted microscope.  Similar results were obtained in at least three different 
experiments. 
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FIGURE 4.13: Sub-cellular localization of N SRMS.  GFP-N SRMS was transiently 
transfected in HEK293 cells. Cells were counter-stained with DAPI. Images were captured at 
60x magnification using the Olympus inverted microscope.  Similar results were obtained in 
at least three different experiments. 
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FIGURE 4.14: Sub-cellular localization of SH2-SRMS, SH3-SRMS and Y380F-
SRMS.  SRMS mutants, GFP-SRMS-Y380F, GFP-SH2-SRMS and GFP-SH3-SRMS 
were transiently transfected in HEK293 cells. Cells were counter-stained with DAPI. Images 
were captured at 60x magnification using the Olympus inverted microscope.  Similar results 
were obtained in at least three different experiments. 
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4.3 Expression and Sub-cellular localization of Dok1 in various breast cancer cell lines. 
4.3.1 Expression of Dok1 in breast cancer cell lines 
Although Dok1 has been validated as a tumor suppressor in several studies, there is little 
information on its expression in cancer cell lines, particularly those derived from the human 
breast, prompting us to investigate its expression in these cell lines.  Endogenous Dok1 
expression was determined and compared alongside SRMS in eight breast cancer cell lines, 
namely BT20, MCF7, MDA-MB-231, MDA-MB-435, MDA-MB-468, AU565, HBL-100 
and SKBR3, besides the non-tumorigenic breast epithelial cell line, 184B5.  Interestingly, 
though Dok1 was found to be low or absent in four cell lines, namely, MCF7, MDA-MB-
468, AU565 and SK-BR3, its elevated expression in the other cell lines, especially in HBL-
100, appeared to correspond with that of endogenous SRMS (Fig 4.15).   
 
  
FIGURE 4.15: Dok1 is differentially expressed in breast cancer cell lines.  Dok1 
expression was surveyed alongside SRMS in 8 breast cancer cell lines and a normal breast 
epithelial cell line, 184B5, using antibodies against Dok1 and SRMS, respectively.  -tubulin 
was used as the loading control.  Similar results were obtained in at least three different 
experiments.  
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4.3.2 Sub-cellular distribution of Dok1 
Through immunocytochemistry analysis using anti-Dok1 antibodies, the sub-cellular 
localization of endogenous Dok1 was determined in the MDA-MB-231 and MDA-MB-435 
cell lines as well as in the HeLa cell line.  Based on such immunofluorescence analysis, 
endogenous Dok1 was found to localize predominantly to the cytosol of the cell lines (Fig 
4.16).  Like endogenous Dok1, ectopically expressed GFP-Dok1, was also found to localize 
to the cytoplasm, as analysed through fluorescence microscopy, in HEK293 cells (Fig 4.17).  
Sub-cellular fractionation studies further corroborated data from immunocytochemistry 
analysis (Fig 4.18).  
 
 
 
FIGURE 4.16: Endogenous Dok1 localizes predominantly to the cytosol in cells.  A. 
Intracellular localization of endogenous Dok1 was detected via indirect immunofluorecence 
in the breast cancer cell lines, MDA-MB-231 and MDA-MB-435 and the cervical cancer cell 
line, HeLa.  Immunoreactivity was visualized using anti-Dok1 and secondary TEXAS RED.  
Cells were counterstained with DAPI (blue).  Similar results were obtained in at least three 
different experiments. 
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FIGURE 4.17: Ectopically expressed Dok1 localizes predominantly to the cytosol in 
cells.  HEK293 cells were transiently transfected with GFP-Dok1 and localization determined 
via fluorescence microscopy.  Cells were counter-stained with DAPI and images taken at 60x 
magnification using the Olympus inverted microscope.  Similar results were obtained in at 
least three different experiments). 
 
 
FIGURE 4.18: Sub-cellular fractionation reveals that Dok1 is a predominantly 
cytoplasmic protein.  Cells from the indicated cell lines were fractionated into the cytosolic, 
membrane and nuclear fractions and immunoblotted for Dok1.  -tubulin and Sam68 were 
used as the fraction markers for the cytosolic/membrane and nuclear compartments, 
respectively. Similar results were obtained in at least three different experiments. 
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 Since Dok1, akin to SRMS, was found to localize to the cytoplasm, it was next determined 
whether both proteins co-localized in cells.  Using antibodies specific to SRMS and Dok1, 
minimal co-localization was observed between endogenous Dok1 and SRMS in the HEK293 
cell line (Fig 4.20).   
 
 
FIGURE 4.19: Co-localization analyses of endogenous Dok1 and SRMS.  Endogenous 
SRMS and Dok1 co-localization was determined via indirect immunofluorescence in the 
HEK293 cell line using antibodies against SRMS (FITC) and Dok1 (Texas Red).  Cells were 
counterstained with DAPI.  Images were taken at 60x magnification using the Olympus 1x51 
inverted microscope.  Similar results were obtained in at least three different experiments 
(n=3). 
 
 
4.4 Characterizing Dok1 as a substrate of SRMS 
4.4.1 Molecular interaction between SRMS and Dok1  
SRMS has SH3 and SH2 domains which in Src family kinases as well as in BRK and FRK 
have been shown to bind to proline-rich sequences and phosphorylated tyrosine residues 
respectively.  The C-terminal tail of Dok1 possesses several proline and tyrosine residues that 
may serve as potential SH3/SH2 binding sites (Fig 1.11).  
Since Dok1 was identified as a potential target of SRMS, we first determined whether both 
proteins interact.  To study binding associations between both proteins, GFP-SRMS and 
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GFP-Dok1 were transiently transfected either alone or together in HEK293 cells.  The cells 
were then lysed and subjected to immunoprecipitation with antibodies against Dok1 and 
SRMS.  Immunoblotting was performed using the same antibodies to determine co-
immunoprecipitation of SRMS with Dok1 and vice-versa.  Immunoblotting the Dok1 
immunoprecipitates with anti-SRMS antibodies revealed the co-precipitation of SRMS with 
Dok1 (Fig 4.20, lane 7). Reciprocal co-precipitation of Dok1 was also observed in SRMS 
immunoprecipitates (Fig 4.20, lane 7).   
 
 
FIGURE 4.20: SRMS interacts with Dok1 in cells.  HEK293 cell lysates from GFP-SRMS, 
GFP-Dok1 or GFP-SRMS/GFP-Dok1 co-transfected cohorts were subjected to 
immunoprecipitation with anti-Dok1 and immunoblotted with Dok1 and SRMS (top 2 
panels).  Conversely, SRMS was immunoprecipitated from such lysates using anti-SRMS and 
the immunoprecipitates (IP) probed for SRMS and Dok1 (bottom 2 panels).  Anti-IgG 
(Rabbit) was used as the control.  Total cell lysates (TCL) indicate the relative expression of 
the proteins.  Similar results were obtained in at least three different experiments. 
 
To ensure that the association between the GFP-tagged SRMS and Dok1 proteins was not due 
to GFP dimerization, HEK293 cells transiently transfected with either pEGFP control vector 
or co-transfected with pEGFP and GFP-Dok1 or GFP-Dok1 and N-SRMS, were subjected 
to immunoprecipitation with anti-GFP antibodies and immunoblotted with the same antibody.  
As can be seen in Fig 4.21, GFP alone did not co-precipitate with GFP-Dok1 (Lane 4) 
whereas GFP-N-SRMS was found to co-precipitate with GFP-Dok1 (Lane 7).  Thus, the 
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results in Figure 4.21 demonstrate that (a) the association between the proteins is not via GFP 
dimerization and (b) Dok1 binds to N-SRMS.  These results clearly suggest that SRMS 
physically associates with Dok1 and that the N-terminal region of SRMS, while being 
indispensible for catalytic activity, is potentially expendable for binding associations of the 
enzyme with its targets.  
 
 
 
FIGURE 4.21: The association between GFP-SRMS and GFP-Dok1 is not mediated via 
GFP dimerization.  Cell lysates were subjected to immunoprecipitation with anti-Dok1 in 
the GFP-Dok1/pEGFP or GFP-Dok1/GFP-N SRMS co-transfected cohorts and 
immunoblotted with antibodies against GFP to probe for GFP dimerization-mediated 
association between the ectopic proteins.  Anti-IgG (Rabbit) was used as the control.  Total 
cell lysates (TCL) indicate the relative expression of the proteins.  Similar results were 
obtained in at least three different experiments. 
                      
 To determine whether SRMS associates with Dok1 via its SH3 and/or SH2 domains, in vitro 
binding assays were performed using the glutathione S-transferase (GST)-fused SH3 and 
SH2 domains of SRMS.  First, the association between endogenous Dok1 and GST-SH3 was 
evaluated using lysates from untransfected HEK293 cells.  Using antibodies against Dok1, 
interactions between GST-SH3 and Dok1 were observed (Fig. 4.22, left panel).  However, 
such binding asociations were not observed with the GST-SH2 protein. Since the SH2 
domain interacts primarily with phosphorylated tyrosine residues, HEK293 cells were 
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transiently transfected with GFP-SRMS to determine whether ectopically expressed SRMS 
will induce the phosphorylation of endogenous Dok1 and its binding to the SH2 domain of 
SRMS.  As shown in Fig 4.23 (left panel), GST-SH2 formed a complex with endogenous 
DOK1 in the presence of GFP-SRMS.  Moreover, immunoblotting with anti-phosphotyrosine 
antibodies revealed the bound Dok1 to be tyrosine phosphorylated.  Such binding interactions 
between GST-SH2 and Dok1 was not observed in the presence of pEGFP vector or the 
kinase-dead mutant of SRMS, SRMS-K258M, thus demonstrating that tyrosine 
phosphorylation of Dok1 is required for associations with the SRMS SH2 domain (Fig 4.24).  
Expression and molecular sizes of the GST, GST-SH3 and GST-SH2 proteins are shown by 
Coomassie Blue staining (Fig 4.22 and 4.23, right panels).  GST alone bound to beads was 
used as control and total cell HEK293 lysates were used to determine the relative expression 
of endogenous Dok1.  These data collectively show that both, the SH3 and SH2, domains of 
SRMS mediate interactions with Dok1. 
 
 
FIGURE 4.22: Dok1 associates with SRMS SH3 domain.  A GST-Pull-down assay was 
conducted with the GST-SH3 and GST-SH2 domains of SRMS using HEK293 cell lysates.  
Bound proteins were resolved via SDS-PAGE and immublotted with anti-Dok1 antibodies 
(left panel).   Expression of the bacterially expressed proteins is shown via Coomassie 
staining of the PAGE gel (right panel).  Similar results were obtained in at least three 
different experiments. 
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FIGURE 4.23: Tyrosine phosphorylated Dok1 associates with SRMS SH2 domain. 
HEK293 cells transfected with GFP-SRMS, were lysed and utilized towards a GST-pull 
down assay with the SRMS GST-SH2 domain.  Bound proteins were resolved via SDS-
PAGE and immunoblotted with anti-Dok1 antibodies (top left panel) and phosphotyrosine 
antibodies (bottom panel).  Expression of the GST-fused proteins is shown in the Coomassie 
stained image of the SDS-PAGE gel (top right panel).  Similar results were obtained in at 
least three different experiments. 
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FIGURE 4.24: Tyrosine phosphorylation is necessary for the association of Dok1 with 
SRMS SH2 domain. A GST-pull down assay was performed using lysates derived from 
HEK293 cells transfected with either pEGFP vector or GFP-SRMS-K258M.  Bound proteins 
were resolved via SDS-PAGE and immublotted with anti-Dok1 antibodies Similar results 
were obtained in at least three different experiments. 
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4.4.2 Validation of Dok1 as a substrate of SRMS  
Dok1 was identified in a high-throughput proteomics screen as a potential substrate of Src-
family kinases as well as SRMS.  In order to begin to characterize the substrate-specificity of 
Dok1 towards SRMS, HEK293 cells were transfected with GFP-Dok1 alone or co-transfected 
with GFP-Dok1 and GFP-SRMS.  Dok1 was then immunoprecipitated from the lysates and 
subjected to immunoblotting against phosphotyrosine, Dok1 and SRMS antibodies.  
Immunoblotting with anti-phosphotyrosine antibodies revealed tyrosine phosphorylation of 
Dok1 in the presence of SRMS (Fig 4.25, lane 4, top panel).  Immunoblotting with anti-
SRMS antibodies revealed the co-precipitation of SRMS with Dok1, suggestive of binding 
associations between both the proteins (Fig 4.25, lane 4, middle panel).  These results, 
therefore, confirmed the phosphorylation of Dok1 in the presence of SRMS and were also 
suggestive of potential binding interactions between both proteins.    
                        To determine the phosphorylation of endogenous Dok1 by SRMS, GFP-
tagged wild-type SRMS or the catalytically-inactive, N-SRMS, were transiently expressed 
in HEK293 cells and endogenous Dok1 was immunoprecipitated to assess for tyrosine 
phosphorylation.  The aim of such an experiment was to determine whether ectopically 
expressed SRMS induces the phosphorylation of endogenous Dok1 and also whether the N-
terminal region of SRMS regulates the mechanism of its substrate recognition.  
Immunoblotting via anti-phosphotyrosine antibodies revealed endogenous Dok1 to be 
phosphorylated upon ectopic expression of SRMS (Fig 4.26, lane 4, bottom panel).  
Furthermore, immunoblotting with an antibody against GFP revealed that, like wild-type 
SRMS, N-SRMS also co-immunoprecipitated with endogenous Dok1, thereby attesting data 
from Figure 4.21 that the N-terminus is expendable in directing substrate recognition and 
association (Fig 4.26, lane 1, middle panel).  
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FIGURE 4.25: SRMS induces the phosphorylation of Dok1 in cells.  Dok1 was 
immunoprecipitated from GFP-Dok1 alone or GFP-Dok1/GFP-SRMS co-transfected cohorts 
of HEK293 cell lysates and probed for tyrosine phosphorylation using anti-phosphotyrosine 
antibodies (top panel), SRMS (middle panel) and Dok1 (bottom panel). Anti-IgG (rabbit) was 
used as control.  Total cell lysates were used to indicate the relative expression of both 
proteins.  Similar results were obtained in at least three different experiments. 
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FIGURE 4.26: Ectopically expressed SRMS induces the phosphorylation of endogenous 
Dok1.  Dok1 was immunoprecipitated from GFP-SRMS or GFP-N-SRMS transfected 
cohorts of HEK293 cell lysates and immunoblotted for Dok1 (top panel), SRMS (middle 
panel) and phosphotyrosine (bottom panel).  Total cell lysates were used to indicate the 
relative expression of the respective proteins.  Anti-IgG (rabbit) was used as control.  Similar 
results were obtained in at least three different experiments. 
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4.4.2.1  Mapping the regions on Dok1 phosphorylated by SRMS 
Dok1 possesses a dense array of prolines and tyrosine residues along its C-terminal segment 
that extends from the phospho-tyrosine binding (PTB) domain into a 222 amino acid chain.  
While several proline residues lie clustered herewith, these remain interspersed between a 
total of 10 tyrosine residues.  In order to map the cluster of tyrosine residues phosphorylated 
by SRMS, a total of five C-terminally truncated mutants of Dok1 were generated, each 
successively containing an increasing number of tyrosine residues (Fig 4.27).  
 
 
 
 
FIGURE 4.27: Mapping Dok1 Tyrosine residue clusters.  A Schematic diagram of wild 
type Dok1 (Dok1 WT) and its five, C-terminally truncated, mutants showing the 
progressively increasing number of tyrosine and proline residues with each mutant.  
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Wild-type Dok1 as well as its mutants were transiently transfected in HEK293 cells, either 
alone or with mCherry-SRMS.  The Dok1 mutants were immunoprecipitated with anti-GFP 
antibodies and the immunoprecipitates and total cell lysates were immunoblotted with 
antibodies against phosphotyrosine, GFP and SRMS.  Immunoblotting the total cell lysates 
with anti-phosphotyrosine antibodies revealed that, besides wild-type Dok1 (Fig. 4.28, lane 
12), Dok-3 (1-345), Dok-4 (1-380) and Dok-5 (1-415) were all phosphorylated in the 
presence of mCherry-SRMS (Fig. 4.28, middle panel).  Barring Dok-(1-259) as the only 
exception, Dok-2 (1-317) was also found to be phosphorylated upon longer exposure of the 
X-ray film to the immunoblotted membrane.  The expression levels of transfected GFP-Dok1 
mutants and mCherry-SRMS proteins are shown in Figure 4.28 (top and bottom panels, 
respectively).  Immunoblotting performed on the immunoprecipitates also demonstrated 
identical results (Fig. 4.29, top panel) which confirmed that all Dok1 mutants, except for 
Dok-1, were phosphorylated in the presence of ectopically expressed mCherry-SRMS.  
Furthermore, that co-immunoprecipitation of ectopic SRMS progressively diminished with 
the smaller Dok1 mutants (Fig 4.29, bottom panel, lanes 1-6), potentially indicates the 
underlying significance of the C-terminal proline and phosphotyrosine residues in mediating 
binding interactions with SRMS.  
                  It was vital to also determine whether Dok1 is a direct substrate of SRMS since 
Dok1 is essentially a scaffolding protein that provides for a docking platform to mediate 
interactions between several proteins.  Therefore, the hypothesis that Dok1 phosphorylation 
could be mediated by SRMS via activation of a third protein seemed plausible.  An in vitro 
kinase assay, using the purified recombinant kinase (GST-SRMS) and substrate (GST-Dok1), 
in the presence or absence of ATP, revealed that Dok1 is a direct bonafide substrate of SRMS 
(Fig. 4.30).  GST alone was not phosphorylated in the presence of SRMS kinase (Fig. 4.31). 
                    Overall, through the employed experimental procedures involving site-directed 
mutagenesis, immunoprecipitation, immunofluorescence microscopy/ immunocytochemistry, 
in vitro GST-pull-down assays and kinase-substrate assays, this thesis concludes with the 
characterization of the catalytic activity of SRMS as well as the characterization of Dok1 as 
its first substrate. 
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FIGURE 4.28: Tyrosine phosphorylation of Dok1 mutants in the presence of SRMS.  
All five Dok1 mutants along with wild type Dok1 were transfected either alone or co-
transfected with mCherry-SRMS in HEK293 cells and total cell lysates were used for 
immunoblotting with antibodies against GFP (top panel), phosphotyrosine (middle panel) and 
SRMS (bottom panel).  Similar results were obtained in at least three different experiments. 
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FIGURE 4.29: Immunoprecipitation analysis depicting the tyrosine phosphorylation of 
Dok1 mutants in the presence of SRMS.  HEK293 cells were co-transfected with GFP-
tagged wild type Dok1 or its five mutants and mCherry-SRMS and subjected to 
immunoprecipitation with anti-GFP (rabbit) antibodies.  Immunoprecipitates were probed for 
tyrosine phosphorylation using antibodies against phosphotyrosine (top panel), for Dok1 
using anti-GFP (mouse) (middle panel) and for SRMS using anti-SRMS (bottom panel).  
Similar results were obtained in at least three different experiments. 
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FIGURE 4.30: Dok1 is a direct substrate of SRMS.  An in vitro kinase assay was 
performed using the active kinase domain, GST-SRMS, and the substrate, GST-Dok1, in the 
presence or absence of ATP.  Tyrosine phosphorylation was probed via anti phosphotyrosine 
antibodies (top panel) and expression of the GST-fused proteins, via anti-GST (bottom 
panel).  Similar results were obtained in at least three different experiments. 
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FIGURE 4.31 SRMS kinase does not phosphorylate GST alone.  A control in vitro kinase 
assay was performed using the active kinase, GST-SRMS and GST alone in the presence of 
ATP.  Tyrosine phosphorylation was probed via anti phosphotyrosine antibodies (left panel) 
and expression of the GST or GST-SRMS, via anti-GST (right panel).  Similar results were 
obtained from two different experiments. 
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5. DISCUSSION 
The non-receptor tyrosine kinase SRMS was cloned in 1994, but the autoregulatory 
mechanisms that dictate its enzymatic activity, substrate identification and recognition have 
never been examined. As well, the expression profile of SRMS in cells derived from the 
normal or cancer tissues has never been determined.  The present study is the first to 
investigate and unravel that (a) SRMS is potentially overexpressed in the majority of breast 
cancer cell lines studied, (b) that its catalytic activity is primarily regulated by the N-terminal 
region, completely divergent from BRK and FRK, and that (c) the adapter protein Dok1 is its 
first novel physiological substrate.  
 
5.1 SRMS and Dok1 expression and intra cellular localization in breast cancer cell lines.  
The expression of BRK and FRK has been previously reported. Such analyses reveal that 
while BRK is overexpressed in over 70% of breast carcinomas, FRK is potentially 
underexpressed in breast cancers (Barker et al., 1997; Cance et al., 1994; Craven et al., 
1995).  However, to date, the expression pattern of SRMS remains uncharacterized in breast 
cancers.  This study presents evidence for SRMS as a potentially over-expressed protein, akin 
to BRK, in different breast cancer cell lines.  The study covered a relatively broad spectrum 
of cell lines derived from the human breast cancer tissues to survey the expression of SRMS.  
Data from Fig 4.1 show that SRMS expression is elevated in the breast cancer cell lines 
evaluated, along the lines of BRK, but reduced in the normal breast cell line, 184B5.  This 
preliminary study, thus, suggests that SRMS is potentially upregulated in breast cancers as 
compared to normal mammary tissues which is reflective of its potential involvement in the 
molecular mechanisms associated human breast cancer.  It was also observed that the 
magnitude of SRMS expression did not vary significantly in the breast carcinomas as 
opposed to that of BRK, which for the latter, is consistent with previous reports (Barker et al., 
1997).                                                                                                                                            
                     While SRMS expression, like BRK, was generally elevated in the breast cancer 
cell lines, a reduced expression of the protein in the non-tumorigenic/ normal breast epithelial 
cell line, 184B5, was observed.  Established from a reduction mammoplasty, and chemically 
immortalized via Benzo(a)pyrene, the 184B5 cell line is a non-malignant human mammary 
epithelial cell line which exhibits no symptoms of tumorigenesis/malignancy.  With the 
exception of AU565 and MDA-MB-468 cell lines, SRMS exhibited a generally elevated 
expression pattern in the breast cancer repertoire examined in this study.  However, SRMS 
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expression appeared elevated in the Estrogen Receptor (ER) positive HBL100 cell line.  The 
expression profile of SRMS, thus, seems similar to BRK in that the majority of carcinoma 
cell lines exhibit high levels of the protein. Such an observation may invite knowledge on the 
genetic loci of the corresponding genes.  SRMS resides in the chromosomal locus 20q13.33, 
which is 1.5 kb upstream of the BRK gene. Such an arrangement of the genes is reflective of 
a potentially tight genetic linkage between BRK and SRMS.  Furthermore and more 
importantly, their genetic loci also correspond to a region that is frequently amplified in 
breast cancer (Harvey and Crompton, 2004) indicating that like BRK, expression of SRMS 
may also potentially be abberrantly upregulated in breast carcinomas.                    
                   However, unlike BRK, the present data on the expression of SRMS in a limited 
panel of breast cancer cell lines currently impedes any attempts to establish a correlation 
between the expression of the PTK and either the cancer molecular subtype or even an 
explicit morphological characteristic pertaining to the cell growth and proliferation.  This 
indicates a need to investigate the expression of SRMS at the transcriptional and post-
transcriptional level in a larger panel of breast cancer cell lines and tissues with varying 
clinical/pathological facets.  Immunohistological analyses on a broad spectrum of breast 
tissue specimens should serve to ascertain the expression of SRMS in breast carcinomas and 
its molecular association with the pathological grade of the specimens and the overall 
etiology of the disease.  
                     We have also presented evidence of Dok1 expression in a subset of breast 
cancer cell lines.  Although Dok1 has been examined for mutations that affect its expression 
in other cancer types (Mercier et al., 2011; Saulnier et al., 2012; Siouda et al., 2012), to our 
knowledge its expression has not been reported.  We identified a differential pattern of Dok1 
expression in the eight breast cancer cell lines, amongst which, akin to SRMS, an elevated 
expression was witnessed in the HBL-100 cell line (Fig 4.15).  Notably though, in the 
AU565, MDA-MB-468 and SK-BR3 cell lines, Dok1 was either too low or absent.  
Considering that Dok1 is a candidate tumor suppressor, its expression profile might be 
clinically significant if investigated on a wider panel of breast cancer cell lines.                    
The sub-cellular localization of endogenous SRMS in the breast cancer cell lines studied was 
determined to be predominantly punctate and cytoplasmic in nature (Fig 4.2).  Besides the 
breast cancer cell lines, MDA-MB-231 and AU565, a similar punctate and cytoplasmic 
localization was also observed in the cervical cancer cell line, HeLa.  However, it is possible 
that this intracellular distribution pattern may vary in the other breast cancer cell lines and 
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that such deviation in the sub-cellular distribution might be potentially associated with 
discrete functionalities specific to certain cell lines.  This may further be dependent on SRMS 
interactions with specific endogenous proteins, organelles or membranes via its functional 
SH3 and/or SH2 domains.  Even as the endogenous levels of SRMS appears low in AU565 
(Fig 4.1), immunocytochemistry analysis yields a strong fluorescent signal for SRMS in the 
same cell line.  This is probably because immunocytochemistry is not necessarily a 
quantitative.  Our fluorescence microscopy results in Fig. 4.12 - 4.14 show that the 
localization of SRMS may be dictated by interactions involving the extended N-terminus or 
the SH2 domain.  The deletion of any of these regions at least partially altered the 
cytoplasmic localization of SRMS from punctate to diffuse.  It is possible that the N-terminal 
region and the SH2 domain mediate intermolecular interactions with other target proteins or 
molecules (e.g. lipids) that sequester SRMS to distinct punctate structures within the cell.  
However, how these critical regions mediate such associations with other cellular 
components is as yet unknown.  Intermolecular interactions involving the SH2 and SH3 
domains of Src family kinases are also known to regulate the sub-cellular localization of 
these kinases (Mayer et al., 1995; Qiu and Miller, 2004; Thomas and Brugge, 1997).   
                    The localization of the inactivating K258M SRMS mutant was cytoplasmic and 
diffused in all cells.  It is not obvious why mutating the ATP binding site would alter the 
intracellular localization of SRMS.  This observation therefore requires further investigation.  
The cellular localization of BRK, for example, may not be as tightly regulated.  The protein 
has been shown to associate with its nuclear substrate, Sam68, in certain breast carcinomas 
besides the normal human prostate epithelial cells and well-differentiated prostate 
carcinomas, but localizes to the cytoplasm in poorly differentiated prostate tumors (Brauer 
and Tyner, 2010).  As well, strategically targeting BRK specifically to the membrane has 
been shown to enhance its oncogenic abilities, a feature that functionally contrasts with its 
nuclear-targeted counterpart (Ie Kim and Lee, 2009).  Nonetheless, it is yet to be determined 
how the localization of SRMS may affect its function.      
                     Although Dok1 predominantly localizes to the cytoplasm/membrane, a few 
published reports have indicated a nuclear distribution of the protein as well (Lee et al., 
2004b; Noguchi et al., 1999b).  Our data in figure 4.17 and 4.18 indicates that the 
intracellular localization of Dok1 is predominantly cytosolic as analyzed in the breast cancer 
cell lines, MDA-MB-231 and MDA-MB-435 as well as in the cervical cancer cell line, HeLa.  
Dok1 possesses a nuclear export signal (NES) that resides within a cluster of amino acids 
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348-359 situated at the C-terminal tail.  Published reports suggest that Dok1 shuttles between 
the nucleus and the cytoplasm, and such intracellular mobility is regulated via 
phosphorylation of Dok1 (Niu et al., 2006).  Along these lines, Woodring et al. reported that 
Dok1 phosphorylation by c-Abl tyrosine kinase promotes the localization of Dok1 to the 
filopodia tips in actin microstructures of mouse embryonic fibroblasts to allow for enhanced 
cell spreading (Woodring et al., 2004a).  Likewise, Dok1 was also shown to localize 
predominantly to the membrane via its PH domain following phosphorylation by v-Src as 
well as stimulation with insulin (Noguchi et al., 1999b).  It is possible that the 
cytoplasmic/membrane localization of Dok1 in breast cancer cell lines might promote similar 
functions.  Nonetheless, this hypothesis is yet to be investigated.  
 
 5.2 Regulation of SRMS tyrosine kinase activity 
Through site-directed mutagenesis and conventional cloning strategies, we have delineated 
the innate regulatory features that govern the catalytic activity of SRMS.  We determined that 
unlike the other Src-related tyrosine kinases, the catalytic activity of SRMS is regulated via 
its N-terminal region.  We report that deleting the entire 51 amino acid spanning N-terminal 
region abrogates the tyrosine kinase activity of SRMS.  This specifically contrasts the 
regulatory mechanism proposed for the c-Abl tyrosine kinase whose autoinhibitory 
intramolecular interactions are relieved upon terminating the 81 amino acid N-terminus 
region, thereby activating the enzyme (Nagar et al., 2003; Pluk et al., 2002).  Furthermore, 
this also distinguishes SRMS from its other 2 family members, BRK and FRK wherein the 
modes of catalytic auto-regulation, unlike the N-terminus, depends instead on the inhibitory 
C-terminal tail possessing a regulatory tyrosine residue.  
                The catalytic activity of Src family kinases is regulated by intramolecular 
interactions.  Studies on BRK have also shown that like Src kinases, BRK is regulated 
negatively by phosphorylation of C-terminal tyrosine 447 (which is analogous to the 
regulatory Y530 of human Src) and positively by phosphorylation of tyrosine 342 in the 
catalytic domain (as with Y419 of human Src) (Derry et al., 2000a; Qiu and Miller, 2002).  c-
Src tyrosine kinase (Csk) regulates Src family kinase activity by phosphorylating their C-
terminal tyrosines thereby promoting intramolecular interactions that inactivate these 
enzymes (Okada and Nakagawa, 1989).  Mutating the C-terminal tyrosine to phenylalanine in 
BRK (BRK-Y447F) and Src family kinases results in the constitutive activation of the 
enzymes.  SRMS lacks a C-terminal regulatory tail and our data is the first to report that full-
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length SRMS is active, as revealed by autophosphorylation and phosphotyrosine content as a 
measure of protein kinase activity in cells (Fig 4.7 and 4.8).  However, the full-length SRMS 
induced a relatively lower level of phosphorylation of cellular targets compared with BRK-
Y447F (Fig. 4.7).  Speculations to this end may be drawn from the observation that SRMS is 
sequestered in specific cytoplasmic compartments within the cell and has lower access to 
cellular substrates compared with BRK which may freely shuttle between the nucleus and 
cytoplasm.   
                   We generated a series of SRMS mutants to understand the autoregulatory 
mechanism of the kinase.  Deletion of the entire 51 amino acid spanning N-terminus region 
completely abrogated catalytic activity.  BRK has a much shorter N-terminus and unlike 
SRMS, the N-terminal amino acid sequence preceding the SH3 domain in BRK is known to 
be dispensable for the regulation of kinase activity (Qiu and Miller, 2004). As well, 
contrasting with SRMS, the deletion of the 81 amino acid N-terminus region of c-Abl 
relieved the enzyme of its autoinhibitory intramolecular interactions, thereby activating the 
enzyme (Nagar et al., 2003; Pluk et al., 2002).  Interestingly, deletion of the SH2 domain of 
SRMS also drastically reduced kinase activity (Fig. 4.12).  On the contrary, Qiu and Miller 
found that the Y447F and SH2 variants of BRK induced comparable and higher levels of 
substrate phosphorylation, which implied that wild type BRK is potentially maintained in an 
inactive (auto-inhibited) conformation by the putative SH2-pY447 interaction.  While the 
BRK-SH2 and SH3 domains play an inhibitory role, our data shows that the SH2 domain in 
SRMS is essential for the enzyme to sustain its catalytic activity in a yet unidentified 
mechanism.  Thus the autoregulatory mechanism of SRMS is distinct from that of BRK and 
Src kinases wherein the modes of catalytic autoregulation  depends on the inhibitory C-
terminal tail possessing a regulatory tyrosine residue (Brauer and Tyner, 2009, 2010).  
                   W260 and W184 situated within the SH2-kinase linker in Src family kinases and 
BRK respectively, have been shown to play opposing roles in maintaining the interactions of 
the SH2 and SH3 domains with their respective intramolecular ligands (LaFevre-Bernt et al., 
1998; Qiu and Miller, 2004).  The crystal structure of inactive Hck revealed that W260 
interacts with its kinase domain, maintaining the kinase in an inactive conformation (Sicheri 
et al., 1997).  Thus, the W260A mutation in Hck activated the enzyme (LaFevre-Bernt et al., 
1998).  However, the analogous W184A mutation in BRK was found to abrogate the kinase 
activity of the enzyme (Qiu and Miller, 2004).  The effect of W184A is reminiscent of the 
analogous W342A mutation in c-Raf, which also resulted in the loss of kinase activity 
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(McPherson et al., 2000).  We found that the analogous W223A mutation in SRMS also 
caused a loss of kinase activity (Fig. 4.7 and 4.8).  Thus, similar to BRK, W223 in SRMS is 
predicted to interact with the kinase domain and promote the active conformation of the 
enzyme. 
                 We also found that mutating the three proline residues within the SH2-kinase 
linker region in SRMS, did not significantly affect its kinase activity.  This contrasts with 
BRK as well as Src family kinases, wherein mutating the linker region proline residues 
resulted in significantly higher tyrosine kinase activity owing to the destabilization of 
autoinhibitory intramolecular interactions (Briggs and Smithgall, 1999; Qiu and Miller, 2004; 
Sicheri et al., 1997).  These proline residues in SRMS are not conserved with either BRK or 
the Src family kinases.  Since mutating these proline residues did not affect the tyrosine 
kinase activity of SRMS, it indicates an indispensable role for these residues in 
intramolecular binding.   
                Furthermore, while our strategy to specifically delete a 13 amino acid proline-rich 
segment in the N-terminal region of SRMS (PN SRMS) failed to alter the kinase activity of 
SRMS, we propose to investigate the involvement of the 38 amino acid sequence that 
precedes this proline-rich segment.  We shall therefore investigate other SRMS mutants to be 
generated along these lines.   
 
5.3 Phosphorylation of Dok1 by SRMS 
 We have also identified the first direct substrate of SRMS, Dok1, an adapter protein that is 
phosphorylated downstream of several tyrosine kinases (Hence the name, Downstream of 
tyrosine kinase1).  Previous studies with Src have revealed that Src phosphorylates Dok1 on 
Y362, Y398 and Y449 (Niu et al., 2006).  Other studies have also indicated Dok1 as a 
constitutively tyrosine phosphorylated target of Bcr-Abl in chronic myelogenous leukemia 
(CML) progenitor cells (Carpino et al., 1997).  Our data indicates that Dok1 is 
phosphorylated on several tyrosine residues along its C-terminal tail (Fig. 4.31 and 4.32).  We 
observe tyrosine phosphorylation signals for the Dok1 mutants, especially Dok4, and 
Dok5, in a manner that is reflective of the number of tyrosine residues that each mutant 
possesses.  Also, our data indicates that the first Dok1 mutant (Dok1), comprising a single 
tyrosine residing between the PH and the PTB domains, is not detectably phosphorylated by 
SRMS.  It may be imperative to note that this mutant lacks the entire C-terminal tail and thus 
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the proline-rich motifs which may be essential for binding interactions with SRMS.  In view 
of this, binding interactions with SRMS were visibly diminished even for Dok2 and Dok3, 
indicating that the prolines in the C-terminal tail of Dok1 are crucially needed for associating 
with SRMS.  This may also, in part, explain the reduced levels of tyrosine phosphorylation of 
these two Dok1 mutants. 
                   Still, the strategy seemed ineffective in specifically identifying the residues that 
are phosphorylated by SRMS since all four C-terminal proline-containing mutants display 
tyrosine phosphorylation.  This is an obvious caveat of the strategy which we propose can be 
resolved via site-directed mutagenesis, generating a series of constructs with successive 
mutations in all the 11 tyrosines.   
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6. FUTURE DIRECTIONS 
 
6.1 Expression of SRMS in breast cancer cell lines and tissues 
From the results presented in Fig 4.1, SRMS expression appeared to be elevated in breast 
cancer cells compared to cells derived from the normal mammary tissues.  It will be 
important to determine the expression of SRMS in a larger panel of cell lines derived from 
both, normal and cancererous  breast tissues to expand upon the findings reported by this 
study.  Immunohistochemistry analyses pursued on a wide panel of tissue microarrays 
comprising breast cancer and matched normal tissue sections, shall further aid in 
characterizing the physiological significance of SRMS expression in breast cancer etiology.  
Such efforts shall particularly help correlate and validate SRMS expression with perhaps 
breast cancer molecular subtypes and/or the pathological grade, characterized by the 
invasiveness and tumorigenecity of the disease.         
 
6.2 Characterization of SRMS cytoplasmic puncta 
Based on the analyses of endogenous SRMS distribution in the breast cancer cell lines 
studied thus far, a predominantly punctate cytoplasmic pattern was observed (Fig 4.3 and 
4.5).  A similar pattern was also observed with ectopically expressed SRMS as studied in 
HEK293 cells (Fig 4.4).  It is possible that the N-terminal sequence, the SH3 and/or the SH2 
domains of SRMS, via intermolecular interactions with endogenous targets, may sequester it 
to specific cellular compartments.  Furthermore, SRMS may either directly or indirectly 
associate with specific cellular organelles or vesicles such as the endoplasmic reticuli, 
mitochondria, lysosomes/endosomes. For instance, similar cytoplasmic puncta formation has 
been previously reported for FRK that is believed to associate with EGFR in cellular 
endosomes (Jin and Craven, 2013).  Cytoplasmic punctate structures are also known to form 
in Anaplastic lymphoma kinase (ALK)-transformed cells where its association with 
characteristic cytoplasmic foci, comprising mRNA and mRNA-processing proteins, has been 
described (Fawal et al., 2011).  Furthermore, the association of microtubule-associated 
protein 1 light chain 3 (abbreviated LC3) with autophagosomal membranes also yield 
cytoplasmic puncta during the induction of autophagy (Mizushima et al., 2010).  Thus, there 
exist several incentives for exploring the punctate distribution exhibited by SRMS. 
Commercially available molecular tracker/probes exhibiting immunospecificity towards 
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certain cellular organelles, such as those described above, may be procured and utilized to aid 
the characterization of SRMS puncta. 
 
6.3 Three-dimensional structural analysis of SRMS and tyrosine phosphorylation 
analyses via mass spectrometry 
To date, there have been no reports describing the three-dimensional structure of either full-
length SRMS or its functional domains.  Structural analysis of c-Src has revealed significant 
information on the intramolecular interactions of the kinase involving its functional domains 
including the auto-regulatory regions(Cowan-Jacob et al., 2005).  For an enzyme, such 
information presents vital clues about its intrinsic functional characteristics pertaining to 
auto-catalytic regulation, substrate recognition/binding and other diverse facets of 
intracellular behaviour which may be crucial to understand the cellular roles of the enzyme. 
                   Recent investigations on c-Abl tyrosine kinase have revealed an autoinhibitory 
mechanism wherein the N-terminal cap preceding the SH3 domain interacts with the SH2 
kinase linker region to inhibit the catalytic activity of the kinase (Corbi-Verge et al., 2013; de 
Oliveira et al., 2013).  Our data demonstrates that unlike BRK and Src family kinases, SRMS 
catalytic activity is apparently positively regulated via its N-terminal region and the SH2 
domain.  However, like BRK, SRMS catalytic activity is attenuated in its W223A mutant.  It 
has been speculated that this tryptophan residue, conserved across Src and FRK/PTK6 family 
kinases, interacts with the kinase domain in BRK thereby stabilizing the active conformation 
of the PTK (Qiu and Miller, 2004).  Furthermore, the functional domains of SRMS, namely 
the SH3, SH2 and the kinase domain, exhibit minimal amino acid sequence homology to that 
of BRK and Src family kinases (Fig 4.10).  This may be reflective of divergent substrate 
specificites and/or catalytic properties that may aid in explaining, for instance, the reduced 
level of total tyrosine phosphorylated protein targets of SRMS compared to BRK.  We 
propose to employ structural studies on full length wild type SRMS, its functional domains 
and specific mutants cloned as GST-fused constructs and expressed in a eukaryotic system.  
                 It is possible that besides Y380 as the site for autophosphorylation, other tyrosine 
residues are also phosphorylated on SRMS.  Mass spectrometry analyses may be employed to 
deduce the tyrosine residues phosphorylated on SRMS.   
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6.4 Investigating the cellular roles of SRMS 
 The present study describes the biochemical characterization of the novel non-receptor 
tyrosine kinase, SRMS as well as the characterization of Dok1 as its substrate.  Considering 
that the biochemical and cellular characteristics of this protein tyrosine kinase remained 
unknown since 1994, the results described in this study shall invoke interest to investigate the 
potential role of SRMS in regulating cellular processes and perhaps breast tumorigenesis.  
This is especially interesting since the other two members of the FRK/PTK6 family kinases 
have been shown to play opposing roles in breast cancer with BRK portraying an oncogenic 
function contrasting with the tumor-suppressive functions of FRK.  
                The stimulus for investigating the functional role of SRMS stems from the 
observation that unlike BRK and FRK, whose kinase activities are tightly controlled upon 
phosphorylation of the negative-regulatory tyrosine residue in their C-termini, SRMSlacks 
such a regulatory C-terminus region and appears to be constitutively active when ectopically 
expressed.  From the biochemical analyses reported in this study, it is now known that SRMS 
is not negatively-regulated like BRK or FRK but that it apparently exists in a 
conformationally active state in cells.  The physiological ramifications shall be investigated 
in our future studies.  
                 We have also characterized Dok1 as a substrate of SRMS. Dok1 is functionally 
characterized by a pleckstrin homology domain (PH) that allows anchorage to the membrane, 
a phosphotyrosine binding domain that is involved in protein-protein interaction, and a C-
terminal region rich in tyrosine, proline and serine residues (Cong et al., 1999).  Even as the 
candidate tumor suppressor protein has been shown to inhibit cell proliferation and 
transformation, it also promotes cell spreading and cell migration (Hosooka et al., 2001).  
Dok1 is a substrate of a variety of receptor and non-receptor tyrosine kinases including the 
Src tyrosine kinase family members Tec and Bcr-Abl.  Such tyrosine phosphorylation of 
Dok1 has been implicated in the regulation of its cellular functions (Gerard et al., 2004; Lee 
et al., 2004b; Liang et al., 2002; Noguchi et al., 1999a; Woodring et al., 2004b).  Niu et al. 
characterized the nuclear export signal (NLS) embedded within the C-terminal segment of 
Dok1 and demonstrated that phosphorylation via Src prevents the entry of Dok1 into the 
nucleus, thereby regulating its sub-cellular localization and functions (Niu et al., 2006).  
More recently, Dok1 has been shown to undergo ubiquitin mediated cellular degradation 
upon phosphorylation by oncogenic tyrosine kinases, v-Src and BCR-ABL (Janas and Van 
Aelst, 2011).  It will be interesting to investigate how SRMS regulates the functions of Dok1 
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via phosphorylation.  Along these lines, it will be interesting to identify other 
substrates/binding partners of SRMS via mass spectrometry analyses in conjunction with the 
identification of tyrosine phosphorylated residues on SRMS. 
                    Overall, this study establishes SRMS as a potential non-receptor tyrosine kinase 
involved in breast tumorigenesis.  This is supported by (a) the results from Fig 4.1 that 
SRMS, like BRK, is potentially overexpressed in the majority of breast cancer cell lines 
studied and (b) the identification of a proposed tumor-suppressor protein, Dok1, as its 
physiological substrate.  This work is significant because it paves the way for further research 
to identify additional factors involved in the regulation of SRMS expression and activity, and 
to determine how SRMS regulates the cellular role of Dok1.  Furthermore, unlike other 
similar tyrosine kinases, the atypical mechanism of catalytic regulation exhibited by SRMS 
hints towards a possibly divergent mode of cellular function.  We, therefore, acknowledge the 
significance of directing subsequent investigations towards unravelling the cellular functions 
of this protein tyrosine kinase in breast cancer.  Thus, for future studies, it may be important 
to determine the functional and possibly the diagnostic, prognostic and therapeutic 
significance of SRMS expression in breast cancer. 
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